Method for the detection of gene transcripts in blood and uses thereof

ABSTRACT

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of application Ser. No. 10/268,730filed on Oct. 9, 2002, which is a continuation of U.S. application Ser.No. 09/477,148 filed Jan. 4, 2000, now abandoned, which claims thebenefit of U.S. Provisional Application No. 60/115,125 filed on Jan. 6,1999, now abandoned. Each of these applications is incorporated hereinby reference in their entirety, including the figures and drawings.

FIELD OF THE INVENTION

The present invention relates generally to the molecular biology ofhuman diseases. More specifically, the present invention relates to aprocess using the genetic information contained in human peripheralwhole blood for the diagnosis, prognosis and monitoring of genetic andinfectious disease in the human body.

DESCRIPTION OF THE RELATED ART

The blood is a vital part of the human circulatory system for the humanbody. Numerous cell types make up the blood tissue including monocytes,leukocytes, lymphocytes and erythrocytes. Although many blood cell typeshave been described, there are likely many as yet undiscovered celltypes in the human blood. Some of these undiscovered cells may existtransiently, such as those derived from tissues and organs that areconstantly interacting with the circulating blood in health and disease.Thus, the blood can provide an immediate picture of what is happening inthe human body at any given time.

The turnover of cells in the hematopoietic system is enormous. It wasreported that over one trillion cells, including 200 billionerythrocytes and 70 billion neutrophilic leukocytes, turn over each dayin the human body (Ogawa 1993). As a consequence of continuousinteractions between the blood and the body, genetic changes that occurwithin the cells or tissues of the body will trigger specific changes ingene expression within blood. It is the goal of the present inventionthat these genetic alterations be harnessed for diagnostic andprognostic purposes, which may lead to the development of therapeuticsfor ameliorating disease.

The complete profile of gene expression in the circulating blood remainstotally unexplored. It is hypothesized that gene expression in the bloodis reflective of body state and, as such, the resultant disruption ofhomeostasis under conditions of disease can be detected through analysisof transcripts differentially expressed in the blood alone. Thus, theidentification of several key transcripts or genetic markers in bloodwill provide information about the genetic state of the cells, tissues,organ systems of the human body in health and disease.

The prior art is deficient in non-invasive methods of screening fortissue-specific diseases. The present invention fulfills thislong-standing need and desire in the art.

SUMMARY OF THE INVENTION

This present invention discloses a process of using the geneticinformation contained in human peripheral whole blood in the diagnosis,prognosis and monitoring of genetic and infectious disease in the humanbody. The process described herein requires a simple blood sample andis, therefore, non-invasive compared to conventional practices used todetect tissue specific disease, such as biopsies.

One object of the present invention is to provide a non-invasive methodfor the diagnosis, prognosis and monitoring of genetic and infectiousdisease in humans and animals.

In one embodiment of the present invention, there is provided a methodfor detecting expression of a gene in blood from a subject, comprisingthe steps of: a) quantifying RNA from a subject blood sample; and b)detecting expression of the gene in the quantified RNA, wherein theexpression of the gene in quantified RNA indicates the expression of thegene in the subject blood.

In another embodiment of the present invention, there is provided amethod for detecting expression of one or more genes in blood from asubject, comprising the steps of: a) obtaining a subject blood sample;b) extracting RNA from the blood sample; c) amplifying the RNA; d)generating expressed sequence tags (ESTs) from the amplified RNAproduct; and e) detecting expression of the genes in the ESTs, whereinthe expression of the genes in the ESTs indicates the expression of thegenes in the subject blood. Preferably, the genes are tissue-specificgenes.

In still another embodiment of the present invention, there is provideda method for detecting expression of one or more genes in blood from asubject, comprising the steps of: a) obtaining a subject blood sample;b) extracting DNA fragments from the blood sample; c) amplifying the DNAfragments; and d) detecting expression of the genes in the amplified DNAproduct, wherein the expression of the genes in the amplified DNAproduct indicates the expression of the genes in the subject blood.

In yet another embodiment of the present invention, there is provided amethod for monitoring a course of a therapeutic treatment in anindividual, comprising the steps of: a) obtaining a blood sample fromthe individual; b) extracting RNA from the blood sample; c) amplifyingthe RNA; d) generating expressed sequence tags (ESTs) from the amplifiedRNA product; e) detecting expression of genes in the ESTs, wherein theexpression of the genes is associated with the effect of the therapeutictreatment; and f) repeating steps a)-e), wherein the course of thetherapeutic treatment is monitored by detecting the change of expressionof the genes in the ESTs. Such a method may also be used for monitoringthe onset of overt symptoms of a disease, wherein the expression of thegenes is associated with the onset of the symptoms.

In still yet another embodiment of the present invention, there isprovided a method for diagnosing a disease in a test subject, comprisingthe steps of: a) generating a cDNA library for the disease from a wholeblood sample from a normal subject; b) generating expressed sequence tag(EST) profile from the normal subject cDNA library; c) generating a cDNAlibrary for the disease from a whole blood sample from a test subject;d) generating EST profile from the test subject cDNA library; and e)comparing the test subject EST profile to the normal subject ESTprofile, wherein if the test subject EST profile differs from the normalsubject EST profile, the test subject might be diagnosed with thedisease.

In still yet another embodiment of the present invention, there isprovided a kit for diagnosing, prognosing or predicting a disease,comprising: a) gene-specific primers; wherein the primers are designedin such a way that their sequences contain the opposing ends of twoadjacent exons for the specific gene with the intron sequence excluded;and b) a carrier, wherein the carrier immobilizes the primer(s). Such akit may be applied to a test subject whole blood sample to diagnose,prognose or predict a disease.

In yet another embodiment of the present invention, there is provided akit for diagnosing, prognosing or predicting a disease, comprising: a)probes derived from a whole blood sample for a specific disease; and b)a carrier, wherein the carrier immobilizes the probes. Such a kit may beapplied to a test subject whole blood sample to diagnose, prognose orpredict a disease.

Furthermore, the present invention provides a cDNA library specific fora disease, wherein the cDNA library is generated from whole bloodsamples.

Other and further aspects, features, and advantages of the presentinvention will be apparent from the following description of thepresently preferred embodiments of the invention. These embodiments aregiven for the purpose of disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

So that the matter in which the above-recited features, advantages andobjects of the invention, as well as others which will become clear, areattained and can be understood in detail, more particular descriptionsof the invention briefly summarized above may be had by reference tocertain embodiments thereof which are illustrated in the appendeddrawings. These drawings form a part of the specification. It is to benoted, however, that the appended drawings illustrate preferredembodiments of the invention and therefore are not to be consideredlimiting in their scope.

FIG. 1 shows the following RNA samples prepared from human blood; FIG.1A: Lane 1, Molecular weight marker; Lane 2, RT-PCR on APP gene; Lane 3,PCR on APP gene; Lane 4, RT-PCR on APC gene; Lane 5, PCR on APC gene;FIG. 1B: Lanes 1 and 2, RT-PCR and PCR of βMyHC, respectively; Lanes 3and 4, RT-PCR of βMyHC from RNA prepared from human fetal and humanadult heart, respectively; Lane 5, Molecular weight marker.

FIG. 2 shows quantitative RT-PCR analysis performed on RNA samplesextracted from a drop of blood. Forward primer(5′-GCCCTCTGGGGACCTGAC-3′, SEQ ID No. 1) of exon 1 and reverse primer(5′-CCCACCTGCAGGTCCTCT-3″, SEQ ID No. 2) of exons 1 and 2 of insulingene. Blood samples of 4 normal subjects were assayed. Lanes 1, 3, 5 and7 represent overnight “fasting” blood sample and lanes 2, 4, 6 and 8represent “non-fasting” samples.

FIG. 3 shows quantitative RT-PCR analysis performed on RNA samplesextracted from a drop of blood. Lanes 1 and 2 represent normal healthyperson and lane 3 represents late-onset diabetes (Type II) and lane 4represents asymptomatic diabetes.

FIG. 4 shows multiple RT-PCR assay in a drop of blood. Primers werederived from insulin gene (INS), zinc-finger protein gene (ZFP) andhouse-keeping gene (GADH). Lane 1 represents normal person. Lane 2represents late-onset diabetes and lane 3 represents asymptomaticdiabetes.

FIG. 5 shows standardized levels of insulin gene (FIG. 5A) and ZFP gene(FIG. 5B) expressed in a drop of blood. The first three subjects werenormal, second two subjects showed normal glucose tolerance, and thelast subject had late onset diabetes type II. FIG. 5C shows standardizedlevels of insulin gene expressed in each fractionated cell from wholeblood.

FIG. 6 shows the differential screening of human blood cell cDNA librarywith different cDNA probes of heart and brain tissue. FIG. 6A showsblood cell cDNA probes vs. adult heart cDNA probes. FIG. 6B shows bloodcell cDNA probes vs. human brain cDNA probes.

FIG. 7 graphically shows the 1,800 unique genes in human blood and inthe human fetal heart grouped into seven cellular functions.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there may be employedconventional molecular biology, microbiology, and recombinant DNAtechniques within the skill of the art. Such techniques are explainedfully in the literature. See, e.g., Sambrook, Fritsch & Maniatis,“Molecular Cloning: A Laboratory Manual (1982); “DNA Cloning: APractical Approach,” Volumes I and II (D. N. Glover ed. 1985);“Oligonucleotide Synthesis” (M. J. Gait ed. 1984); “Nucleic AcidHybridization” [B. D. Hames & S. J. Higgins eds. (1985)]; “Transcriptionand Translation” [B. D. Hames & S. J. Higgins eds. (1984)]; “Animal CellCulture” [R. I. Freshney, ed. (1986)]; “Immobilized Cells And Enzymes”[IRL Press, (1986)]; B. Perbal, “A Practical Guide To Molecular Cloning”(1984). Therefore, if appearing herein, the following terms shall havethe definitions set out below.

A “cDNA” is defined as copy-DNA or complementary-DNA, and is a productof a reverse transcription reaction from an mRNA transcript. “RT-PCR”refers to reverse transcription polymerase chain reaction and results inproduction of cDNAs that are complementary to the mRNA template(s).

The term “oligonucleotide” is defined as a molecule comprised of two ormore deoxyribonucleotides, preferably more than three. Its exact sizewill depend upon many factors which, in turn, depend upon the ultimatefunction and use of the oligonucleotide. The term “primer” as usedherein refers to an oligonucleotide, whether occurring naturally as in apurified restriction digest or produced synthetically, which is capableof acting as a point of initiation of synthesis when placed underconditions in which synthesis of a primer extension product, which iscomplementary to a nucleic acid strand, is induced, i.e., in thepresence of nucleotides and an inducing agent such as a DNA polymeraseand at a suitable temperature and pH. The primer may be eithersingle-stranded or double-stranded and must be sufficiently long toprime the synthesis of the desired extension product in the presence ofthe inducing agent. The exact length of the primer will depend upon manyfactors, including temperature, source of primer and the method used.For example, for diagnostic applications, depending on the complexity ofthe target sequence, the oligonucleotide primer typically contains 15-25or more nucleotides, although it may contain fewer nucleotides. Thefactors involved in determining the appropriate length of primer arereadily known to one of ordinary skill in the art.

As used herein, random sequence primers refer to a composition ofprimers of random sequence, i.e. not directed towards a specificsequence. These sequences possess sufficient complementary to hybridizewith a polynucleotide and the primer sequence need not reflect the exactsequence of the template.

“Restriction fragment length polymorphism” refers to variations in DNAsequence detected by variations in the length of DNA fragments generatedby restriction endonuclease digestion.

A standard Northern blot assay can be used to ascertain the relativeamounts of mRNA in a cell or tissue obtained from plant or other tissue,in accordance with conventional Northern hybridization techniques knownto those persons of ordinary skill in the art. The Northern blot uses ahybridization probe, e.g. radiolabelled cDNA, either containing thefull-length, single stranded DNA or a fragment of that DNA sequence atleast 20 (preferably at least 30, more preferably at least 50, and mostpreferably at least 100 consecutive nucleotides in length). The DNAhybridization probe can be labelled by any of the many different methodsknown to those skilled in this art. The labels most commonly employedfor these studies are radioactive elements, enzymes, chemicals whichfluoresce when exposed to untraviolet light, and others. A number offluorescent materials are known and can be utilized as labels. Theseinclude, for example, fluorescein, rhodamine, auramine, Texas Red, AMCAblue and Lucifer Yellow. A particular detecting material is anti-rabbitantibody prepared in goats and conjugated with fluorescein through anisothiocyanate. Proteins can also be labeled with a radioactive elementor with an enzyme. The radioactive label can be detected by any of thecurrently available counting procedures. The preferred isotope may beselected from ³H, ¹⁴C, ³²P, ³⁵S, ³⁶Cl, ⁵¹Cr, ⁵⁷Co, ⁵⁸Co, ⁵⁹Fe, ⁹⁰Y,¹²⁵I, ¹³¹I, and ¹⁸⁶Re. Enzyme labels are likewise useful, and can bedetected by any of the presently utilized colorimetric,spectrophotometric, fluorospectrophotometric, amperometric or gasometrictechniques. The enzyme is conjugated to the selected particle byreaction with bridging molecules such as carbodiimides, diisocyanates,glutaraldehyde and the like. Many enzymes which can be used in theseprocedures are known and can be utilized. The preferred are peroxidase,β-glucuronidase, β-D-glucosidase, β-D-galactosidase, urease, glucoseoxidase plus peroxidase and alkaline phosphatase. U.S. Pat. Nos.3,654,090, 3,850,752, and 4,016,043 are referred to by way of examplefor their disclosure of alternate labeling material and methods.

As used herein, “individual” refers to human subjects as well asnon-human subjects. The examples herein are not meant to limit themethodology of the present invention to human subjects only, as theinstant methodology is useful in the fields of veterinary medicine,animal sciences and such.

In one embodiment of the present invention, there is provided a methodfor detecting expression of a gene in blood from a subject, comprisingthe steps of: a) quantifying RNA from a subject blood sample; and b)detecting expression of the gene in the quantified RNA, wherein theexpression of the gene in quantified RNA indicates the expression of thegene in the subject blood. An example of the quantifying method is bymass spectrometry.

In another embodiment of the present invention, there is provided amethod for detecting expression of one or more genes in blood from asubject, comprising the steps of: a) obtaining a subject blood sample;b) extracting RNA from the blood sample; c) amplifying the RNA; d)generating expressed sequence tags (ESTs) from the amplified RNAproduct; and e) detecting expression of the genes in the ESTs, whereinthe expression of the genes in the ESTs indicates the expression of thegenes in the subject blood. Preferably, the subject is a fetus, anembryo, a child, an adult or a non-human animal. The genes arenon-cancer-associated and tissue-specific genes. Still preferably, theamplification is performed by RT-PCR using random sequence primers orgene-specific primers.

In still another embodiment of the present invention, there is provideda method for detecting expression of one or more genes in blood from asubject, comprising the steps of: a) obtaining a subject blood sample;b) extracting DNA fragments from the blood sample; c) amplifying the DNAfragments; and d) detecting expression of the genes in the amplified DNAproduct, wherein the expression of the genes in the amplified DNAproduct indicates the expression of the genes in the subject blood.

In yet another embodiment of the present invention, there is provided amethod for monitoring a course of a therapeutic treatment in anindividual, comprising the steps of: a) obtaining a blood sample fromthe individual; b) extracting RNA from the blood sample; c) amplifyingthe RNA; d) generating expressed sequence tags (ESTs) from the amplifiedRNA product; e) detecting expression of genes in the ESTs, wherein theexpression of the genes is associated with the effect of the therapeutictreatment; and f) repeating steps a)-e), wherein the course of thetherapeutic treatment is monitored by detecting the change of expressionof the genes in the ESTs. Such a method may also be used for monitoringthe onset of overt symptoms of a disease, wherein the expression of thegenes is associated with the onset of the symptoms. Preferably, theamplification is performed by RT-PCR, and the change of the expressionof the genes in the ESTs is monitored by sequencing the ESTs andcomparing the resulting sequences at various time points; or byperforming single nucleotide polymorphism analysis and detecting thevariation of a single nucleotide in the ESTs at various time points.

In still yet another embodiment of the present invention, there isprovided a method for diagnosing a disease in a test subject, comprisingthe steps of: a) generating a cDNA library for the disease from a wholeblood sample from a normal subject; b) generating expressed sequence tag(EST) profile from the normal subject cDNA library; c) generating a cDNAlibrary for the disease from a whole blood sample from a test subject;d) generating EST profile from the test subject cDNA library; and e)comparing the test subject EST profile to the normal subject ESTprofile, wherein if the test subject EST profile differs from the normalsubject EST profile, the test subject might be diagnosed with thedisease.

In still yet another embodiment of the present invention, there isprovided a kit for diagnosing, prognosing or predicting a disease,comprising: a) gene-specific primers; wherein the primers are designedin such a way that their sequences contain the opposing ends of twoadjacent exons for the specific gene with the intron sequence excluded;and b) a carrier, wherein the carrier immobilizes the primer(s).Preferably, the gene-specific primers are selected from the groupconsisting of insulin-specific primers, atrial natriureticfactor-specific primers, zinc finger protein gene-specific primers,beta-myosin heavy chain gene-specific primers, amyloid precurser proteingene-specific primers, and adenomatous polyposis-coli proteingene-specific primers. Further preferably, the gene-specific primers areselected from the group consisting of SEQ ID Nos. 1 and 2; and SEQ IDNos. 5 and 6. Such a kit may be applied to a test subject whole bloodsample to diagnose, prognose or predict a disease by detecting thequantitative expression levels of specific genes associated with thedisease in the test subject and then comparing to the levels of samegenes expressed in a normal subject. Such a kit may also be used formonitoring a course of therapeutic treatment or monitoring the onset ofovert symptoms of a disease.

In yet another embodiment of the present invention, there is provided akit for diagnosing, prognosing or predicting a disease, comprising: a)probes derived from a whole blood sample for a specific disease; and b)a carrier, wherein the carrier immobilizes the probes. Such a kit may beapplied to a test subject whole blood sample to diagnose, prognose orpredict a disease by detecting the quantitative expression levels ofspecific genes associated with the disease in the test subject and thencomparing to the levels of same genes expressed in a normal subject.Such a kit may also be used for monitoring a course of therapeutictreatment or monitoring the onset of overt symptoms of a disease.

Furthermore, the present invention provides a cDNA library specific fora disease, wherein the cDNA library is generated from whole bloodsamples.

The following examples are given for the purpose of illustrating variousembodiments of the invention and are not meant to limit the presentinvention in any fashion.

Example 1

Construction of a cDNA Library

RNA extracted from human tissues (including fetal heart, adult heart,liver, brain, prostate gland and whole blood) were used to constructunidirectional cDNA libraries. The first mammalian heart cDNA librarywas constructed as early as 1982. Since then, the methodology has beenrevised and optimal conditions have been developed for construction ofhuman heart and hematopoietic progenitor cDNA libraries (Liew et al.,1984; Liew 1993, Claudio et al., 1998). Most of the novel genes whichwere identified by sequence annotation can now be obtained as fulllength transcripts.

Example 2 Catalogue of Blood Cell ESTs

Random partial sequencing of expressed sequence tags (ESTs) of cDNAclones from the blood cell library was carried out to establish an ESTdatabase of blood. The known genes as derived from the ESTs werecategorized into seven major cellular functions (Hwang, Dempsey et al.,1997).

Example 3

Differential Screening of cDNA Library

cDNA probes generated from transcripts of each tissue were used tohybridize the blood cell cDNA clones (Liew et al., 1997). The “positive”signals which were hybridized with P-labelled cDNA probes were definedas genes which shared identity with blood and respective tissues. The“negative” spots which were not exposed to P-labelled cDNA probes wereconsidered to be blood-cell-enriched or low frequency transcripts.

Example 4 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Assay

RNA extracted from samples of human tissue was used for RT-PCR analysis(Jin et al. 1990). Three pairs of forward and reverse primers weredesigned for human cardiac beta-myosin heavy chain gene (βMyHC), amyloidprecurser protein (APP) gene and adenomatous polyposis-coli protein(APC) gene. The PCR products were also subjected to automated DNAsequencing to verify the sequences as derived from the specifictranscripts of blood.

Example 5 Detection of Tissue Specific Gene Expression in Human BloodUsing RT-PCR

The beta-myosin heavy chain gene (βMyHC) transcript (mRNA) is known tobe highly expressed in ventricles of the human heart. This sarcomericprotein is important for heart muscle contraction and its presence wouldnot be expected in other non-muscle tissues and blood. In 1990, the genefor human cardiac βMyHC was completely sequenced (Liew et al. 1990) andwas comprised of 41 exons and 42 introns.

The method of reverse transcription polymerase chain reaction (RT-PCR)was used to determine whether this cardiac specific mRNA is also presentin human blood. A pair of primers was designed; the forward primer (SEQID No. 3) was on the boundary of exons 21 and 22, and the reverse primer(SEQ ID No. 4) was on the boundary of exons 24 and 25. This region ofmRNA is only present in βMyHC and is not found in the alpha-myosin heavychain gene (αMyHC).

A blood sample was first treated with lysing buffer and then undergonecentrifuge. The resulting pellets were further processed with RT-PCR.RT-PCR was performed using the total blood cell RNA as a template. Anested PCR product was generated and used for sequencing. The sequencingresults were subjected to BLAST and the identity of exons 21 to 25 wasconfirmed to be from βMyHC (FIG. 1A).

Using the same method just described, two other tissue specificgenes—amyloid precursor protein (APP, forward primer, SEQ ID No. 7;reverse primer, SEQ ID No. 8) found in the brain and associated withAlzheimer's disease, and adenomatous polyposis coli protein (APC) foundin the colon and rectum and associated with colorectal cancer (Groden etal. 1991; Santoro and Groden 1997)—were also detected in the RNAextracted from human blood (FIG. 1B).

Example 6

Multiple RT-PCR Analysis on a Drop of Blood from a Normal/DiseasedIndividual

A drop of blood was extracted to obtain RNA to carry out quantitativeRT-PCR analysis. Specific primers for the insulin gene were designed:forward primer (5′-GCCCTCTGGGGACCTGAC-3′, SEQ ID No. 1) of exon 1 andreverse primer (5′-CCCACCTGCAGGTCCTCT-3″, SEQ ID No. 2) of exons 1 and 2of insulin gene. Such reverse primer was obtained by deleting the intronbetween the exons 1 and 2. Blood samples of 4 normal subjects wereassayed. It was found that the insulin gene is expressed in the bloodand the quantitative expression of the insulin gene in a drop of bloodis influenced by fasting and non-fasting states of normal healthysubjects (FIG. 2). This very low level of expression of the insulin genereflects the phenotypic status of a person and strongly suggests thatthere is a physiological and pathological role for its expression,contrary to the basal or illegitimate theory of transcription suggestedby Chelly et al. (1989) and Kimoto (1998).

Same quantitative RT-PCR analysis was performed using insulin specificprimers on RNA samples extracted from a drop of blood from a normalhealthy person, a person having late-onset diabetes (Type II) and aperson having asymptomatic diabetes. It was found that the insulin geneis expressed differentially amongst subjects that are healthy, diagnosedas type II diabetic, and also in an asymptomatic preclinical patient(FIG. 3).

Similarly, specific primers for the atrial natriuretic factor (ANF) genewere designed (forward primer, SEQ ID No. 5; reverse primer, SEQ ID No.6) and RT-PCR analysis was performed on a drop of blood. ANF is known tobe highly expressed in heart tissue biopsies and in the plasma of heartfailure patients. However, atrial natriuretic factor was observed to beexpressed in the blood and the expression of the atrial natriureticfactor gene is significantly higher in the blood of patients with heartfailure as compared to the blood of a normal control patient.

Specific primers for the zinc finger protein gene (ZFP, forward primer,SEQ ID No. 9; reverse primer, SEQ ID No. 10) were also designed andRT-PCR analysis was performed on a drop of blood. ZFP is known to behigh in heart tissue biopsies of cardiac hypertrophy and heart failurepatients. In the present study, the expression of ZFP was observed inthe blood as well as differential expression levels of ZFP amongst thenormal, diabetic and asymptomatic preclinical subjects (FIG. 4);although neither of the non-normal subjects has been specificallydiagnosed as suffering from cardiac hypertrophy and/or heart failure,the higher expression levels of the ZFP gene in their blood may indicatethat these subjects are headed in that general direction.

It was hypothesized that a housekeeping gene such as glyceraldehydedehydrogenase (GADH) which is required and highly expressed in all cellswould not be differentially expressed in the blood of normal vs. diseasesubjects. This hypothesis was confirmed by RT-PCR using GADH specificprimers (FIG. 4). Thus, GADH is useful as an internal control.

Standardized levels of insulin gene or ZFP gene expressed in a drop ofblood were estimated using a housekeeping gene as an internal controlrelative to insulin or ZFP expressed (FIGS. 5A & 5B). The levels ofinsulin gene expressed in each fractionated cell from whole blood werealso standardized and shown in FIG. 5C.

Example 7

Human Blood Cell cDNA Library

In order to further substantiate the present invention, differentialscreening of the human blood cell cDNA library was conducted. cDNAprobes derived from human blood, adult heart or brain were respectivelyhybridized to the human blood cDNA library clones. As shown in FIG. 7,more than 95% of the “positively” identified clones are identicalbetween the blood and other tissue samples.

DNA sequencing of randomly selected clones from the human whole bloodcell cDNA library was also performed. This allowed information regardingthe cellular function of blood to be obtained concurrently with geneidentification. More than 20,000 expressed sequence tags (ESTs) havebeen generated and characterized to date, 17.6% of which did not resultin a statistically significant match to entries in the GenBank databasesand thus were designated as “Novel” ESTs. These results are summarizedin FIG. 7 together with the seven cellular functions related to percentdistribution of known genes in blood and in the fetal heart.

From 20,000 ESTs, 1,800 have been identified as known genes which maynot all appear in the hemapoietic system. For example, the insulin geneand the atrial natriuretic factor gene have not been detected in these20,000 ESTs but their transcripts were detected in a drop of blood,strongly suggesting that all transcripts of the human genome can bedetected by performing RT-PCR analysis on a drop of blood.

In addition, approximately 400 novel genes have been identified from the20,000 ESTs characterized to date, and these will be subjected to fulllength sequencing and open reading frame alignment to reduce the actualnumber of novel ESTs prior to screening for disease markers.

Analysis of the approximately 6,283 ESTs which have known matches in theGenBank databases revealed that this dataset represents over 1,800unique genes. These genes have been catalogued into seven cellularfunctions. Comparisons of this set of unique genes with ESTs derivedfrom human brain, heart, lung and kidney demonstrated a greater than 50%overlap in expression (Table 1).

TABLE 1 Overlap of Genes Expressed in Blood * Tissues ESTs ** Overlap inBlood brain 134,000 60% heart 65,000 59% lung 60,200 58% kidney 32,30054% * Estimated from limited known genes of about 1,800 as derived fromthe database of 6,297 ESTs from human blood cell library. ** Obtainedfrom the National Centre of Biotechnology Information (NCBI), U.S.A.

Example 8 Blood Cell ESTs

The results from the differential screening clearly indicate that thetranscripts expressed in the whole blood are reflective of genesexpressed in all cells and tissues of the body. More than 95% ofdetectable spots were identical from two different tissues. Theremaining 5% of spots may represent cell- or tissue-specifictranscripts; however, results obtained from partial sequencing togenerate ESTs of these clones revealed most of them not to be cell- ortissue-specific transcripts. Therefore, the negative spots arepostulated to be reflective of low abundance transcripts in the tissuefrom which the cDNA probes were derived.

An alternative approach that was employed to identify transcriptsexpressed at low levels is the large-scale generation of expressedsequence tags (ESTs). There is substantial evidence regarding theefficiency of this technology to detect previously characterized (known)and uncharacterized (unknown or novel) genes expressed in thecardiovascular system (Hwang & Dempsey et al. 1997). In the presentinvention, 20,000 ESTs have been produced from a human blood cell cDNAlibrary and resulted in the identification of approximately 1,800 uniqueknown genes (Table 2)

In the most recent GenBank release, analysis of more than 300,000 ESTsin the database (dbESTs) generated more than 48,000 gene clusters whichare thought to represent approximately 50% of the genes in the humangenome. Only 4,800 of the dbESTs are blood-derived. In the presentinvention, 20,000 ESTs have been obtained to date from a human bloodcDNA library, which provides the world's most informative database withrespect to blood cell transcripts. From the limited amount ofinformation generated so far (i.e. 1,800 unique genes), it has alreadybeen determined that more than 50% of the transcripts are found in othercells or tissues of the human body (Table 2). Thus, it is expected thatby increasing the number of ESTs generated, more genes will beidentified that have an overlap in expression between the blood andother tissues. Furthermore, the transcripts for several genes which areknown to have tissue-restricted patterns of expression (i.e. βMyHC, APP,APC, ANF, ZFP) have also been demonstrated to be present in blood.

Most recently, a cDNA library of human hematopoietic progenitor stemcells has also been constructed. From the limited set of 1,000 ESTs,there are at least 200 known genes that are shared with other tissuerelated genes (Claudio et al. 1998).

Table 2 demonstrates the expression of known genes of specific tissuesin blood cells. Previously, only the presence of “housekeeping” geneswould have been expected. Additionally, the presence of at least 25 ofthe currently known 500 genes corresponding to molecular drug targetswas detected. These molecular drug targets are used in the treatment ofa variety of diseases which involve inflammation, renal andcardiovascular function, neoplastic disease, immunomodulation and viralinfection (Drews & Ryser, 1997). It is expected that additional novelESTs will represent future molecular drug targets.

TABLE 2 Comparison of 1,800 Unique Genes Identified in the Blood CellcDNA Library to Genes Previously Identified in Specific Tissues No. ofAccession Tissue Distribution Gene Identification ESTs No. Bl Br H K LiLu 100 kDa coactivator 2 U22055 + + 10 kD protein (BC10) 2AF053470 + + + + 14-3-3 epsilon 2 U54778 + + + 14-3-3 protein 11U28964 + + + 15 kDa selenoprotein 1 AF051894 + + + (SEP15)1-phosphatidylinositol-4- 1 S78798 phosphate 5-kinase isoform C 23 kDhighly basic protein 21 X56932 + + + + + + 2-5A-dependent RNase 1 L103812′-5′oligoadenylate 4 M87284 B synthetase 2 (OAS2) 26S proteasomesubunit 11 1 AF086708 36 kDa phosphothyrosine 2 AJ223280 T + protein 3-7gene product (non- 1 D64159 exact 86% aa) 3-phosphoglycerate 1 AF006043T + + + dehydrogenase (PGAD) 3-prime-phosphoadenosine 2 U53447 + + + + +5-prime-phosphosulfate synthase 1 (PAPSS1) 46 kd mannose 6- 1 X56257phosphate receptor (MPR46) (low match) 5-aminoimidazole-4- 1 D89976carboxamide ribonucleotide transformylase 5′-nucleotidase 3 D38524 T + +6-phosphofructo-2- 1 D49818 + kinase/fructose-2,6- biphosphatase 4(PFKFB4) 6-phosphofructo-2- 1 AF041829 kinase/fructose-2,6-bisphosphatase (PF2K) 71 kd heat shock cognate 23 Y00371 protein hsc7076 kDa membrane protein 2 U81006 + + + + + (P76) 8-oxoguanine DNA 1U96710 B + + glycosylase (OGG1) a disintegrin and 1 AF009615 T +metalloprotease domain 10 (ADAM10) a disintegrin and 1 D26579 B +metalloprotease domain 8 (ADAM8) A kinase anchor protein 95 2 Y11997 B,T + + (AKAP95) activated A kinase anchor protein, 2 X97335 + + + + 149kD (AKAP149) A4 differentiation- 1 U93305 dependent protein (A4), tripleLIM domain protein (LMO6), and synaptophysin (SYP); calcium channelalpha-1 subunit (CACNA1F) ABL and putative M8604 1 U07561 Met proteinAbsent in melanoma 1 1 U83115 + + + (AIM1) accessory proteins 2Z31696 + + BAP31/BAP29 (DXS1357E) acetyl-Coenzyme A 2 X12966 + + + + + +acyltransferase (peroxisomal 3-oxoacyl- Coenzyme A thiolase) (ACAA)acetyl-Coenzyme A 1 D88152 T lymphoma + + transporter (ACATN) acidic 82kDa protein 4 U15552 acidic protein rich in 1 Y07969 B + + + + leucines(SSP29) Aconitase 2, mitochondrial 1 U80040 + + + + + (ACO2) actinbinding protein 1 AF059569 MAYVEN actin, beta (ACTB) 158 X04098 T,B + + + actin, beta (ACTB) (non- 1 M10277 exact, low match 73%) actin,gamma (low score) 1 K00791 actin, gamma 1 (ACTG1) 4 X04098 + + + + + +high in many libraries actin-binding LIM protein 4 D31883 + + + +(ABLIM) Actinin, alpha 1 (ACTN1) 8 M95178 + + + + actinin, alpha 4(ACTN4) 1 D89980 + + + activated p21cdc42Hs 1 L13738 B + + kinase (ACK)activated RNA polymerase 1 X79805 + + + + + II transcription cofactor 4(PC4) activating transcription 1 X55544 + factor 1 (ATF1) activatingtranscription 1 X15875 + + + factor 2 (ATF2) activating transcription 2M86842 + + factor 4 (tax-responsive enhancer element B67) (ATF4) activeBCR-related gene 1 U01147 + + + + + (ABR) acyl-CoA oxidase (AOX) 1U03254 acyl-Coenzyme A 2 M16827 dehydrogenase, C-4 to C- 12 straightchain (ACADM) acyl-Coenzyme A 3 D43682 + + + + + + dehydrogenase, verylong chain (ACADVL) acyloxyacyl hydrolase 3 M62840 T + + + (neutrophil)(AOAH) adaptin, delta (ADTD) 2 U91930 + + + adaptin, delta (ADTD) (non-1 AC005328 exact 59%) adaptin, gamma (ADTG) 1 Y12226 + + + + adaptorcomplex sigma3B 2 X99459 + + + (AP3S3) adaptor protein p150 1 Y08991adducin 1 (alpha) (ADD1) 2 L07261 + + + adducin 1 (alpha) (add1) 3L29296 + + + + + adducin 3 (gamma) (ADD3) 3 U37122 B, W + + + + adeninenucleotide 2 M57424 + + + translocator 2 (fibroblast) (ANT2) adeninenucleotide 1 J02683 translocator 2 (fibroblast) (ANT2) (non-exact 81%)adenine nucleotide 1 J02683 translocator 2 (fibroblast) (ANT2)(non-exact, 79%) adenine nucleotide 1 J02683 translocator 2 (fibroblast)(ANT2) (non-exact, 86%) adenine nucleotide 3 J03592 + + + + translocator3 (liver) (ANT3) adenosine deaminase, 6 U18121 + + + RNA-specific (ADAR)adenylate cyclase 3 2 AF033861 + + + + + (ADCY3) adenylate cyclase 7 1D25538 (ADCY7) adenylate kinase 2 (AK2) 2 U39945 + + + + adenylatekinase 3 (AK3) 1 X60673 (non-exact, 67%) adenylyl cyclase- 28 M98474T + + associated protein (CAP) adipose differentiation- 1 X97324 + + +related protein; adipophilin (ADFP) ADP-ribosylation factor 1 13M84326 + + + + (ARF1) ADP-ribosylation factor 3 2 M33384 + + + (ARF3)ADP-ribosylation factor 4 1 M36341 T lymphoma + + + (ARF4)ADP-ribosylation factor 5 1 M57567 + + + + (ARF5) ADP-ribosylationfactor 1 L04510 + domain protein 1, 64 kD (ARFD1) ADP-ribosyltransferase4 M32721 + + + + + + (NAD+; poly (ADP-ribose) polymerase) (ADPRT)adrenergic, beta, receptor 2 X61157 B + + kinase 1 (ADRBK1)adrenoleukodystrophy-like 1 AJ000327 1 (ALDL1) AE-binding protein 1 1D86479 (AEBP1) (non-exact, 62%) AF-17 1 U07932 A-gamma-globin 1 V00514A-gamma-globin 1 J00176 (chromosome 11 allele) agammaglobulinaemia 1U78027 tyrosine kinase (ATK) AHNAK nucleoprotein 4 M80899 + + + + +(desmoyokin) (AHNAK) alanyl (membrane) 1 X13276 + + aminopeptidase(aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13,p150) (ANPEP) alcohol dehydrogenase 5 1 M29872 (class III), chipolypeptide (ADH5) aldehyde dehydrogenase 1 AF003341 + + + 1, soluble(ALDH1) aldehyde dehydrogenase 2 U75286 10 (fatty aldehydedehydrogenase) (ALDH10) aldehyde reductase 1 (low 3 J04795 B + + + + Kmaldose reductase) (ALDR1) aldo-keto reductase family 2 J04794 B + + + 1,member A1 (aldehyde reductase) (AKR1A1) aldo-keto reductase family 1D17793 + + + + 1, member C3 (3-alpha hydroxysteroid dehydrogenase, typeII) (AKR1C3) aldo-keto reductase family 1 Y16675 + + + + 7, member A2(aflatoxin aldehyde reductase) (AKR7A2) aldolase A, fructose- 7X12447 + + + bisphosphate (ALDOA) aldolase C, fructose- 2 X05196 + + +bisphosphate (ALDOC) alkaline phosphatase, 1 4502062 liver/bone/kidney(ALPL) ALL-1 (=L04731; L04284 4 Z69780 HRX) alpha mannosidase II 1D55649 + + isozyme alpha thalassemia/mental 3 U75653 + + + + +retardation syndrome X- linked (ATRX) alpha-2 macroglobulin 1 Z11711alpha-2-globin 2 V00516 alpha-2-macroglobulin 1 U06985receptor/lipoprotein receptor protein (A2MR/LRP) alpha-polypeptide of N-1 M13520 acetyl-alpha- glucosaminidase (HEXA) alpha-spectrin 1 X86901alpha-subunit of Gi2 a 1 X07854 (GTP-binding signal transductionprotein) aminin receptor 1 (67 kD); 2 J03799 T + + + + Ribosomal proteinSA (LAMR1) aminolevulinate, delta-, 1 X64467 + dehydratase (ALAD)amino-terminal enhancer of 2 X73358 + + + + + split (AES) amino-terminalenhancer of 3 U04241 B + + + + split (AES) AMP deaminase isoform L 8M91029 + + (AMPD2) amphiphysin (Stiff-Mann 1 U07616 B + + syndrome withbreast cancer 128 kD autoantigen) (AMPH) amphiphysin (Stiff-Mann 1U07616 syndrome with breast cancer 128 kD autoantigen) (AMPH)(non-exact,68%) amphiphysin (Stiff-Mann 1 U07616 syndrome with breast cancer 128 kDautoantigen) (AMPH)(non-exact, 68%) amphiphysin II 4 U87558 + + +amphiphysin II (67% aa 1 AF068915 amphiphysin?) amphiphysin II(non-exact 1 AF001383 69% aa) amphiphysin-like (AMPHL) 1 U68485 + +amphiphysin-like (AMPHL) 1 AF068918 (low match) AMY-1 1 D50692 B, T +amyloid beta (A4) 1 L77864 + + + + precursor protein-binding, family B,member 1 (Fe65) (APBB1) amyloid beta (A4) 6 L27631 T lymphoma + + + +precursor-like protein 2 (APLP2) ankyrin 3, node of Ranvier 1 U43965(ankyrin G) (ANK) (non- exact, 50%) annexin I (lipocortin I) 1X05908 + + + + (ANX1) annexin II 1 D28364 annexin II (lipocortin II; 7D00017 + + + + + + high in many libraries calpactin I, heavypolypeptide) (ANX2) annexin IV (placental 1 M19383 + + + + +anticoagulant protein II) (ANX4) annexin V (endonexin II) 2M21731 + + + + (ANX5) annexin V (endonexin II) 1 M19384 + + + + (ANXV)annexin VI (p68) (ANX6) 6 Y00097 + + + + annexin VII (synexin) 1J04543 + + + + (ANX7) antigen identified by 2 M16279 + + + + monoclonalantibodies 12E7, F21 and O13 (MIC2) antigen identified by 3J02939 + + + + + monoclonal antibodies 4F2, TRA1.10, TROP4, and T43(MDU1) antigen TQ1 1 anti-oxidant protein 2 (non- 1 D14662 + + + + +selenium glutathione peroxidase, acidic calcium- independentphospholipase A2) (KIAA0106) APEX nuclease 5 X66133 + + + +(multifunctional DNA repair enzyme) (APEX) Apolipoprotein L (APOL) 1Z82215 (59% aa) apoptosis inhibitor 1 (API1) 1 L49431 + + + + +apoptosis inhibitor 4 1 U75285 B, W + + + (survivin) (API4) apoptosisinhibitor 5 (API5) 1 U83857 T lymphoma + + apoptosis specific protein 1Y11588 B + + + (ASP) apoptotic protease 1 AF013263 B + + + activatingfactor (APAF1) aquaporin 3 (AQP3) 1 AB001325 T + aquaporin 9 (AQP9) 7AB008775 T activated + arachidonate 12- 1 M58704 T + + lipoxygenase(ALOX12) arachidonate 5- 3 X52195 + + + + lipoxygenase-activatingprotein (ALOX5AP) ariadne homolog (ARI) 1 AJ009771 + + + + + ariadne-2(D. melanogaster) 1 AF099149 + + + + + homolog (all-trans retinoic acidinducible RING finger) (ARI2) ARP1 (actin-related protein 1 X82206 + +1, yeast) homolog A (centractin alpha) (ACTR1A) ARP2 (actin-relatedprotein 9 AF006082 + + + + 2, yeast) homolog (ACTR2) ARP2/3 proteincompex 5 AF006085 T activated, W + + + subunit 34 (ARC34) Arp2/3 proteincompex 6 AF006084 monocyte + + + subunit p41 (ARC41) stimulated Arp2/3protein compex 1 AF006084 subunit p41 (ARC41)) (low match) Arp2/3protein complex 20 AF017807 + + + + subunit p16 (ARC16) Arp2/3 proteincomplex 2 AF006087 + + + + subunit p20 (ARC20) Arp2/3 protein complex 3AF006086 W + + subunit p21(ARC21) ARP3 (actin-related protein 11AF006083 W + + + 3, yeast) homolog (ACTR3) arrestin, beta 2 (ARRB2) 1AF106941 B, T, W + + + arsA (bacterial) arsenite 1 AF047469 B, T + +transporter, ATP-binding, homolog 1 (ASNA1) aryl hydrocarbon receptor 2AF044288 B + + + nuclear translocator-like (ARNTL) aryl hydrocarbonreceptor- 1 U31913 + + + + + interacting protein (AIP) arylsulfatase A(ARSA) 1 X52151 T activated + + asialoglycoprotein receptor 1 M11025 + +2 (ASGR2) asparaginyl-tRNA 3 D84273 + + + synthetase (NARS)aspartyl-tRNA synthetase 1 J05032 B + + + (DARS) ataxia telangiectasia 1U82828 B, T + + mutated (includes complementation groups A, C and D)(ATM) ataxin-2-like protein A2LP 1 AF034373 B, T + + + (A2LG) activatedATF6 1 AF005887 + + ATP binding cassette 1 U88667 transporter (ABCR)(non- exact 80%) ATP synthase (F1-ATPase) 1 X59066 alpha subunit,mitochondrial ATP synthase beta subunit 1 M19482 gene ATP synthase, H+ 1X60221 + + + + + transporting, mitochondrial F0 complex, subunit b,isoform 1 (ATP5F1) ATP synthase, H+ 1 X69907 T activated + + + +transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 1(ATP5G1) ATP synthase, H+ 3 D14710 transporting, mitochondrial F1complex, alpha subunit, isoform 1, cardiac muscle (ATP5A1) ATP synthase,H+ 1 D14710 transporting, mitochondrial F1 complex, alpha subunit,isoform 1, cardiac muscle (ATP5A1) (low match) ATP synthase, H+ 2 M27132transporting, mitochondrial F1 complex, beta polypeptide (ATP5B) ATPsynthase, H+ 1 D16563 W + + + + transporting, mitochondrial F1 complex,gamma polypeptide 1 (ATP5C1) ATP synthase, H+ 1 AF092124 + + + + + +transporting, mitochondrial F1F0, subunit g (ATP5JG) ATP/GTP-bindingprotein 2 U73524 + + + + + (HEAB) ATPase, Ca++ 5 Z69881 + transporting,ubiquitous (ATP2A3) ATPase, H+ transporting, 2 D89052 + + + + +lysosomal (vacuolar proton pump) 21 kD (ATP6F) ATPase, H+ transporting,1 X76228 + + + + lysosomal (vacuolar proton pump) 31 kD (ATP6E) ATPase,H+ transporting, 5 X69151 + + + + lysosomal (vacuolar proton pump) 42kD; Vacuolar proton-ATPase, subunit C; V-ATPase, subunit C (ATP6D)ATPase, H+ transporting, 3 L09235 + + lysosomal (vacuolar proton pump),alpha polypeptide, 70 kD, isoform 1 (ATP6A1) ATPase, H+ transporting, 6X62949 + + + + + lysosomal (vacuolar proton pump), beta polypeptide,56/58 kD, isoform 2 (ATP6B2) ATPase, H+ transporting, 2AF038954 + + + + + high in testis lysosomal (vacuolar proton pump),member J (ATP6J) ATPase, H+ transporting, 1 D16469 + + + + lysosomal(vacuolar proton pump), subunit 1 (ATP6S1) ATP-binding cassette 50 1AF027302 + + + + + (TNF-alpha stimulated) (ABC50) ATP-binding cassette 1AF047690 protein M-ABC1 (mitochondrial) ATP-dependent RNA 1 AJ010840 Tlymphoma + + helicase autoantigen (Hs.75528) 2 L05425 T activated +autoantigen (Hs.75528) 1 L05425 (non-exact 84%) autoantigen (Hs.75682) 1U17474 B + + autoantigen La/SS-B 1 Z35127 axin (AXIN1) 1 AF009674 T +axonemal dynein heavy 1 AJ000522 + chain (DNAH17) BAI1-associatedprotein 3 1 AB017111 (BAIAP3) (non-exact 54%) basement membrane- 1AF044896 induced gene (ICB1) basic leucine zipper 2 U79751 nuclearfactor 1 (JEM-1) (BLZF1) basic transcription factor 3 5X74070 + + + + + + (BTF3) basigin (BSG) 1 L10240 + + BC-2 1 AF042384B + + + B-cell CLL/lymphoma 6 1 U00115 + + (zinc finger protein 51)(BCL6) B-cell translocation gene 1, 1 X61123 + + anti-proliferative(BTG) BCL2/adenovirus E1B 1 U15173 B + + + 19 kD-interacting protein 2(BNIP2) BCL2/adenovirus E1B 2 AF067396 + + + + 19 kD-interacting protein3- like (BNIP3L) beclin 1 (coiled-coil, 1 AF077301 B + + + myosin-likeBCL2- interacting protein) (BECN1) beta-1,2-N- 2 U15128acetylglucosaminyltransferase II (MGAT2) beta-2-microglobulin (B2M) 63S82297 + + + + + + high in invasive prostate tumor beta-hexosaminidasealpha 1 M16411 chain (HEXA) beta-tubulin 7 V00599 + + + + + + high inmany libraries beta-tubulin (non-exact, 1 AF070561 76%) beta-tubulin,pseudogene 1 J00315 BING4 1 Z97184 biotinidase (BTD) (non-eact 1 U0327462%) biotinidase (BTD) (non- 1 U03274 exact 70%) biotinidase (BTD) (non-1 U03274 exact, 56%) BIOTINIDASE 1 P43251 PRECURSOR biphenylhydrolase-like 1 X81372 + + (serine hydrolase) (BPHL) bone marrowstromal cell 1 D21878 + antigen 1 (BST1) box-dependent myc- 1 AF043900interacting protein isoform BIN1-10 (BIN1) box-dependent myc- 1 AF043900interacting protein isoform BIN1-10 (BIN1) (non-exact, 64%) brain my047protein 1 AF063605 T + + + branched chain keto acid 3 Z14093 T + + +dehydrogenase E1, alpha polypeptide (maple syrup urine disease) (BCKDHA)BRCA1 associated protein- 1 D87462 + + + + 1 (ubiquitin carboxy-terminal hydrolase) (BAP1) BRCA1, Rho7 and vatl 1 L78833 genes, andipf35 breakpoint cluster region 2 AF044773 + + protein, uterineleiomyoma, 1; barrier to autointegration factor (BCRP1) breakpointcluster region 2 AF044774 + + + + protein, uterine leiomyoma, 2 (BCRP2)breast cancer anti-estrogen 1 U92715 resistance 3 (BCAR3) (non-exact73%) bromodomain-containing 2 M91585 + protein, 140 kD (peregrin)(BR140) Bruton's 1 U13424 agammaglobulinemia tyrosine kinase (Btk)Bruton's tyrosine kinase 1 U78027 (BTK) Bruton's tyrosine kinase 1U78027 (BTK), alpha-D- galactosidase A (GLA), L44-like ribosomal protein(L44L) and FTP3 (FTP3) BS4 1 AF108083 BTG2 (BTG2) 6 Y09943 + + + + + BTKregion clone ftp 1 U78027 + + + + + BTK region clone ftp-3 1U01923 + + + BUB3 (budding uninhibited 4 AF053304 + + + + + bybenzimidazoles 3, yeast) homolog (BUB3) butyrate response factor 1 4X79067 + + + + + (EGF-response factor 1) (BRF1) butyrophilin (BTF1) 7U90543 + + + butyrophilin like receptor 1 AB020625.1 CAG repeatcontaining 2 U80744 + + (CTG4A) CAGH32 2 U80743 + + + calcium channel,voltage- 1 M83566 dependent, L type, alpha 1D subunit (CACNA1D) (lowmatch) calcium/calmodulin- 1 AF069765 + + + + dependent protein kinase(CaM kinase) II gamma (CAMK2G) calcium/calmodulin- 1 AF101264 B + + +dependent protein kinase kinase (KIAA0787) calmodulin (=M19311) 7 D45887calmodulin 1 6 M27319 B + + + + (phosphorylase kinase, delta) (CALM1)calnexin (CANX) 3 M94859 T + + + calpain, large polypeptide 5X04366 + + + + L1 (CAPN1) calpain, large polypeptide 5 M23254 + + L2(CANP2) calpain, small polypeptide 1 X04106 + + + + (CAPN4) calpastatin(CAST) 3 D16217 + Calponin 2 2 D83735 + + + calponin 2 (CNN2) 1 D83735B, T + + calponin 2 (CNN2) (low 1 D83735 score) calumenin (CALU) 3AF013759 B + + + cAMP response element- 4 L05912 binding protein CRE-Bpa(H_GS165L15.1) cAMP-dependent protein 1 M90360 kinase type II (Ht31)canicular multispecific 1 AF009670 + + + organic anion transporter(CMOAT2) capping protein (actin 6 U56637 B, T + + filament) muscleZ-line, alpha 1 (CAPZA1) capping protein (actin 2 U03269 B + + filament)muscle Z-line, alpha 2 (CAPZA2) capping protein (actin 1U03271 + + + + + filament) muscle Z-line, beta (CAPZB) capping protein(actin 8 M94345 + + + + filament), gelsolin-like (CAPG)carbamoyl-phosphate 1 D78586 + + + + + synthetase 2, aspartatetranscarbamylase, and dihydroorotase (CAD) carbonic anhydrase V, 1L19297 + + mitochondrial (CA5) carboxypeptidase D (CPD) 3 U65090 B + +carnitine/acylcarnitine 1 Y10319 + + + translocase (CACT) Cas-Br-M(murine) 2 X57110 + ecotropic retroviral transforming sequence (cbl)casein kinase 1, alpha 1 1 L37042 + + + + + (CSNK1A1) casein kinase 2,alpha 1 2 M55265 B + + + polypeptide (CSNK2A1) casein kinase I gamma 3L1 AF049090.1 (CSNK1G3L) casein kinase II alpha 1 X69951 subunit(=S72393) CASP8 and FADD-like 4 AF015450 + + + + + apoptosis regulator(CFLAR) caspase 1, apoptosis- 7 U13697 + + related cysteine protease(interleukin 1, beta, convertase) (CASP1) caspase 10, apoptosis- 1U60519 B, T + related cysteine proteas activated, T (CASP10) lymphomacaspase 3, apoptosis- 3 U13737 B, T + + + + related cysteine protease(CASP3) caspase 4, apoptosis- 6 U25804 + + + + + related cysteineprotease (CASP4) caspase 5, apoptosis- 1 U28015 + related cysteineprotease (CASP5) caspase 8, apoptosis- 2 X98173 + + + related cysteineprotease (CASP8) caspase 9, apoptosis- 1 U56390 B + + related cysteineprotease (CASP9) catalase (CAT) 5 X04076 B + + + catechol-O- 1M65213 + + + methyltransferase (COMT) catenin (cadherin- 6 D14705 + +associated protein), alpha 1 (102 kD) (CTNNA1) cathelicidinantimicrobial 1 X89658 B peptide (CAMP) cathepsin B (CTSB) 4L16510 + + + cathepsin C (CTSC) 3 U79415 + + + + cathepsin D (lysosomal4 M11233 + + + aspartyl protease) (CTSD) cathepsin E (CTSE) 1 J05036 +cathepsin G (CTSG) 1 M16117 T, W + cathepsin S (CTSS) 34 M86553 B,Monocyte + + stimulated, T lymphoma cathepsin W (lymphopain) 4AF013611 + (CTSW) CBF1 interacting 1 AF098297 corepressor CIR (=U03644recepin) CCAAT/enhancer binding 3 X87248 + + + + protein (C/EBP), alpha(CEBPA) CCAAT/enhancer binding 1 S63168 + + + protein (C/EBP), delta(CEBPB) CCAAT-box-binding 2 M37197 T lymphoma + + transcription factor(CBF2) CCR5 receptor (CCR5) 1 AF011504 (non-exact?) CD14 antigen (CD14)11 M86511 + + + + + CD18 (=M95293) 4 X64071 CD1C antigen, c 2 M28827 +polypeptide (CD1C) CD2 antigen (cytoplasmic 1 AF104222 tail)-bindingprotein 2 (CD2BP2) CD2 antigen (p50), sheep 4 M14362 + + + + red bloodcell receptor (CD2) CD2 cytoplasmic tail- 2 AF038602 + binding protein 1(CD2BP1) CD20 antigen (CD20) 1 X12530 CD20 receptor (S7) 1 X07203 CD22antigen (CD22) 1 U62631 B CD24 signal transducer 1 M58664 CD33 antigen(gp67) 1 M23197 + (CD33) CD33 antigen-like 2; OB 1 U71383 bindingprotein-2 (CD33L2) (non-exact, 68%) CD33L2 (61% aa) 1 D86359 CD36antigen (collagen 7 M98398 T lymphoma + + + type I receptor,thrombospondin receptor) (CD36) CD37 antigen (CD37) 5 X14046 + + + +CD38 alt 1 D84277 CD39 antigen (CD39) 1 U87967 B + + + CD3D antigen,delta 1 X03934 + + + polypeptide (TiT3 complex) (CD3D) CD3E antigen,epsilon 1 X03884 + + polypeptide (TiT3 complex) (CD3E) CD3G antigen,gamma 2 X06026 W + polypeptide (TiT3 complex) (CD3G) CD3Z antigen, zeta2 J04132 + + polypeptide (TiT3 complex) (CD3Z) CD3-zeta (clone pBS NK1)1 X55510 CD4 (low match) 1 S68043 CD4 antigen (p55) (CD4) 4 M12807 + + +CD44 antigen (homing 6 X56794 W + + function and Indian blood groupsystem (CD44) CD48 antigen (B-cell 3 X06341 + + + + + membrane protein)(CD48) CD53 antigen (CD53) 10 L11670 + + + + CD53 antigen (CD53) (low 1M60871 match) CD63 antigen (melanoma 1 3 M59907 antigen) (CD63) CD68antigen (CD68) 2 S57235 + + + + CD74 antigen (invariant 72K01144 + + + + + + high in many libraries polypeptide of majorhistocompatibility complex, class II antigen-associated) (CD74) CD79Aantigen 2 M80462 + (immunoglobulin- associated alpha) (CD79A) CD79Bantigen 2 M89957 + (immunoglobulin- associated beta) (CD79B) CD8antigen, alpha 2 M27161 + + + polypeptide (p32) (CD8A) CD8 antigen, beta1 X13445 W polypeptide 1 (p37) (CD8B1) CD81 antigen (target of 1M33680 + + + antiproliferative antibody 1 (CD81) CD83 antigen (activatedB 1 Q01151 B + + + lymphocytes, mmunoglobulin superfamily) (CD83) CD84antigen (leukocyte 1 U82988 + + + antigen) (CD84) CD86 antigen 1L25259 + CD9 antigen (p24) (CD9) 2 M38690 + + + CD97 antigen (CD97) 12X84700 + + + CD97 antigen (CD97) 1 P48960 (noin-exact 59%) CD97 antigen(CD97) (non- 1 X94630 + + + exact 62%) CDC23 (cell division cycle 1AF053977 + + + 23, yeast, homolog) (CDC23) CDC37 homolog 1 U63131B + + + + Cdc42 effector protein 3 2 AF104857 B + + + (CEP3) CDC-likekinase (CLK) 1 L29219 + + + + CDC-like kinase 2 (CLK2) 1 AF023268 B + +CDW52 antigen 13 X15183 T activated + + + (CAMPATH-1 antigen) (CDW52)cell cycle progression 1 AF011794 restoration 8 protein(CPR8) celldivision cycle 10 4 S72008 + + + + + (homologous to CDC10 of S.cerevisiae) (CDC10) cell division cycle 20, 1 U05340 + + + S. cerevisiaehomolog (CDC20) cell division cycle 25B 6 Z68092 + + + + + (CDC25B) celldivision cycle 2-like 1 1 AF067514 (PITSLRE proteins) (CDC2L1)(non-exact 42%) cell division cycle 42 (GTP- 5 M35543 + + + + + bindingprotein, 25 kD) (CDC42) cell division protein (non- 1 AF063015 exact68%) CELL-CYCLE NUCLEAR 1 Q13033 AUTOANTIGEN SG2NA (S/G2 NUCLEARANTIGEN) centromere protein B 1 X55039 + + (80 kD) (CENPB) cep250centrosome 3 AF022655 B + + associated protein ceroid-lipofuscinosis, 7AF017456 + + + + + + high in bone neuronal 2, late infantile(Jansky-Bielschowsky disease) (CLN2) c-fgr (=M63877 6 X52206 nonreceptorprotein- tyrosine kinase (fgr)) CGI-19 protein 3 AF132953.1 chaperonincontaining 1 X74801 + + + TCP1, subunit 3 (gamma) (CCT3) chaperonincontaining 1 AF026291 + + + + TCP1, subunit 4 (delta) (CCT4) chaperonincontaining 4 L27706 B + + TCP1, subunit 6A (zeta 1) (CCT6A) chaperonincontaining 4 AF026292 B + + TCP1, subunit 7 (eta) (CCT7) Chediak-Higashisyndrome 1 U67615 B, T + + + 1 (CHS1) lymphoma Chediak-Higashi syndrome1 U67615 1 (CHS1) (low score) chemokine (C-C motif) 4 U03905 receptor 2(CCR2) chemokine (C-C motif) 1 X85740 receptor 4 (CCR4) (low match) (maycontain repeat) chemokine (C-C motif) 6 L31581 receptor 7 (CCR7)chemokine (C—X3—C) 5 U20350 + receptor 1 (CX3CR1) chemokine (C—X—Cmotif), 5 M99293 + + + + + receptor 4 (fusin) (CXCR4) chitinase 3-like 1(cartilage 2 M80927 + + + glycoprotein-39) (CHI3L1) chitinase 3-like 2(CHI3L2) 2 U49835 + + + chloride channel 1, 1 G18280 skeletal muscle(CLCN1) chloride channel 6 1 D28475 + + (CLCN6) Chloride intracellular 1U93205 + + + + + channel 1 (CLIC1) chondroitin sulfate 5 X15998 +proteoglycan 2 (versican) (CSPG2) chondroitin sulfate 2 J02814 + +proteoglycan core protein chromatin assembly factor 1 Q09028 1 p48subunit (CAF-1 P48 subunit) (retinoblastoma binding protein p48)(retinoblastoma-binding protein 4) (MSI1 protein homolog) chromodomainhelicase 2 AF006513 DNA binding protein 1 (CHD1) chromodomain helicase 1AF054177 DNA binding protein 1-like (CHD1L) chromodomain helicase 1AF006514 B + + + DNA binding protein 2 (CHD2) chromodomain helicase 1AF006515 DNA binding protein 3 (CHD3) chromodomain helicase 5X86691 + + + + + DNA binding protein 4 (CHD4) chromosome 1 open 1AF054176 reading frame 7 (C1ORF7) chromosome 1 specific 1 AB007962transcript KIAA0493 chromosome 17 open 1 AJ008112 T + reading frame 1B(C17ORF1B) chromosome 4 open 1 AF006621 + + + + reading frame 1 (C4ORF1)chromosome condensation 2 AF060219 + + + + 1-like (CHC1L) chromosome Xopen 1 Y15164 B + + + reading frame 5 (CXORF5) chromosome-associated 2AF092564 B + + + + polypeptide C (CAP-C) cig42 1 AF026944 cig5 3AF026941 citrate synthase (CS) 2 AF047042 B + + + + class I major 2U31372 histocompatibility antigen (HLA-Cw3) class I major 1 U31372histocompatibility antigen (HLA-Cw3) (low match) clathrin assemblyprotein 3 U45976 B + + + lymphoid myeloid leukemia (CALM) clathrin heavychain 1 X55878 clathrin, heavy polypeptide- 1 D21260 like 2 (CLTCL2)clathrin, light polypeptide 1 M20472 (Lca) (CLTA) (low match) clathrin-3 D63475 + + + + + associated/assembly/adaptor protein, medium 1(CLAPM1) cleavage stimulation factor, 1 M85085 3′ pre-RNA, subunit 2 64kD (CSTF2) (non-exact 82%) cleavage stimulation factor, 1 U15782 B + + +3′ pre-RNA, subunit 3, 77 kD (CSTF3) clk3 1 L29220 B + + clone 23815(Hs.82845) 1 U90916 + + + clone 24592 mRNA 1 D88378 + + + + + sequenceClq/MBL/SPA receptor 1 U94333 C1qR(p) ( ) clusterin (complement lysis 1M64722 + + + + + + inhibitor, SP-40,40, sulfated glycoprotein 2,testosterone-repressed prostate message 2, apolipoprotein J) (CLU)CMP-sialic acid transporter 1 D87969 B + + (CMPST) CMRF35 3 X66171 c-myconcogene containing 1 X54629 coxIII coagulation factor II 1 M62424 + + +(thrombin) receptor (F2R) coagulation factor V 1 M14335 + + +(proaccelerin, labile factor) (F5) coagulation factor XIII a 3 M21998subunit coagulation factor XIII, A1 6 M14354 + + + + polypeptide (F13A1)coated vesicle membrane 1 X92098 + + + + + + protein (RNP24) coatomerprotein complex, 5 U24105 T + + subunit alpha (COPA) Cofilin 1(non-muscle) 13 X95404 + + + + + + high in fetal brain (CFL1) coldinducible RNA-binding 7 D78134 + + + protein (CIRBP) cold shock domainprotein 3 X95325 + + A (CSDA) collagen, type IX, alpha 2 3 AF019406 B(COL9A2) colony stimulating factor 1 3 X03663 + + + receptor, formerlyMcDonough feline sarcoma viral (v-fms) oncogene homolog (CSF1R) colonystimulating factor 2 5 M59941 receptor, beta, low-affinity(granulocyte-macrophage) (CSF2RB) colony stimulating factor 2 1 M59941receptor, beta, low-affinity (granulocyte-macrophage) (CSF2RB) (lowmatch) colony stimulating factor 3 16 X55720 + receptor (granulocyte)(CSF3R) complement component 5 1 M62505 L receptor 1 (C5a ligand) (C5R1)conserved gene amplified 2 AF000152 + + + + in osteosarcoma (OS4) COP9(constitutive 2 AF031647 + + + photomorphogenic, Arabidopsis, homolog)subunit 3 (COPS3) COP9 homolog (HCOP9) 2 U51205 B + + + + + COPIIprotein, homolog of 4 X97064 + + s. cerevisiae SEC23p (SEC23A) copine I(CPNE1) 2 U83246 B + + + copine I (CPNE1) (low 1 U83246 score)coproporphyrinogen 1 D16611 + + + oxidase (coproporphyria,harderoporphyria) (CPO) core-binding factor, beta 1 L20298 + subunit(CBFB) coronin 22 X89109 T, W + + + coronin (low match) 1 U34690 coronin(non-exact, 71%) 1 X89109 cot (cancer Osaka thyroid) 1 D14497 + + + + +oncogene (COT) cryptochrome 1 1 D84657 + + + (photolyase-like) (CRY1)CTD (carboxy-terminal 1 AF081287 + + + + domain, RNA polymerase II,polypeptide A) phosphatase, subunit 1 (CTDP1) C-terminal binding protein1 U37408 B + + + 1 (CTBP1) C-terminal binding protein 2 AF016507 + + + 2(CTBP2) CUG triplet repeat, RNA- 3 U63289 + + + + binding protein 1(CUGBP1) cullin 1 (CUL1) 3 U58087 + + + + cullin 3 (CUL3) 2U58089 + + + + cut (Drosophila)-like 1 1 M74099 B + (CCAAT displacementprotein) (CUTL1) cyclin D2 (CCND2) 2 D13639 + + + + cyclin D3 (CCND3) 5M92287 B, T + + lymphoma cyclin G1 (CNNG1) 1 D78341 B + + + cyclin I 3D50310 B + + cyclin T2 (CNNT2) 1 AF048732 B, T B lymphomacyclin-dependent kinase 2 1 X62071 (CDK2) cyclin-dependent kinase 1S76986 inhibitor (p27Kip1) cyclin-dependent kinase 2 S67388 + + + + + +inhibitor 1A (p21, Cip1) (CDKN1A) CYP2D7-CYP2D6 1 X90926 intergenicregion (partial) cystatin B (stefin B) (CSTB) 1 L03558 + + + cysteineand glycine-rich 5 L54057 + protein 3 (cardiac LIM protein) (CSRP3)cytidine deaminase (CDA) 2 L27943 + cytochrome b 1 AF042500 cytochrome b(CYTB) 1 AF042518 (isolate Aus5) cytochrome b(-245) beta 2 X05895 chainN-terminal region (X- linked granulomatous disease gene) cytochromeb-245, beta 2 X04011 + + + polypeptide (chronic granulomatous disease)(CYBB) cytochrome C 1 P00001 cytochrome c oxidase 1 U90915 T + + + +subunit IV (COX4) cytochrome c oxidase 2 M59250 + subunit Vb (COX5B)cytochrome c oxidase 6 AB007618 + + + + + subunit VII-related protein(COX7RP) cytokine suppressive anti- 1 L35263 lymphocyte + + +inflammatory drug binding protein 1 (p38 MAP kinase) (CSBP1) Cytoplasmic1 S69272 + antiproteinase = 38 kda intracellular serine proteinaseinhibitor cytotoxic granule- 1 S70114 associated RNA-binding proteinp40-TIA-1 D123 (D123) 1 D14878 + + + + D2-2 1 AF019226 D38 1 X74802damage-specific DNA 2 AJ002955 + + + + + + binding protein 1 (127 kD)(DDB1) DCHT (low match) 1 AF017635 DEAD/H (Asp-Glu-Ala- 1U78524 + + + + + Asp/His) box binding protein 1 (DDXBP1) DEAD/H(Asp-Glu-Ala- 2 U59321 T + + + + Asp/His) box polypeptide (72 KD) (P72)DEAD/H (Asp-Glu-Ala- 1 X70649 + + + Asp/His) box polypeptide 1 (DDX1)DEAD/H (Asp-Glu-Ala- 2 AB001636 Asp/His) box polypeptide 15 (DDX15)DEAD/H (Asp-Glu-Ala- 2 AB011149 + + + + + Asp/His) box polypeptide 16(DDX16) DEAD/H (Asp-Glu-Ala- 3 U50553 + + + + + Asp/His) box polypeptide3 (DDX3) DEAD/H (Asp-Glu-Ala- 37 X15729 + + + + + Asp/His) boxpolypeptide 5 (RNA helicase, 68 kD) (DDX5) DEAD/H (Asp-Glu-Ala- 1AF015812 Asp/His) box polypeptide 5 (RNA helicase, 68 kD) (DDX5) (lowmatch) DEAD/H (Asp-Glu-Ala- 2 D17532 + + Asp/His) box polypeptide 6 (RNAhelicase, 54 kD) (DDX6) DEAD/H (Asp-Glu-Ala- 1 D50487 + + + + Asp/His)box polypeptide 8 (RNA helicase, 54 kD) (DDX8) DEAD/H (Asp-Glu-Ala- 3L13848 + + + + + Asp/His) box polypeptide 9 (RNA helicase A, nuclear DNAhelicase II; leukophysin) (DDX9) DEAD/H (Asp-Glu-Ala- 1 AF000985 + + +Asp/His) box polypeptide, Y chromosome (DBY) Death associated protein 32 X83544 + + + + + + (DAP3) death effector domain- 1 AF083236 + + + +containing protein (DEDD) death-associated protein 6 2 AF039136 + + + +(DAXX) dedicator of cyto-kinesis 2 4 D86964 + + + + (DOCK2) defenderagainst cell death 1 D15057 + + + 1 (DAD1) Defensin, alpha 1, myeloid- 4L12690 + + + related sequence (DEFA1) DEK gene (D6S231E) 1 X64229 B + +delta sleep inducing 4 Z50781 + + + + + peptide, immunoreactor (DSIPI)dendritic cell protein 3 AF064603 + + + + + (GA17) deoxycytidine kinase(DCK) 1 M60527 deoxyribonuclease II, 3 AB004574 lysosomal (DNASE2) DGS-I2 L77566 + diacylglycerol kinase 3 D16440 diacylglycerol kinase alpha 3AF064771 + (DAGK1) (clone 24) diacylglycerol kinase alpha 1 AF064771(DAGK1) (clone 24) (low match) diaphanous (Drosophila, 1 AF051782 B,monocyte + + + + homolog) 1 (DIAPH1) stimulated diaphorase (NADH) 1Y09501 + + + + + + (cytochrome b-5 reductase) (DIA1) differentiatedEmbryo 1 AB004066 + + + Chondrocyte expressed gene 1 (DEC1)differentiated Embryo 1 AB004066 Chondrocyte expressed gene 1 (DEC1)(low match) differentiation antigen 1 L23415 CD20 DiGeorge syndromecritical 1 X84076 + + + region gene 2 (DGCR2) dihydrolipoamide 2J03620 + + + dehydrogenase (E3 component of pyruvate dehydrogenasecomplex, 2-oxo-glutarate complex, branched chain keto acid dehydrogenasecomplex) (DLD) dihydrolipoamide S- 1 Y00978 B + + acetyltransferase (E2component of pyruvate dehydrogenase complex) (DLAT)dihydropyrimidinase-like 2 1 D78013 + + + + (DPYSL2) dinG gene 1 Y10571diptheria toxin resistance 3 AF053003 B + + + + protein required fordiphthamide biosynthesis (Saccharomyces)-like 2 (DPH2L2)disintegrin-protease (non- 1 Y13323 exact 72%) DJ-1 protein 2AF021819 + + + + + Dmx-like 1 (DMXL1) 1 AJ005821 + + + DNA(cytosine-5-)- 3 X63692 T activated, + + + methyltransferase 1 lymphoma(DNMT1) DNA fragmentation factor, 1 AF064019 40 kD, beta subunit (DFFB)DNA fragmentation factor, 2 U91985 T + + + 45 kD, alpha subunit (DFFA)DNA mismatch repair 1 U17840 protein (hMLH1) DNA segment on 3M64241 + + + + + + high in many libraries chromosome X (unique) 648expressed sequence DNA segment, single copy 3 M73547 + + + + probeLNS-CAI/LNS-CAII (deleted in polyposis (D5S346) DNA-damage-inducible 1L24498 transcript 1 (DDIT1) (low match) DnaJ protein 1 AJ001309 DnaJprotein 1 AJ001309 docking protein 2, 56 kD 1 AF034970 (DOK2) dolichyl-1 D89060 + + + + + + activated T cell diphosphooligosaccharide- proteinglycosyltransferase (DDOST) dolichyl-phosphate 1 D86198 Tactivated + + + mannosyltransferase polypeptide 1, catalytic subunit(DPM1) down-regulated by 1 AJ223183 + activation (immunoglobulinsuperfamily) (DORA) down-regulated in 1 P40879 adenoma DRA (low match)D-type cyclin-interacting 1 AF082569 B + + protein 1 (DIP1) dualspecificity 4 X68277 + + + + + + phosphatase 1 (DUSP1) dual specificity1 AF023917 + + + + + phosphatase 11 (RNA/RNP complex 1-interacting)(dusp11) dual specificity 1 L05147 + + + + phosphatase 3 (vaccinia virusphosphatase VH1- related) (DUSP3) dual specificity 6 X93920 + + + + + +phosphatase 6 (DUSP6) dynactin 1 (p150, Glued 3 X98801 (Drosophila)homolog) (DYTN1) dynactin 1 (p150, Glued 1 X98801 B + + (Drosophila)homolog) (DYTN1) (low match) dynamin 2 (DNM2) 1 L36983 dynamitin(dynactin 1 U50733 complex 50 kD subunit) (DCTN-50) (non-exact 88%)dynein, axonemal, heavy 1 X99947 polypeptide 17-like (non- exact, 57%aa) dynein, cytoplasmic, light 1 AF035812 B + + + intermediatepolypeptide 2 (DNCLI2) dynein, cytoplasmic, light 1 AF035812intermediate polypeptide 2 (DNCLI2) (non-exact, 69%) dyskeratosiscongenita 1, 1 U59151 B + + + dyskerin (DKC1) dystonia 1, torsion 1AF007871 + + + + (autosomal dominant) (DYT1) dystrobrevin, beta (DTNB) 1AF022728 + dystrophia myotonica- 1 L19267 + + + + containing WD repeatmotif (DMWD) dystrophia myotonica- 1 L08835 + + + + protein kinase(DMPK) dystrophin (muscular 1 X14298 dystrophy, Duchenne and Beckertypes) (DMD) (low match, 59% aa) E1B-55 kDa-associated 1 AJ007509W + + + + protein E2F transcription factor 3 2 D38550 + + + + + (E2F3)E2F transcription factor 4, 1 X86096 B + + p107/p130-binding (E2F4) E2Ftranscription factor 5, 2 U15642 + + + + p130-binding (E2F5) E74-likefactor 1 (ets 1 M82882 B + + + domain transcription factor) (ELF1)E74-like factor 4 (ets 3 U32645 + + + domain transcription factor)(ELF4) E74-like factor 4 (ets 1 U32645 domain transcription factor)(ELF4) (non-exact, 71%) early development 4 U89278 + + + + + regulator 2(homolog of polyhomeotic 2) (EDR2) EBV induced G-protein 1 L08177 Wcoupled receptor (EBI2) ecotropic viral integration 3 M60830 + + site 2B(EVI2B) ectin, galactoside-binding, 1 J04456 + soluble, 1 (galectin 1)(LGALS1) EGF-like-domain, multiple 1 AB011541 4 (EGFL4) elF-2-associatedp67 3 U13261 B + + homolog elastin (supravalvular aortic 1 M24782 + +stenosis, Williams-Beuren syndrome) (ELN) (low match) elav-typeRNA-binding 3 U69546 protein (ETR-3) electron-transfer- 2 J04058 +flavoprotein, alpha polypeptide (glutaric aciduria II) (ETFA) ELK3,ETS-domain protein 2 Z36715 + + (SRF accessory protein 2) (ELK3)elongation factor 1-beta 1 L26404 elongation factor Ts 1 AF110399(mitochondrial protein) elongation factor Tu- 1 X84694 nuclear encodedmitochondrial eMDC II protein 1 AJ242015.1 ems1 sequence (mammary 1M98343 + + + + tumor and squamous cell carcinoma-associated (p80/85 srcsubstrate) (EMS1) endogenous retroviral 1 Z70664 element HC2 endosulfinealpha (ENSA) 1 X99906 T + endothelial differentiation, 2 M31210 + + + +sphingolipid G-protein- coupled receptor, 1 (EDG1) endothelialdifferentiation, 1 M31210 sphingolipid G-protein- coupled receptor, 1(EDG1) (low match 66%) endothelial monocyte- 1 U10117 + + + + +activating polypeptide (EMAPII) enolase 1, (alpha) (ENO1) 12M14328 + + + + + + enolase 2, (gamma, 1 X51956 + neuronal) (ENO2)enolase-alpha 1 D28437 enoyl Coenzyme A 2 U16660 hydratase 1,peroxisomal (ECH1) enoyl Coenzyme A 1 D13900 + + + + + + hydratase,short chain, 1, mitochondrial (ECHS1) ENOYL-COA 1 P30084 HYDRATASE,MITOCHONDRIAL PRECURSOR (SHORT CHAIN ENOYL-COA HYDRATASE) (SCEH)(ENOYL-COA HYDRATASE 1) (low match, non-exact 56%) epidermal growthfactor 2 U07707 + + + receptor pathway substrate 15 (EPS15) EPIDIDYMAL 2Q15668 SECRETORY PROTEIN E1 PRECURSOR (EPI-1) (HE1) (EPIDIDYMALSECRETORY PROTEIN 14.6) (ESP14.6) epithelial membrane 1 U87947 + + + + +Protein 3 (EM[P3) Epoxide hydrolase 1, 1 L29766 + microsomal(xenobiotic) only (EPHX1) ERCC2 (=L47234) 1 X52221 ERF-2 3U07802 + + + + + high in gall bladder ERp28 protein 1 X94910 + + + + +erythrocyte membrane 2 M81635 protein erythroleukemic cells K562 2L25343 EST (Hs.189509) 2 U24166 estrogen receptor-related 1 L38487protein (hERRa1) ESTs, Highly similar to 1 X66503 B, T + +ADENYLOSUCCINATE SYNTHETASE ESTs, Moderately similar to 1U28811 + + + + + cysteine-rich fibroblast growth factor receptor ETbinding factor 1 (SBF1) 1 U93181 + + + ets domain protein ERF 1U15655 + + + + + eukaryotic translation 326 X03558 T + + + elongationfactor 1 alpha 1 (EEF1A1) eukaryotic translation 1 X03558 elongationfactor 1 alpha 1 (EEF1A1) (low match) eukaryotic translation 1 X03558elongation factor 1 alpha 1 (EEF1A1) (low match) eukaryotic translation5 X60489 + + + + + elongation factor 1 beta 2 (EEF1B2) eukaryotictranslation 1 Z21507 + + + + + + elongation factor 1 delta (guaninenucleotide exchange protein) (EEF1D) eukaryotic translation 31 Z11531elongation factor 1 gamma (EEF1G) eukaryotic translation 2 X51466 + +elongation factor 2 (EEF2) eukaryotic translation 1 J02645 initiationfactor 2, subunit 1 (alpha, 35 kD) (EIF2S1) eukaryotic translation 1M29536 initiation factor 2, subunit 2 (beta, 38 kD) (EIF2S2) eukaryotictranslation 3 L19161 + + initiation factor 2, subunit 3 (gamma, 52 kD)(EIF2S3) eukaryotic translation 2 U78311 initiation factor 3, subunit 10(theta, 150/170 kD) (EIF3S10) eukaryotic translation 3U36764 + + + + + + high in white blood initiation factor 3, subunit 2cells (beta, 36 kD) (EIF3S2) eukaryotic translation 6 U54559 + + + + +high in spleen initiation factor 3, subunit 3 (gamma, 40 kD) (EIF3S3)eukaryotic translation 9 AF020833 + + + + initiation factor 3, subunit 4(delta, 44 kD) (EIF3S4) eukaryotic translation 4 U94175 + + + + + highin bladder initiation factor 3, subunit 6 (48 kD) (EIF3S6) eukaryotictranslation 1 U62962 + + + + Highly represented initiation factor 3,subunit 6 (1.4833 pct) in library (EIF3S6) 36 human gall bladdereukaryotic translation 3 U54558 + + + + + initiation factor 3, subunit 7(zeta, 66/67 kD) (EIF3S7) eukaryotic translation 5 U46025 + + + + + +high in testis initiation factor 3, subunit 8, 110 KD (EIF3S8)eukaryotic translation 1 AF012088 initiation factor 4 gamma, 1 (EIF4G)eukaryotic translation 1 AF012088 initiation factor 4 gamma, 1 (EIF4G)(low match) eukaryotic translation 2 D12686 initiation factor 4 gamma, 1(EIF4G1) eukaryotic translation 6 U73824 + + + + + + initiation factor 4gamma, 2 (EIF4G2) eukaryotic translation 2 U76111 + + + + + + initiationfactor 4 gamma, 2 (EIFG2) eukaryotic translation 29 D13748 initiationfactor 4A, isoform 1 (EIF4A1) eukaryotic translation 11D30655 + + + + + + initiation factor 4A, isoform 2 (EIF4A2) eukaryotictranslation 18 X55733 + + + + + initiation factor 4B (EIF4B) eukaryotictranslation 1 P06730 initiation factor 4E (EIF4E) Eukaryotic translation3 L36056 T, B + + + initiation factor 4E binding protein 2 (EIF4EBP2)eukaryotic translation 2 Q15056 initiation factor 4H (EIF4H) eukaryotictranslation 2 U49436 + + + + + + initiation factor 5 (EIF5) eukaryotictranslation 2 U90176 + + + + + termination factor 1 (ETF1) EV12 protein1 M55266 + Ewing sarcoma breakpoint 1 X66899 + + + + + region 1 (EWSR1)EWS/FLI1 activated 2 AF020264 transcript 2 homolog (EAT- 2) EWS-E1A-Fchimeric 1 U35622 protein excision repair cross- 1 M28650 + + + + +complementing rodent repair deficiency, complementation group 1(includes overlapping antisense sequence) (ERCC1) excision repair cross-1 X69978 + + + + complementing rodent repair deficiency, complementationgroup 5 (xeroderma pigmentosum, complementation group G (Cockaynesyndrome)) (ERCC5) exostoses (multiple)-like 3 1 AF001690 + + + +(EXTL3) F11 1 X77744 + F1-ATPase beta subunit 2 X03559 (F-1 beta)Fanconi anaemia group A 2 Z83095 Fanconi anemia, 1 X99226 + + + +complementation group A (FANCA) far upstream element 2 U05040 + + +(FUSE) binding protein 1 (FUBP1) farnesyl diphosphate 1 J05262 + + + + +synthase (farnesyl pyrophosphate synthetase,dimethylallyltranstransferase, geranyltranstransferase) (FDPS)farnesyl-diphosphate 2 X69141 + + + + + + farnesyltransferase 1 (FDFT1)farnesyltransferase, CAAX 2 L00635 + + box, beta (FNTB) Fas ligand (geneand 1 AF044583 promoter region) Fas-ligand associated 1 U70667 factor 1fatty-acid-Coenzyme A 4 D10040 + + + + + + ligase, long-chain 1 (FACL1)Fc fragment of IgA, 1 X54150 receptor for (FCAR) Fc fragment of IgE,high 1 M33195 + + + + + affinity I, receptor for; gamma polypeptide(FCER1G) Fc fragment of IgE, low 2 X04772 + + affinity II, receptor for(CD23A) (FCER2) Fc fragment of IgG, low 6 M31932 + + + + + + affinityIIa, receptor for (CD32) Fc fragment of IgG, low 1 X62572 + + + + + +affinity IIa, receptor for (CD32) (FCGR2A) Fc fragment of IgG, low 34X07934 + + + + + affinity IIIa, receptor for (CD16) (FCGR3A) Fc fragmentof IgG, 3 U12255 + + + + + high in many libraries receptor, transporter,alpha (FCGRT) fc-fgr 1 Z13983 Fc-gamma-receptorIIIB 2 M90746 (FCGR3B)feline sarcoma (Snyder- 3 X06292 Theilen) viral (v- fes)/Fujinami aviansarcoma (PRCII) viral (v- fps) oncogene homolog(FES) c-fes/fps) femalesterile homeotic- 2 X96670 + + + + + related gene 1 (mouse homolog)(FSRG1) ferritin L-chain 9 Y09188 ferritin, heavy polypeptide 1 4M11146 + + + + + + (FTH1) fertilin alpha pseudogene 1 Y09232 fetalAlzheimer antigen 2 U05237 + (FALZ) fetal Ig heavy chain 1 M34024variable region fibrillarin (FBL) 1 X56597 + + + + + + fibrinogen-likeprotein 2 3 Z36531 + (T49) fibroblast growth factor 1 M35718 + + + + + +receptor 2 (bacteria- expressed kinase, keratinocyte growth factorreceptor, craniofacial dysostosis 1, Crouzon syndrome) syndrome,Pfeiffer syndrome, Jackson-Weiss) (FGFR2) ficolin (collagen/fibrinogen19 D83920 + + domain-containing) 1 (FCN1) filamin A, alpha (actin- 2X53416 binding protein-280) (FLNA) filamin B, beta (actin- 1AF043045 + + + binding protein-278) (FLNB) Finkel-Biskis-Reilly murine 2X65923 + + + + + + Highly represented in sarcoma virus (FBR-MuSV)intraepithelial ubiquitously expressed (fox neoplasia and derived);ribosomal protein invasive prostate S30 (FAU) tumor FK-506 bindingprotein 1 M80199 + + + + + FK506-binding protein 1A 2 M34539 (12 kD)(FKBP1A) FK506-binding protein 1B 1 M92423 + + + (12.6 kD) (FKBP1B)FK506-binding protein 5 4 U71321 + + + + (FKBP5) Flightless I(Drosophila) 3 U80184 + homolog (FLII) Flightless I (Drosophila) 1U80184 homolog (FLII) (low match) FLN29 (FLN29) 2 AB007447 + + +flotillin 2 (FLOT2) 5 M60922 + + + + + + folate receptor 2 (fetal) 1AF000380 + + + + (FOLR2) forkhead (Drosophila) 1 AF032886 + + + +homolog (rhabdomyosarcoma) like 1 (FKHRL1) Formyl peptide receptor 1 9M60627 + + + + + (FPR1) formyl peptide receptor-like 1 M84562 Found onlyin 1 (FPRL1) libraries from placenta formyl peptide receptor-like 1M84562 1 (FPRL1) (low score) fragile X mental retardation 1L29074 + + + + 1 (FMR1) fragile X mental 1 U25165 + + + + retardation,autosomal homolog 1 (FXR1) Friend leukemia virus 3 M93255 + +integration 1 (FLI1) fructose-bisphosphatase 1 1 D26054 + + (FBP1)FSHD-associated repeat 1 U85056 DNA, proximal region fucose-1-phosphate1 AF017445 + + + guanylyltransferase (FPGT) full length insert cDNA 1AF086122 clone ZA78A09 full length insert cDNA 1 AF075061 YP07G10fumarate hydratase (FH) 1 U59309 + + + + FUS (low match) 1 X99006FYN-binding protein (FYB- 16 U93049 + + 120/130) (FYB) G alphainteracting protein 1 X91809 (GAIP) (low score) G protein betasubunit-like 2 D28398 protein 12.3 G protein-coupled receptor 1 X81892 +64 (HE6) (non-exact 59%) G protein-coupled receptor 2 L16862 + + + +kinase 6 (GPRK6) G1 to S phase transition 1 2 X17644 + + + + + (GSPT1)GA-binding protein 1 D13316 + + + + + transcription factor, beta subunit2 (47 kD) (GABPB2) galactose-1-phosphate 2 M60091 uridylyltransferase(GALT) galactosidase, beta 1 3 M27508 + + + (GLB1) galactosyltransferase1 M13701 (=X13223 N- acetylglucosamide-(beta 1-4)-galactosyltransferase) galectin-9 isoform 1 AB006782 + + +gamma2-adaptin (G2AD) 1 AF068706 + + + + gamma-actin 2 M37130gamma-aminobutyric acid 2 AJ012187 + + + (GABA) B receptor 1 (GABBR1)GATA-binding protein 2 1 M68891 + + (GATA2) GATA-binding protein 3 1M69106 + + + (GATA3) GCN5 (general control of 3 D64007 + + + + +amino-acid synthesis, yeast, homolog)-like 1 (GCN5L1) GDP dissociationinhibitor 1 D45021 + + + + + high in adult brain 1 (GDI1) GDPdissociation inhibitor 4 Y13286 2 (GCI2) GDS-related protein 4U68142 + + + + + (HKE1.5) gelsolin (amyloidosis, 3 X04412 + + + + +Finnish type) (GSN) general transcription factor 4 Y14946 + + + + + +II, I (GTF2I) general transcription factor 1 AF038968 + + + + + + highin fetal brain II, i, pseudogene 1 (GTF2IP1) general transcriptionfactor 4 X64037 + + + + + IIF, polypeptide 1 (74 kD subunit) (GTF2F1)general transcription factor 2 Z30093 B, T IIH, polypeptide 3 (34 kDsubunit) (GTF2H3) general transcription factor 3 Y07595 + + + IIH,polypeptide 4 (52 kD subunit) (GTF2H4) general transcription factor 1U14134 + + + + IIIA (GTF3A) general transcription factor 1 U02619 + +IIIC, polypeptide 1 (alpha subunit, 220 kD) (GTF3C1) generaltranscription factor 3 D13636 + + + + + + IIIC, polypeptide 2 (betasubunit, 110 kD) (GTF3C2) germline immunoglobulin 1 L06612 heavy chain(IGHV@) germline immunoglobulin 1 X92236 heavy chain, variabl regiongermline immunoglobulin 1 X92343 heavy chain, variable region, (21-2)GLE1 (yeast homolog)-like, 1 AF058922 + + RNA export mediator (GLE1L)glia maturation factor, beta 1 AB001106 + + + + (GMFB) glioma-associated1 X07384 oncogene homolog (zinc finger protein) (GLI) glioma-associated1 X07384 oncogene homolog (zinc finger protein) (GLI) (low score)globin, alpha 2 1 V00516 glucocorticoid receptor 1 M32284 (=M69104)glucocorticoid receptor 2 U80947 + + + + + (GRL) glucos phosphate 1L09105 isomerase (CONTAINS LARGE REPEAT) glucosamine (N-acetyl)-6- 1Z12173 + sulfatase (Sanfilippo disease IIID) (GNS) glucosamine(N-acetyl)-6- 1 Z12173 sulfatase (Sanfilippo disease IIID) (GNS) (non-exact 56%) glucose transporter-like 1 M20681 + + + + + protein-III(GLUT3) glucose transporter-like 1 M20681 protein-III (GLUT3) (lowmatch) glucosidase, alpha; acid 1 Y00839 + + + + (Pompe disease,glycogen storage disease type II) (GAA) glucosidase, beta; acid 1K02920 + + + + + (includes glucosylceramidase) (GBA) glutamatedehydrogenase 1 M20867 + + + + + 1 (GLUD1) glutamate-ammonia ligase 12X59834 + + + + + (glutamine synthase) (GLUL) glutamate-ammonia ligase 1Y00387 (glutamine synthase) (GLUL) (low score) glutamate-cysteine ligase1 M90656 + (gamma-glutamylcysteine synthetase), catalytic (72.8 kD)(GLCLC) glutamine cyclotransferase 1 X71125 + + glutamine-fructose-6- 1M90516 + + phosphate transaminase 1 (GFPT1) glutaminyl-tRNA 1 X72396synthetase glutaminyl-tRNA 6 X76013 + + + + + synthetase (QARS)glutamyl-prolyl-tRNA 1 X54326 synthetase (EPRS) glutathione peroxidase 12 M21304 + + + + + + (GPX1) glutathione peroxidase 4 1 X71973 + + + + +(phospholipid hydroperoxidase) (GPX4) glutathione S-transferase pi 1U30897 + + + + + (GSTP1) glutathione S-transferase 1 AF070657 subunit 13homolog glyceraldehyde-3- 12 J02642 + phosphate dehydrogenase (GAPD)glycogenin (GYG) 1 U31525 + + + + glycophorin C (Gerbich 1X12496 + + + + blood group) (GYPC) glycoprotein M6B (GPM6B) 1 U45955 + +glycyl-tRNA synthetase 1 U09587 + + + + (GARS) glyoxalase I (lactoyl 1L07837 + + + + + glutathione lyase) (GLYI) golgi autoantigen, golgin 1U51587 + + subfamily a, 1 (GOLGA1) golgi autoantigen, golgin 1 L06147subfamily a, 2 (GOLGA2) (non-exact, 70%) golgi autoantigen, golgin 1U31906 subfamily a, 4 (GOLGA4) golgi autoantigen, golgin 1X75304 + + + + subfamily b, macrogolgin (with transmembrane signal), 1(GOLGB1) gp25L2 protein 4 X90872 grancalcin 8 M81637 + + + granulin(GRN) 16 X62320 + + + + + granulin (GRN) (low match) 1 X62320 Granulysin(NKG5) 5 M85276 + + granzyme A (granzyme 1, 1 M18737 + + + + + cytotoxicT-lymphocyte- associated serine esterase 3) (GZMA) GRB2-related adaptor1 U52518 T only protein (GRAP) Grb2-related adaptor 1 AF090456 T +protein 2 (GRAP2) GRO1 oncogene 1 X54489 + + (melanoma growthstimulating activity, alpha) (GRO1) growth arrest and DNA- 1 S40706damage-inducible gene (GADD153) growth arrest-specific 7 4 AB007854 + +(GAS7) growth factor receptor- 1 X62852 B + + + bound protein 2 (GRB2)GS1 (protein of unknown 1 M86934 + + + function) GS3955 4 D87119 + + + +GTP binding protein 1 1 U87964 + + + (GTPBP1) GTP binding proteinsimilar 1 U87791 + + + + to S. cerevisiae HBS1 (HBS1) GTPase activatingprotein- 1 AB011110 + + + + high fetal brain like (GAPL) GTP-bindingprotein (low 1 Z49068 match) GTP-binding protein G(K), 1 P08754 alphasubunit (=G(I) ALPHA-3) (=GTP-binding regulatory protein Gi alpha- 3chain) Gu protein (GURDB) 2 U41387 + + + + guanine nucleotide binding 1protein guanine nucleotide binding 4 J03004 + + + + + protein (Gprotein), alpha inhibiting activity polypeptide 2 (GNAI2) guaninenucleotide binding 7 M20597 + + + + + protein (G protein), alphainhibiting activity polypeptide 3 (GNAI3) guanine nucleotide binding 2X04409 B, T + + + protein (G protein), alpha stimulating activitypolypeptide 1 (GNAS1) guanine nucleotide binding 1 Z18859 protein (Gprotein), alpha transducing activity polypeptide 2 (GNAT2) guaninenucleotide binding 2 AF017656 + + + + protein (G protein), beta 5 (GNB5)guanine nucleotide binding 5 M36430 + + + + + + protein (G protein),beta polypeptide 1 (GNB1) guanine nucleotide binding 2 AF011496 + + +protein (G protein), q polypeptide (GNAQ) guanine nucleotide binding 1L25665 + + + + + protein-like 1 (GNL1) guanine nucleotide 1L13857 + + + + exchange factor guanine nucleotide 1 X15610 + + + + +regulatory factor (LFP40) guanine nucleotide 1 U72206 + + + + +regulatory factor (LFP40) GUANINE NUCLEOTIDE- 1 P25388 BINDING PROTEINBETA SUBUNIT-LIKE PROTEIN 12.3 (P205) (RECEPTOR OF ACTIVATED PROTEINKINASE C 1) (RACK1) GUANINE- 1 U10860 + MONOPHOSPHATE SYNTHETASE (GMPS)guanosine monophosphate 1 M24470 reductase (GMPR) (non- exact, 72%)guanosine-diphosphatase 1 AF016032 like protein guanylate bindingprotein 2 M55542 + + + + + 1, interferon-inducible, 67 kD (GBP1)guanylate binding protein 6 M55543 + + + + + 2, interferon-inducible(GBP2) H2A histone family, 1 Z83742 member C (H2AFC) H2A histone family,2 AF041483 + + + + + member Y (H2AY) H2B histone family, 2Z80783 + + + + + + high in adrenal gland member L (H2BFL) tumorh2-calponin 1 D86059 H-2K binding factor-2 1 L08904 + + + + H3 histonefamily, member 1 Z83735 K (H3FK) H3 histone, family 3A 7M11353 + + + + + high in ovary (H3F3A) H3 histone, family 3B 15Z48950 + + + + + high in endothelial (H3.3B) (H3F3B) cells hbc647 1U68494 + + + + heat shock 27 kD protein 1 1 U12404 + + + + (HSPB1) heatshock 40 kD protein 1 4 D85429 + + + + + + high in testis (HSPF1) heatshock 60 kD protein 1 3 M22382 + + + + + + (chaperonin) (HSPD1) heatshock 70 kD protein 1 7 M59828 + + + + + + high in activated T (HSPA1A)cells heat shock 70 kD protein 5 13 X87949 + + + (glucose-regulatedprotein, 78 kD) (HSPA5) heat shock 70 kD protein 6 4 X51757 + + +(HSP70B′) (HSPA6) heat shock 70 kD protein 2 L15189 + + + + + 9B(mortalin-2) (HSPA9B) HEAT SHOCK COGNATE 1 P11142 71 KD PROTEIN heatshock factor binding 2 AF068754 protein 1 (HSBP1) heat shock protein 9013 M27024 + + + + + + high in many libraries heat shock protein, DNAJ- 1D13388 + + + + like 2 (HSJ2) Hect (homologous to the 1 U50078 + + +E6-AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain(RLD) 1 (HERC1) hect domain and RLD 2 1 AB002391 + + + + + (HERC2)helicase-like protein (HLP) 1 X98378 + + + + helix-loop-helix protein 1M65214 + HE47 (E2A) hematopoietic cell-specific 18 X16663 + + + + Lynsubstrate 1 (HCLS1) heme oxygenase 1 X06985 + + + + (decycling) 1(HMOX1) HEMOGLOBIN ALPHA 1 P19015 CHAIN hemoglobin beta (beta 5 AF117710globin) hemoglobin, alpha 1 301 V00491 + + + (HBA1) hemoglobin, alpha 11 V00491 (HBA1) (low match) hemoglobin, alpha 1 (low 1 V00493 match)hemoglobin, alpha 1 (non- 1 J00153 exact, 76%) hemoglobin, alpha 1 (non-1 V00493 exact, 82%) hemoglobin, beta (HBB) 129 V00497 + + + + + + highin many libraries hemoglobin, beta (HBB) 1 V00497 (low match)hemoglobin, beta (HBB) 1 L48220 (low match) hemokine (C—X—C motif), 1D10924 + + + + + receptor 4 (fusin) (CXCR4) hemopoietic cell kinase 5M16591 + + (HCK) hepatitis C-associated 2 D28908 microtubular aggregateprotein p44 hepatoma-derived growth 1 D16431 + + + + + factorHermansky-Pudlak 2 U65676 syndrome (HPS) HERV-E integrase (non- 1AF026246 exact 76% aa) heterogeneous nuclear 2 S63912 + + + + proteinsimilar to rat helix destabilizing protein (FBRNP) heterogeneous nuclear4 M16342 ribonucleoprotein (C1/C2) (HNRPC) heterogeneous nuclear 1M65028 + + + + + + ribonucleoprotein A/B (HNRPAB) heterogeneous nuclear20 X12671 + + + + + + High in alveolar ribonucleoprotein A1rhabdomyosarcoma (HNRPA1) heterogeneous nuclear 3 M29064 + + + + + +High in activated T ribonucleoprotein A2/B1 cell, fetal brain (HNRPA2B1)heterogeneous nuclear 2 D55673 + + + + + + ribonucleoprotein D (hnRNP D)heterogeneous nuclear 5 D89092 + + + + + + ribonucleoprotein D-like(HNRPDL) heterogeneous nuclear 1 L28010 + + + + + ribonucleoprotein F(HNRPF) heterogeneous nuclear 1 L28010 ribonucleoprotein F (HNRPF) (83%)heterogeneous nuclear 2 Z23064 + + + + ribonucleoprotein G (HNRPG)heterogeneous nuclear 3 P55795 ribonucleoprotein H (HNRPH) (FTP-3)heterogeneous nuclear 1 P31943 ribonucleoprotein H (HNRPH) (low match)heterogeneous nuclear 2 L22009 + + + + + ribonucleoprotein H1 (H)(HNRPH1) heterogeneous nuclear 21 S74678 + + + + + + ribonucleoprotein K(HNRPK) heterogeneous nuclear 1 AF000364 + + + + + ribonucleoprotein R(HNRPR) heterogeneous nuclear 3 X65488 + + + + + + ribonucleoprotein U(scaffold attachment factor A) (HNRPU) hexokinase 1 (HK1) 2X66957 + + + + hexokinase 2 (HK2) 3 Z46376 + + + + + hexokinase 3 (HK3)2 U51333 hexosaminidase A (alpha 1 S62047 polypeptide) (HEXA HGMP07Igene for 2 U76377 olfactory receptor High density lipoprotein 2M64098 + + + + + + binding protein (HDLBP) high-mobility group 5X12597 + + + + + + (nonhistone chromosomal) protein 1 (HMG1)high-mobility group 1 D63874 (nonhistone chromosomal) protein 1 (HMG1)(non- exact 60%) High-mobility group 2 M12623 + + + + + (nonhistonechromosomal) protein 17 (HMG17) high-mobility group 2 M83665 + + + + + +(nonhistone chromosomal) protein 2 (HMG2) high-mobility group 2L17131 + + + + + (nonhistone chromosomal) protein isoforms I and Yhigh-risk humanpapilloma 1 AF090990.1 viruses E6 oncoproteins targetedprotein E6TP1 beta (=AB007900 KIAA0440) histidine ammonia-lyase 1 D16626+, (HAL) only histidyl-tRNA synthetase 2 Z11518 + + + + + + (HARS)histocompatibility antigen 1 U31372 (HLA-Cw3), class I histonedeacetylase 1 4 U50079 + + + + + (HDAC) histone deacetylase 1 2D50405 + + + + + (HDAC1) histone deacetylase 5 (NY- 1 AF039691 + + CO-9)HK2 gene for hexokinase II 1 Z46362 HL9 monocyte inhibitory 2 U91928 +receptor precursor HLA class I heavy chain 1 (HLA-Cw*1701) HLA class Ilocus C heavy 1 X58536 chain HLA class II SB 4-beta 1 X03022 chain HLAclass III region 1 U89335 + + + + + containing NOTCH4 gene HLA-A 1Z72423 HLA-A 2 AJ006020 HLA-A*7402 1 AJ223060 HLA-A11 1 U02934 HLA-B 2X75953 HLA-B 1 X83401 HLA-B 1 X78426 HLA-B associated 1Z37166 + + + + + + transcript-1 (D6S81E) HLA-B associated 2M33509 + + + + transcript-2 (D6S51E) HLA-B*1529 4 D44501 HLA-Bw72antigen 119 L09736 + + + + + + high in many libraries HLA-C gene (HLA- 1D83957 Cw*0701 allele) HLA-Cw*0701 9 Z46810 HLA-Cw*0801 1 D64151HLA-Cw*1203 1 D64146 HLA-DC classII 2 X00370 histocompatibility antigensalpha-chain (=K01160) HLA-DR alpha-chain 17 M60333 + + + + + + high inspleen HLA-F (leukocyte antigen 3 X17093 + + + F) HMG box containing 3AF019214 protein 1 hMLH1 (=U83845) 1 AB017806.1 Hmob33 3 Y14155 HMT1(hnRNP 2 U80213 + + + + + methyltransferase, S. cerevisiae)- like 1(HRMT1L1) hnRNP C1/C2 2 D28382 homeobox (=X58250 1 M60721 Mouse homeobox protein, put. transcription factor involved in embryogenesis andhematopoiesis) homeobox protein (HLX1) 1 U14326 (=M60721)homeodomain-interacting 1 AF004849 + + + + protein kinase 3 (HIPK3)homolog of Drosophila past 2 AF001434 + + + + + (PAST) homolog of yeast(S. cerevisiae) 3 D50916 + + + + ufd2 (UFD2) HPV16 E1 protein binding 1U96131 + + + protein HRIHFB2157 1 AB015344 + + + HRX-like protein 1Y08836 (=AF010403 ALR) hsc70 gene for 71 kd heat 3 Y00371 shock cognateprotein HSPC012 1 AF077036.1 HSPC021 1 AF077207.1 HsPex13p 1 U71374htra2-beta-2 1 U87836 + + + + + HU-K4 1 U60644 hunc18b2 1 U63533 + + + +HUNKI 1 Y12059 + + + + + huntingtin-interacting 1 AF049528 proteinHYPA/FBP11 (HYPA) hVps41p (HVPS41) 1 U87309 hydroxyacyl-Coenzyme A 1U04627 + + + dehydrogenase/3-ketoacyl- Coenzyme Athiolase/enoyl-Coenzyme A hydratase (trifunctional protein), alphasubunit (HADHA) hydroxyacyl-Coenzyme A 1 D16481 + + + + +dehydrogenase/3-ketoacyl- Coenzyme A thiolase/enoyl-Coenzyme A hydratase(trifunctional protein), beta subunit (HADHB) hydroxysteroid (17-beta) 1U34879 + + dehydrogenase 1 (HSD17B1) hypothetical protein 1 hypotheticalprotein 1 (AL008729) (dJ257A7.2) hypothetical protein 1 U96629(CIT987SK_2A8_1 chromosome 8) hypothetical protein (clone 1 AF05500424640) hypothetical protein (clone 1 Z70222 ICRFp507G2490). hypotheticalprotein 1 AL022238 (dJ1042K10.4) (non-exact 76%) hypothetical protein 2AL031432 (dJ465N24.1 similar to predicted yeast and worm proteins)hypothetical protein 2 AL008730 (dJ487J7.1.1) hypothetical protein 2AL023653 (dJ753P9.2) hypothetical protein 1 AL050131.1 (DKFZp586I111)hypothetical protein 1 AL008729 (J257A7.2) hypothetical protein 1AB007900 (KIAA0440) (=AF026504 R. norvegicus SPA-1 like protein)hypothetical protein (L1H 3′ 1 region) hypothetical protein (S164) 1P49756 hypothetical protein (similar 1 AF109907 to thrombospondin) (non-exact 56%) hypothetical protein 3 1 hypothetical protein B 1 U47926(HSU47926) (non-exact, 56%) hypothetical protein from 3 U50532 + + + + +BCRA2 region (CG005) hypoxia-inducible factor 1, 1 AF050115 alphasubunit (basic helix- loop-helix transcription factor) (HIF1A)Ia-associated invariant 1 M13555 gamma-chain (clones lambda-y (1,2,3))iduronate 2-sulfatase 2 M58342 + + + + + (Hunter syndrome) (IDS) Igheavy chain V region 1 L20779 (=D11016) Ig heavy chain variable 2 M34024region Ig heavy chain variable 1 Z75378 region (VH4DJ) (clone T14.4) Igheavy chain variable 1 Z75392 region (VH4DJ) (clone T22.18) Ig J chain 1M12378 Ig kappa 1 S49007 IG kappa light chain 1 X63398 variable regionA20 Ig kappa light chain, V- and 1 D90158 J-region (=X59315) Ig lambdalight chain 1 Z85052 variable region (26- 34ITIIIF120) Ig mu-chainVDJ4-region 1 M16949 Ig rearranged anti-myelin 1 M29469 kappa-chain(V-J4-region, hybridoma AE6-5) Ig rearranged H-chain 2 M97920 mRNAV-region Ig rearranged light-chain V 1 M74020 region (=D90158) IGF-IImRNA-binding 1 U97188 + + + protein 3 (KOC1) (non- exact, 75%) IgG Fcbinding protein 1 D84239 + + + + (FC(GAMMA)BP) IgG heavy chain variable1 M83136 region (vH26) IgM heavy chain (C mu, 1 X14939 membrane exons)IkB kinase-beta (IKK-beta) 1 AF029684 IL-1 receptor type II 1 U14177IL2-inducible T-cell kinase 2 S65186 (ITK) immediate early protein 1M62831 + + + + (ETR101) immunogloblin light chain 1 D87018 (lambda)Immunoglobulin (CD79A) 1 Y08915 B, T + + + binding protein 1 (IGBP1)immunoglobulin C (mu) 2 X57331 and C (delta) heavy chain (=K02878)immunoglobulin G Fc 1 Z46223 receptor IIIB immunoglobulin gamma 3 3Y14737 + + + high in many libraries (Gm marker) (IGHG3) immunoglobulingamma 1 Z66542 heavy chain variable region (=X61011) immunoglobulinheavy 1 X62109 chain (VI-3B) immunoglobulin heavy 1 X86356 chain Jregion immunoglobulin heavy 2 X86355 chain J region, B1 haplotypeimmunoglobulin heavy 1 AF062126 chain variable region (IGH) (clone21u-48) immunoglobulin heavy 1 AF062212 chain variable region (IGH)(clone 23u-1) immunoglobulin heavy 2 M99641 chain variable region V1-18(IGHV@) (=X60503) immunoglobulin heavy 2 M99672 chain variable regionV3-43 (IGHV@) immunoglobulin heavy 3 M99649 chain variable region V3-7(IGHV@) immunoglobulin IgH heavy 1 U07986 chain Fd fragmentimmunoglobulin kappa light 1 X58081 chain immunoglobulin kappa light 1X12686 chain V-segment A27 immunoglobulin light chain 1 D86990immunoglobulin light chain 1 D86996 (low match) immunoglobulin lightchain 1 L29157 variable region (lambda IIIb subgroup) from IgMrheumatoid factor immunoglobulin M heavy 1 S50735 chain V region =anti-lipid A antibody immunoglobulin mu (IGHM) 9 X57086 + + + +immunoglobulin mu binding 1 L24544 T + + protein 2 (IGHMBP2)immunoglobulin 1 Z33642 superfamily, member 2 (IGSF2) Immunoglobulin VHmRNA 1 X61013 (487 bp) (=M99652 immunoglobulin heavy chain variableregion V3-11 (IGHV@)) imogen 38 (IMOGEN38) 1 Z68747 + + + + IMP (inosine1 J05272 + + + + monophosphate) dehydrogenase 1 (IMPDH1) IMP (inosine 2L39210 + + + + + monophosphate) dehydrogenase 2 (IMPDH2) inc fingerprotein 151 (pHZ- 1 Y09723 + + + + + 67) (ZNF151) inc finger protein,C2H2, 1 AF011573 + + rapidly turned over (ZNF20) induciblepoly(A)-binding 1 U33818 + + + + + protein (IPABP) induciblepoly(A)-binding 1 U33818 protein (IPABP) (low match) inducible protein 2L47738 + + + + + (Hs.80313) inhibitor of DNA binding 2, 4M97796 + + + + + + dominant negative helix- loop-helix protein (ID2)inhibitor of kappa light 2 AF044195 polypeptide gene enhancer inB-cells, kinase complex- associated protein (IKBKAP) inositol1,3,4-trisphosphate 1 U51336 + + + + + + 5/6-kinase inositol 1,4,5trisphosphate 1 U23850 + + + receptor type 1 (ITPR1) inositol1,4,5-trisphosphate 2 X57206 B + + + 3-kinase B (ITPKB) inositolmonophosphatase 1 S38980 inositol polyphosphate-5- 2 U84400 + + + + +phosphatase, 145 kD (INPP5D) Ins(1,3,4,5)P4-binding 1 X89399 + + proteininsulin-like growth factor 2 5 Y00285 + + + + + receptor (IGF2R)integral membrane protein 1 L38961 + + + 1 (ITM1) integral membraneprotein 1 AF038953 T + + + 2C (ITM2C) integral membrane protein 3U61734 + + + + + + Tmp21-I (p23) integrin beta 4 binding 2 AF047433 + +protein (ITGB4BP) integrin, alpha 2b (platelet 3 M34480 + + glycoproteinIIb of IIb/IIIa complex, antigen CD41B) (ITGA2B) integrin, alpha 5 4X06256 + + + + + (fibronectin receptor, alpha polypeptide) (ITGA5)integrin, alpha L (antigen 6 Y00796 CD11A (p180), lymphocytefunction-associated antigen 1; alpha polypeptide) (ITGAL) integrin,alpha M 1 M18044 (complement componentreceptor 3, alpha; also known asCD11b (p170), macrophage antigen alpha polypeptide) (ITGAM) integrin,alpha X (antigen 1 M81695 + + + CD11C (p150), alpha polypeptide) (ITGAX)integrin, beta 1 (fibronectin 2 X07979 receptor, beta polypeptide,antigen CD29 includes MDF2 MSK12) (ITGB1) integrin, beta 2 (antigen 32M15395 + + + + CD18 (p95), lymphocyte function-associated antigen 1;macrophage antigen 1 (mac-1) beta subunit) (ITGB2) integrin, beta 7(ITGB7) 1 M68892 + Integrin-linked kinase (ILK) 1 U40282 + + + + +intercellular adhesion 1 J03132 + + + + molecule 1 (CD54), humanrhinovirus receptor (ICAM1) intercellular adhesion 1 X15606 + + + + +molecule 2 (ICAM2) intercellular adhesion 6 X69819 + + molecule 3(ICAM3) intercellular adhesion 1 L27670 + molecule 4, Landsteiner-Wiener blood group (ICAM4) Interferon consensus 1 M91196 W, T sequencebinding protein 1 lymphoma (ICSBP1) Interferon consensus 1 M91196sequence binding protein 1 (ICSBP1) (low match) interferon regulatoryfactor 4 X15949 + + + + 2 (IRF2) interferon regulatory 4L05072 + + + + + factor1 (IRF1) interferon regulatory 1 U51127 + + +factor5 (IRF5) interferon, gamma- 2 M63838 + + + + + inducible protein16 (IFI16) interferon, gamma- 9 J03909 + + + + inducible protein 30(IFI30) INTERFERON-INDUCED 1 P32455 GUANYLATE-BINDING PROTEIN 1 (GUANINENUCLEOTIDE-BINDING PROTEIN 1) (non-exact 62%) interferon-induced protein3 X84958 + + + + 17 (IFI17) interferon-induced protein 5 M14660 54(IFI54) interferon-inducible (1-8D) 5 X57351 T + + +interferon-inducible (1-8U) 1 X57352 + + + interferon-related 5Y10313 + + + developmental regulator 1 (IFRD1) interferon-stimulated 2M87503 + + + transcription factor 3, gamma (48 kD) (ISGF3G) interleukin1 receptor, type 1 U64094 + II (IL1R2) Interleukin 10 receptor, 1 U08988T activated + + beta (I.10RB) interleukin 12 receptor, 2 U03187 + onlyfound in T cell beta 1 (IL12RB1) interleukin 13 receptor, 2Y09328 + + + + + alpha 1 (IL13RA1) interleukin 16 (lymphocyte 6 U82972 +chemoattractant factor) (IL16) interleukin 18 receptor 1 1 U43672(IL18R1) interleukin 2 receptor, beta 9 M26062 (IL2RB) interleukin 2receptor, 6 D11086 + + + gamma (severe combined immunodeficiency)(IL2RG) interleukin 4 receptor 3 X52425 + + + + (IL4R) interleukin 6receptor 5 X12830 + + (IL6R) interleukin 6 signal 1 M57230 transducer(gp130, oncostatin M receptor) (IL6ST) interleukin 7 receptor 14M29696 + + (IL7R) interleukin 7 receptor 1 AF043123 (IL7R) (low match)interleukin 8 (IL8) 8 Y00787 + + + High in activated T cells, bone andpancreatic islets interleukin 8 receptor alpha 11 L19591 (IL8RA)interleukin 8 receptor, beta 14 M94582 (IL8RB) interleukin enhancer 3U10323 + + + + + + high in uterus binding factor 2, 45 kD (ILF2)interleukin enhancer 2 U10324 binding factor 3, 90 kD (ILF3)interleukin-1 receptor- 2 L76191 + + + + associated kinase 1 (IRAK1)interleukin-1 receptor- 1 U52112 associated kinase 1 (low match)interleukin-10 receptor, 5 U00672 + + + + alpha (IL10RA) interleukin-11receptor, 7 Z38102 + + alpha (IL11RA) INTERLEUKIN-14 1 P40222 PRECURSOR(IL-14) (HIGH MOLECULAR WEIGHT B-CELL GROWTH FACTOR) (HMW-BCGF)(non-exact 46%) intestinal carboxylesterase; 1 U60553 + + livercarboxylesterase-2 (ICE) inversin protein (non-exact 1 AF084367 52%) IQmotif containing 6 L33075 GTPase activating protein 1 (IQGAP1) IQ motifcontaining 1 U51903 + + GTPase activating protein 2 (IQGAP2) isocitratedehydrogenase 1 1 AF020038 + + + + + + (NADP+), soluble (IDH1)isocitrate dehydrogenase 2 2 X69433 + + + + + + (NADP+), mitochondrial(IDH2) isocitrate dehydrogenase 3 2 U07681 + (NAD+) alpha (IDH3A)isocitrate dehydrogenase 3 1 Z68907 + + + + + (NAD+) gamma (IDH3G)isolate Aus3 cytochrome b 1 AF042516 (CYTB) isolate TzCCR5-179 CCR5 1AF011524 receptor (CCR5) isopentenyl-diphosphate 5 X17025 + + + + +delta isomerase (IDI1) Janus kinase 1 (a protein 4 M64174 + + + + +tyrosine kinase) (JAK1) Janus kinase 2 (a protein 1 AF005216 tyrosinekinase) (JAK2) Jk-recombination signal 2 L07876 binding protein (RBPJK)JM1 protein 1 AJ005890 + + jumonji (mouse) homolog 1 U57592 + + + +(JMJ) jun D proto-oncogene 1 X51346 + + + + + (JUND) jun dimerizationprotein 1 AF111167 only found in germ junction plakoglobin (JUP) 1M23410 + + + + kangai 1 (suppression of 1 U20770 + + + + + +tumorigenicity 6, prostate; CD82 antigen (R2 leukocyte antigen, antigendetected by monoclonal and antibody IA4)) (KAI1) karyopherin (importin)beta 2 L39793 + + + + + + 1 (KPNB1) karyopherin (importin) beta 1U72395 + + + + 2 (KPNB2) karyopherin alpha 1 1 S75295 + + + + (importinalpha 5) (KPNA1) karyopherin alpha 2 (RAG 1 U09559 cohort 1, importinalpha 1) (DPNA2) karyopherin alpha 3 1 D89618 + + (importin alpha 4)(KPNA3) karyopherin alpha 4 1 M17887 + + (KPNA4) Katanin (80 kDa) (KAT)1 AF052432 + + + + KE03 protein 2 AF064604 Kelch-like ECH-associated 1D50922 protein 1 (KIAA0132) (66% aa) Keratin 8 (KRT8) 1 X74929 + + + + +ketohexokinase 1 X78678 + + + (fructokinase) (KHK) KIAA0001 (KIAA0001) 1Q15391 (72% aa) KIAA0001 (KIAA0001) 1 Q15391 (76% aa) KIAA0001(KIAA0001) 1 Q15391 (non-exact 72%) KIAA0002 (KIAA0002) 5 D13627 + + + +KIAA0005 (KIAA0005) 4 D13630 + + + + KIAA0010 (KIAA0010) 1 D13635 + +KIAA0016 (KIAA0016) 1 D13641 + + + + + KIAA0017 (KIAA0017) 2 D87686KIAA0022 (KIAA0022) 2 D14664 + + + KIAA0023 (KIAA0023) 1 D14689 +KIAA0024 (KIAA0024) 1 D14694 + + + + + KIAA0025 (KIAA0025) 1D14695 + + + + + KIAA0026 (KIAA0026) 2 D14812 + + + + KIAA0027 1D25217 + KIAA0032 (KIAA0032) 2 D25215 + + + KIAA0040 (KIAA0040) 1D25539 + + + + + KIAA0050 (KIAA0050) 4 D26069 KIAA0053 (KIAA0053) 17D29642 + + + KIAA0057 (KIAA0057) 1 D31762 + + + + + + high in fetal lungKIAA0058 (KIAA0058) 11 D31767 + + + + + KIAA0063 (KIAA0063) 3D31884 + + + + + KIAA0064 (KIAA0064) 1 D31764 + + + + + KIAA0066 1D31886 + + + + + KIAA0068 1 D38549 + + + + + KIAA0073 3 D38552 + + + +KIAA0081 2 D42039 + + + KIAA0084 2 D42043 + + + + + KIAA0085 26U30498 + + + + + + KIAA0088 3 D42041 + + + + + + KIAA0090 2D42044 + + + + + + KIAA0092 (KIAA0092) 1 D42054 + + + + KIAA0094 3D42084 + + KIAA0095 (KIAA0095) 1 D42085 KIAA0096 1 D43636 + + + + +KIAA0097 (KIAA0097) 1 X92474 T + + + KIAA0099 (KIAA0099) 3D43951 + + + + + + KIAA0102 (KIAA0102) 2 D14658 + + + + KIAA0105 1D14661 B + + + KIAA0120 2 P37802 KIAA0120 (non-exact, 1 M83106 65%)KIAA0121 (KIAA0121) 1 D50911 + + + + + KIAA0123 1 D21064 + + + +KIAA0128 1 D50918 + + + + + KIAA0129 (KIAA0129) 1 D50919 + + + +KIAA0130 (KIAA0130) 1 AF055995 + + + KIAA0136 2 D50926 KIAA0137(KIAA0137) 1 AB004885 + + + + KIAA0140 (KIAA0140) 1 D50930 + + + +KIAA0141 (KIAA0141) 3 D50931 KIAA0144 (KIAA0144) 3 D63478 + + + + +KIAA0144 (KIAA0144) (low 1 D63478 match) KIAA0144 (non-exact 61%) 1Q14157 KIAA0144 (non-exact 65%) 1 Q14157 KIAA0146 2 D63480 + + + +KIAA0148 (KIAA0148) 1 D63482 + + KIAA0154 2 D63876 + + + + + KIAA0156 1D63879 + + + + KIAA0160 2 D63881 KIAA0161 (KIAA0161) 1 D79983 + + +KIAA0164 (KIAA0164) 3 D79986 KIAA0167 (KIAA0167) 1 D79989 + KIAA0168(KIAA0168) 3 D79990 + + + + KIAA0169 3 D79991 KIAA0171 (KIAA0171) 3D79993 + + + + KIAA0174 (KIAA0174) 7 D79996 + + + + + KIAA0179 2D80001 + + + + KIAA0181 1 D80003 + + + + KIAA0183 4 D80005 + + + + + +KIAA0184 1 D80006 + + + + + KIAA0191 (72% aa) 1 D83776 KIAA0191(non-exact 77%) 1 KIAA0193 (KIAA0193) 1 D83777 + + + + + KIAA0200(KIAA0200) 1 D83785 + + + + KIAA0210 (KIAA0210) 3 D86965 KIAA0217 2D86971 + + + + + KIAA0219 2 U77700 + + + + KIAA0222 (KIAA0222) 1 D86975KIAA0223 2 D86976 KIAA0229 1 D86982 + + KIAA0232 (KIAA0232) 1D86985 + + + + KIAA0233 (KIAA0233) 1 D87071 KIAA0235 2 D87078 + + + +KIAA0239 1 D87076 + + KIAA0239 (non-exact 80%) 1 D87076 KIAA0240 1D87077 KIAA0242 4 D87684 + + + + + + KIAA0248 2 D87435 + + + + KIAA0249(KIAA0249) 3 D87436 + + + + + KIAA0253 5 D87442 + + + + + + KIAA0254(KIAA0254) 1 D87443 + + + KIAA0255 (KIAA0255) 4 D87444 + + + + KIAA0262(KIAA0262) 3 D87451 + + + + + KIAA0263 (KIAA0263) 1 D87452 + + + + +KIAA0264 3 D87453 + + + + KIAA0268 1 D87742 + + + + KIAA0269 1 Q92558KIAA0275 (KIAA0275) 13 D87465 + + + + KIAA0304 (KIAA0304) 2AB002302 + + + + + + KIAA0308 2 AB002306 + + + KIAA0310 (KIAA0310) 1AB002308 + + + + KIAA0314 (=U96635 3 AB002312 M. musculus ubiquitinprotein ligase Nedd-4) KIAA0315 (KIAA0315) 4 AB002313 + + + + + KIAA0325(=L08505 2 AB002323 R. norvegicus cytoplasmic dynein heavy chain(MAP1C)) KIAA0329 (KIAA0329) 1 AB002327 + + + + KIAA0330 1AB002328 + + + + KIAA0332 1 AB002330 + + + + KIAA0333 2AB002331 + + + + + KIAA0336 (KIAA0336) 3 AB002334 + + + + + KIAA0336(KIAA0336) (low 1 AB002334 match) KIAA0342 (KIAA0342) 1 AB002340 + + +KIAA0344 (KIAA0344) 2 AB002342 + + KIAA0354 (KIAA0354) 1AB002352 + + + + + KIAA0365 (KIAA0365) 3 AB002363 + + + + + + KIAA0370 6AB002368 + + + + + KIAA0372 (KIAA0372) 1 AB002370 KIAA0373 (KIAA0373) 1AB002371 + + KIAA0375 (KIAA0375) 1 AB002373 + + KIAA0377 (KIAA0377) 1AB002375 + + + KIAA0379 1 AB002377 + KIAA0379 (non-exact, 1 AB00237765%) KIAA0380 (KIAA0380) 1 AB002378 + + + + KIAA0380 (KIAA0380) 1AB002378 (60% aa) KIAA0382 (KIAA0382) 2 AB002380 + + + + KIAA0383 1AB002381 KIAA0386 (KIAA0386) 5 AB002384 KIAA0392 1 AB002390 KIAA0397(KIAA0397) 4 AB007857 + + + + + KIAA0403 3 AB007863 KIAA0404 1AB007864 + + KIAA0409 1 AB007869 + + KIAA0421 1 AB007881 + + + +KIAA0424 (non-exact 82%) 1 AB007884 KIAA0428 (KIAA0428) 9 Y13829KIAA0429 (KIAA0429) 2 AB007889 + + + + + KIAA0430 (KIAA0430) 2 AB007890only in ovary KIAA0432 (KIAA0432) 2 U86753 T + + KIAA0435 (KIAA0435) 1AB007895 KIAA0438 (KIAA0438) 1 AB007898 + + + + KIAA0447 (KIAA0447) 3AB007916 + + + + + KIAA0449 1 AB007918 + + KIAA0456 1 AB007925 + + + +KIAA0458 (KIAA0458) 1 AB007927 KIAA0462 1 AB007931 + + + + + KIAA0465 1AB007934 + + + + + KIAA0476 (KIAA0476) 1 AB007945 + + + KIAA0489 1AB007958 KIAA0494 (KIAA0494) 1 AB007963 + + + + + KIAA0515 1AB011087 + + + + + KIAA0521 3 AB011093 + + + KIAA0525 1 AB011097 + +KIAA0530 1 AB011102 + + + KIAA0532 1 AB011104 + + + + + KIAA0537(KIAA0537) 1 AB011109 KIAA0540 1 AB011112 + + + + + KIAA0543 1AB011115 + + + KIAA0544 1 AB011116 + + + + KIAA0549 2 AB011121 + + + +KIAA0551 2 AB011123 + + KIAA0554 8 AB011126 + + + + KIAA0561 1AB011133 + + KIAA0562 (KIAA0562) 1 AB011134 KIAA0563 (KIAA0563) 1AB011135 KIAA0569 (KIAA0569) 2 AB011141 + + + + KIAA0571 (KIAA0571) 2AB011143 + + + KIAA0573 1 AB011145 + + + KIAA0576 1 AB011148 KIAA0580 1AB011152 KIAA0584 1 AB011156 + KIAA0592 3 AB011164 + + + + + KIAA0596 1AB011168 + + KIAA0598 (KIAA0598) 1 AB011170 + + + KIAA0608 1AB011180 + + KIAA0614 2 AB014514 + + + + + KIAA0615 (KIAA0615) 1AB014515 KIAA0621 1 AB014521 + + + KIAA0648 1 AB014548 + + + + KIAA0652(KIAA0652) 1 AB014552 + + + + + KIAA0668 1 AB014568 KIAA0669 1 AB014569KIAA0671 (KIAA0671) 1 AB014571 + + + KIAA0675 (KIAA0675) 1AB014575 + + + KIAA0676 1 AB014576 + + + + KIAA0677 (KIAA0677) 2AB014577 + + + + + KIAA0678 1 AB014578 + + + + + KIAA0679 6AB014579 + + + + KIAA0680 (KIAA0680) 1 AB014580 KIAA0692 1AB014592 + + + + + KIAA0697 1 AB014597 KIAA0699 1 AB014599 + + + + +KIAA0700 1 AB014600 + + + + KIAA0737 (KIAA0737) 3 AF014837 + + + + +KIAA0748 (KIAA0748) 2 AB018291 + KIAA0763 (KIAA0763) 2AB018306 + + + + + KIAA0769 (KIAA0769) 2 AB018312 + + + + KIAA0782 1AB018325 + + + high in BPH stroma KIAA0796 1 AB018339 + + + + KIAA0798(KIAA0798) 1 AB018341 KIAA0823 1 AB020630 KIAA0854 1 AB020661 + + + + +KIAA0856 1 AB020663 + + + + KIAA0860 1 AB020667 + + KIAA0862 1AF054828 + + + KIAA0871 (non-exact 88%) 1 AB020678 KIAA0873 1AB020680 + + + + KIAA0892 1 AB020699 + + + + + KIAA0906 1AB020713 + + + + + KIAA0991 1 AB023208.1 killer cell lectin-like 1U11276 + + + receptor subfamily B, member 1 (KLRB1) killer celllectin-like 1 U96846 receptor subfamily C, member 4 (KLRC4) kinectin 1(kinesin receptor) 1 D13629 (KTN1) kinesin family member 5B 2X65873 + + + (KIF5B) kinesin-like DNA binding 1 AB017430 + + + + +protein Krueppel-related DNA- 1 M61869 binding protein (TF6) (low match)Kruppel related gene 1 M20675 (clone pHKR1RS) Kruppel-like zinc finger 3U51869 + + + + + + protein Zf9 Kruppel-like zinc finger 1 U44975 + + + +protein Zf9 (non-exact 76%) kruppel-type zinc finger 1 AB011414.1protein, ZK1 L apoferritin 3 X03742 lactate dehydrogenase A 3X02152 + + + + + (LDHA) lactate dehydrogenase A 1 X02152 (LDHA)(non-exact, 81%) lactate dehydrogenase B 6 X13794 + + + + + + high infetal lung (LDHB) fibrablast lactotransferrin (LTF) 1 U07643 + + + highin bone marrow laminin binding protein (low 1 D28372 score) lamininreceptor 1 (67 kD); 20 X15005 + + + + + + high in many librariesRibosomal protein SA (LAMR1) laminin receptor homolog 1 S35960 {3′region} laminin, gamma 1 (formerly 2 J03202 + + + + LAMB2) (LAMC1)latent transforming growth 2 M34057 + + + + factor beta binding protein1 (LTBP1) LAZ3/BCL6 1 Z79581 (=Z79582; D28522/4) LDLC 2 Z34975 + + + + +lecithin-cholesterol 1 M17959 acyltransferase (LCAT) (non-exact, 66%)lectin, galactoside-binding, 1 M87842 + soluble, 2 (galectin 2) (LGALS2)lectin, galactoside-binding, 1 L13210 + + + + + soluble, 3 bindingprotein (galectin 6 binding protein) (LGALS3BP) leucine rich repeat (inFLII) 5 AJ223075 + + + + + + interacting protein 1 (LRRFIP1) leucocyteimmunoglobulin- 2 AF072099 + like receptor-5 (LIR-5) leucocyteimmunoglobulin- 7 AF025530 like receptor-6a (LIR-6) leucocyteimmunoglobulin- 2 U82275 + only found in CNS like receptor-7 (LIR-7)leukemia virus receptor 1 1 L20859 + + + + + (GLVR1) leukocyte adhesionprotein 1 M29484 p150,95 alpha subunit leukocyte antigen, HLA-A2 3Y13267 leukocyte immunoglobulin- 3 AF025528 + like receptor (MIR-10)leukocyte tyrosine kinase 1 X60702 + found only in blood (LTK)leukocyte-associated Ig- 3 AF013249 + like receptor 1 (LIAR1)leukotriene A4 hydrolase 6 J03459 + + + + + + (LTA4H) leupaxin (LDPL) 2AF062075 + + + ligase I, DNA, ATP- 1 M36067 B, T + + + + dependent(LIG1) LIM and SH3 protein 1 2 X82456 + + + + + + (LASP1) LIM domainkinase 2 2 AC002073 + + + + + (LIMK2) line-1 protein 1 Line-1 repeatmRNA with 2 1 U93566 + + + + + + open reading frames Line-1 repeat with2 open 1 M22332 + + + + + + high in gastric tumor reading frames LINE-1REVERSE 1 P08547 TRANSCRIPTASE HOMOLOG lipase A, lysosomal acid, 4X76488 + + + + + cholesterol esterase (Wolman disease) (LIPA) lipase,hormone-sensitive 1 L11706 + + + (LIPE) LMP7 1 L11045 Lon protease-likeprotein 2 X74215 + + + + + (LONP) low density lipoprotein- 2 AF058414 +only in liver related protein 1 (alpha-2- macroglobulin receptor) (LRP1)low density lipoprotein- 1 M63959 + + + + related protein-associatedprotein 1 (alpha-2- macroglobulin receptor- associated protein 1)(LRPAP1) low density lipoprotein- 1 M63959 related protein-associatedprotein 1 (alpha-2- macroglobulin receptor- associated protein 1)(LRPAP1) (non-exact, 75%) low-affinity Fc-gamma 1 L08107 receptor IIALPS-induced TNF-alpha 9 AF010312 + + + + + + factor (PIG7) Lst-1 1U00921 + + + + + L-type amino acid 1 AF104032 transporter subunit LAT1lung resistance-related 1 X79882 + + + + + protein (LRP) Lymphocyteantigen 75 1 AF011333 B (LY75) lymphocyte antigen 9 (LY9) 2 L42621lymphocyte antigen HLA- 2 L42345 B*4402 and HLA-B*5101 lymphocytecytosolic 42 J02923 protein 1 (L-plastin) (LCP1) lymphocyte cytosolic 4U20158 T protein 2 (SH2 domain- lymphoma, containing leukocyte Tactivated protein of 76 kD) (LCP2) lymphocyte glycoprotein 2 X04391 + +T1/Leu-1 lymphocyte-specific protein 16 M33552 + + + + + 1 (LSP1)lymphocyte-specific protein 7 M36881 + + tyrosine kinase (LCK) lymphoidphosphatase 1 AF001847 LyP1 lymphoid-restricted 4 U10485 + + + membraneprotein (LRMP) lymphoid-specific SP100 1 U36500 + homolog (LYSP100-A)lymphoma proprotein 2 U33849 + + + + + convertase (LPC) LYSOSOMAL 1P10619 PROTECTIVE PROTEIN PRECURSOR (CATHEPSIN A) (CARBOXYPEPTIDASE C)lysosomal-associated 1 J04182 + + + + + + membrane protein 1 (LAMP1)Lysosomal-associated 1 J04183 + + + + + membrane protein 2 (LAMP2)lysozyme (renal 39 M19045 + + + + + amyloidosis) (LYZ) lysyl-tRNAsynthetase 2 D32053 + + + + + (KARS) M phase phosphoprotein 1 X98494 10(U3 small nucleolar ribonucleoprotein) (MPP- 10) M1-type and M2-type 2X56494 pyruvate kinase m6A methyltransferase 7 AF014837 + + + (MT-A70)mab-21 (C. elegans)-like 1 1 U38810 + + + + (MAB21L1) MacMarcks 1X70326 + + + + + + macrophage-associated 1 Z22968 + + + + antigen(MM130) MADS box transcription 1 U49020 + + + + enhancer factor 2,polypeptide A (myocyte enhancer factor 2A) (MEF2A) MADS boxtranscription 1 L08895 + + + + enhancer factor 2, polypeptide C (myocyteenhancer factor 2C) (MEF2C) major cytoplasmic tRNA- 1 X17516 Val(IAC)(=M33940) major histocompatibility 1 M95531 complex class I beta chain(HLA-B) major histocompatibility 41 Z93949 + + + + + high in villouscomplex, class I, A (HLA-A) adenoma major histocompatibility 1 Z72422complex, class I, A (HLA-A) (low match) major histocompatibility 82M24097 + + + + + + complex, class I, C (HAL- C) major histocompatibility77 M20022 + + + + + complex, class I, E (HLA-E) major histocompatibility2 U15085 + + + + + complex, class II, DM BETA (HLA-DMB) majorhistocompatibility 10 M57466 + + + + + complex, class II, DP beta 1(HLA-DPB1) major histocompatibility 9 V00522 + + + + + complex, classII, DR beta 1 (HLA-DRB1) Major histocompatibility 2 M24070 + + + +complex, class II, Y box- binding protein I; DNA- binding protein B(YB1) malate dehydrogenase 1, 1 D55654 + + + + + + NAD (soluble) (mdh1)malate dehydrogenase 1, 3 D55654 + + + + NAD (soluble) (MDH1)malonyl-CoA 2 AF097832 decarboxylase precursor maltase-glucoamylase 1AF016833 + (mg) manic fringe (Drosophila) 1 U94352 + + + + + homolog(MFNG) mannose phosphate 1 X76057 + + + + isomerase (MPI) mannosephosphate 2 X76057 + + + + isomerase (mpi) mannose-6-phosphate 3X56253 + + + + receptor (cation dependent) (M6PR) mannose-P-dolichol 1AF038961 + + + + utilitzation defect 1 (MPDU1) mannosidase, alpha B, 1U60885 + + + + lysosomal (MANB) mannosyl (alpha-1,3-)- 1M55621 + + + + + + glycoprotein beta-1,2-N-acetylglucosaminyltransferase (MGAT1) map 4q35 repeat region 1 AF064849MAP kinase-interacting 2 AB000409 + + + + + serine/threonine kinase 1(MKNK1) MAP/ERK kinase kinase 3 5 U78876 + (MEKK3) MAP/ERK kinase kinase5 1 D84476 + + + (MEKK5) MAP/microtubule affinity- 4 M80359 + + +regulating kinase 3 (MARK3) Marenostrin protein 1 Y14441 MASL1 1AB016816 MAX dimerization protein 3 L06895 + (MAD) MaxiK potassiumchannel 1 AF035046 beta subunit MBP-2 for MHC binding 1 X65644 + + + +protein 2 Meis (mouse) homolog 3 1 U68385 + + + + (MEIS3)melanoma-associated 1 M12154 antigen p97 (melanotransferrin) membranecofactor protein 4 X59405 + + + + (CD46, trophoblast- lymphocytecross-reactive antigen) (MCP) membrane component, 4 D14696 + + + + +chromosome 17, surface marker 2 (ovarian carcinoma antigen CA125)(M17S2) membrane metallo- 2 J03779 B + + + + endopeptidase (neutralendopeptidase, enkephalinase, CALLA, CD10) (MME) membrane protein, 2M64925 + + + + + palmitoylated 1 (55 kD) (MPP1) meningioma expressed 1U94780 + antigen (MGEA) meningioma-expressed 1 U73682 + + + + antigen 11(MEA11) Menkes Disease (ATP7A) 1 L06133 + putative Cu++-transportingP-type ATPase metallothionein 2A (MT2A) 1 V00594 + + + + + metaxin 1(MTX1) 1 U46920 + + + methionine 2 X68836 + + + + + adenosyltransferaseII, alpha (MAT2A) methyl-CpG binding 1 Y10746 domain protein 1 (MBD1)(non-exact 59% aa) methylene tetrahydrofolate 2 X16396 + + + + +dehydrogenase (NAD+ dependent), methenyltetrahydrofolate cyclohydrolase(MTHFD2) methylenetetrahydrofolate 1 J04031 + + + + + dehydrogenase(NADP+ dependent), methenyltetrahydrofolate cyclohydrolase,formyltetrahydrofolate synthetase (MTHFD1) methyltransferase, putative 2AJ224442 MHC antigen (HLA-B) 1 U14943 (=L42024) MHC class 1 region 2AF055066 MHC class I antigen (HLA- 1 U70863 A2) MHC class I antigen(HLA- 1 U19736 A33) MHC class I antigen (HLA- 1 U38975 C) MHC class Iantigen 1 U52813 B*5801 (HLA-B) MHC class I antigen HLA-A 2 AF015930(HLA-A) MHC class I antigen HLA-A 1 U36687 (HLA-A-2402 allele) MHC classI antigen HLA- 2 X13112 A11K MHC class I antigen HLA-B 1 U67331 (B*0801variant) (=AF028596) MHC class I antigen HLA-B 1 U67330 (B*0801 variant)(=U88254) MHC class I antigen HLA-B 1 AF017328 (B*48 allele) MHC class Iantigen HLA-B 1 AF014770 (HLA-B*1502 allele) MHC class I antigen HLA-B 1U58643 (HLA-B*40MD) MHC class I antigen HLA-B 1 AF028596 (HLA-B*4103allele) MHC class I antigen HLA-B 1 AF035648 gene (HLA-B*4402 variantallele) MHC class I antigen HLA-B 1 U52175 GN00110-B*3910 MHC class Iantigen HLA- 1 D83030 Cw*04011 MHC class I antigen 1 U56434 R69772 HLA-A(A*0302) MHC class I antigen 1 U58469 SHCHA (HLA-B*4403 variant) MHCclass I 1 U06697 histocompatibility antigen (HLA-B) (clone C21/14) MHCclass I HLA B71 2 L07950 MHC class I HLA-A 1 Flp (Aw33.1) MHC class IHLA-B 1 U18660 MHC class I HLA-B (HLA- 1 U18661 B-07ZEL allele)(=X86704) MHC class I HLA-B (HLA- 1 U28759 B-08NR allele) MHC class IHLA-B*3512 1 L76094 MHC class I HLA-B41 3 U17572 variant (=U17572) MHCclass I HLA-B44.2 1 M24038 chain MHC class I HLA-B51- 1 L41086 cd3.3 MHCclass I HLA-C allele 2 Z33459 MHC class I HLA-Cw*0304 1 D64150 (=M84172;M99389) MHC class I HLA-Cw*0803 3 Z15144 MHC class I HLA-Cw6 1 M28206MHC class I HLA-J antigen 1 L56139 MHC class I lymphocyte 1 M19670antigen A2 (A2.1) variant DK1 MHC class I mic-B antigen 1 X91625 MHCclass I polypeptide- 1 L14848 + related sequence A (MICA) MHC class Iprotein HLA-C 1 U61274 heavy chain (C*0701new allele) (=AF017331) MHCclass II DNA 1 L18885 Sequence (clone A37G7- 1C11) MHC class II DQ-alpha1 M16995 + + + + associated with DRw6, DQw1 protein MHC class II DQ-beta2 M17564 + + + associated with DR2, DQw1 protein MHC class II HAL-DQ- 1M33842 LTR5 (DQ, w8) DNA fragment, long terminal repeat region MHC classII hla-dr alpha- 1 J00195 chain (=J00197; M60334; K011171; J00194;M60333; X00274) MHC class II HLA-DRB1 1 AF007883 MHC class II HLA-DRw11-1 M21966 beta-I chain (DRw11.3) MHC class II lymphocyte 1 M23907 antigen(DPw4-beta-1) MHC CLASS II 1 P33076 TRANSACTIVATOR CIITA (non-exact 57%)MHC HLA-E2.1 (=X87679) 1 M32507 MHC HLA-E2.1 (alpha-2 1 M32507 domain)(low match) Mi-2 autoantigen 240 kDa 1 U08379 protein (non-exact 84%)microsomal stress 70 1 U04735 protein ATPase core (stch)microtubule-associated 1 U19727 + + + + + protein 4 (MAP4)microtubule-associated 1 X73882 protein 7 (MAP7) mineralocorticoidreceptor 2 M16801 + + + (aldosterone receptor) (MLR) minichromosome 1X62153 + + + + maintenance deficient (S. cerevisiae) 3 (MCM31)minichromosome 1 AB011144 + + + + maintenance deficient (S. cerevisiae)3-associated protein (MCM3AP) minichromosome 2 X74795 + + + + + +maintenance deficient (S. cerevisiae) 5 (cell division cycle 46) (MCM5)mitochondiral cytochrome b 1 AF042517 (CYTB) mitochondrial 16S rRNA 11Z70759 mitochondrial ATP 2 X59066 synthase (F1-ATPase) alpha subunitmitochondrial ATP 1 X69907 synthase c subunit (P1 form) mitochondrialcytochrome b 6 AF042508 (CYTB) mitochondrial cytochrome b 1 AB006202small subunit of complex II mitochondrial 1 P00395 CYTOCHROME C OXIDASEPOLYPEPTIDE I mitochondrial 1 P00403 CYTOCHROME C OXIDASE POLYPEPTIDE IImitochondrial cytochrome 2 P00403 C oxidase subunit II mitochondrialcytochrome 5 U12691 oxidase subunit II (COII) (=U12692 Hsa4mitochondrion cytochrome oxidase subunit II) mitochondrial DNA loop 1X89763 attachment sequences (clone LAS34) mitochondrial DNA 1 U94703 +polymerase accessory subunit precursor (MtPolB) nuclear gene encodingmitochondrial protein, mitochondrial DNA, 1 X93334 complete genomemitochondrial genes for 8 V00710 several tRNAs (Phe, Val, Leu) and 12Sand 16S ribosomal RNAs. mitochondrial genes for 3 V00660 tRNA (Phe) and12S rRNA (fragment) mitochondrial inner 1 AF106622 membrane preproteintranslocase Tim17a mitochondrial isolate Afr7 1 AF042503 cytochromeb(CYTB) mitochondrial loop 1 X89843 attachment sequence (clone LAS88)mitochondrial NADH 14 AF014893 dehydrogenase subunit 2 (ND2)mitochondrial translational 1 L34600 + + + + initiation factor 2 (MTIF2)mitochondrion cytochrome b 1 U09500 mitogen inducible gene 1Z24725 + + + + mig-2 mitogen inducible gene 1 Z24725 mig-2 (non-exact,71%) mitogen-activated protein 2 U43784 + + + + kinase-activated proteinkinase 3 (MAPKAPK3) MLN51 2 X80199 + + + + + MLN64 (=D38255 CAB1) 1X80198 + + + + moesin (MSN) 14 M69066 + + + + + monocytic leukaemia zinc2 U47742 + + + + finger protein (MOZ) MOP1 ( ) 2 U29165 motor protein(Hs.78504) 2 D21094 + + + + + mouse double minute 2, 1 U39736 + + humanhomolog of; p53- binding protein (MDM2) M-phase phosphoprotein 6 1X98263 + + + + (MPP-6) M-phase phosphoprotein, 1 X98260 mpp11 MPS1 1L20314 Mr 110,000 antigen 2 D64154 + + + + MRC OX-2, V-like region 1X05324 (=M17227) mu-adaptin-related protein- 1 Y08387 2; mu subunit ofAP-4 (MU- ARP2) multifunctional polypeptide 1 X53793 + + + + + similarto SAICAR synthetase and AIR carboxylase (ADE2H1) murine leukemia viral(bmi- 1 L13689 + + + 1) oncogene homolog (BMI1) mutant (Daudi) beta2 -44 X07621 microglobulin mutated in colorectal 1 M62397 + + + cancers(MCC) myeloid cell leukemia 9 L08246 + + + + + + sequence 1(BCL2-related) (MCL1) myeloid cell nuclear 11 M81750 + + differentiationantigeN (MNDA) myeloid differentiation 4 U70451 + + + + primary responsegene (88) (MYD88) myeloid leukemia factor 2 3 U57342 + + + (MLF2)myeloid/lymphoid or mixed- 8 U89867 + + + + lineage leukemia (trithorax(Drosophila) homolog); translocated to, 7 (MLLT7) MYH9 (cellular myosin1 M81105 heavy chain) myomesin (M-protein) 2 1 X69089 (165 kD) (MYOM2)myosin IE (MYO1E) 11 X98411 + + myosin light chain kinase 1U48959 + + + + (MLCK) myosin phosphatase, 2 D87930 + + + + targetsubunit 1 (MYPT1) myosin regulatory light 2 D50372 chain (=U26162)myosin VIIa (low match 71) 1 U55208 myosin, heavy polypeptide 3M81105 + + + + + 9, non-muscle (MYH9) myosin, light polypeptide, 6X54304 + + + + + + regulatory, non-sarcomeric (20 kD) (MLCB) myosin-Ibeta 1 X98507 + + + + + myristoylated alanine-rich 1 D10522 + + proteinkinase C substrate (MARCKS, 80K-L) (MACS) myxovirus (influenza) 1M30817 + + + + + resistance 1, homolog of murine (interferon-inducibleprotein p78) (MX1) myxovirus (influenza) 3 M30818 + resistance 2,homolog of murine (MX2) N-acetylgalactosaminidase, 2 M62783 + + + +alpha-(NAGA) N-acetylglucosamine 1 L03532 + + + + receptor 1 (thyroid)(NAGR1) NACP/alpha-synuclein 2 U46896 N-acylaminoacyl-peptide 1D38441 + + + + hydrolase (APEH) N-acylsphingosine 11 U47674 + + + + +amidohydrolase (acid ceramidase) (ASAH) NAD+-specific isocitrate 1U49283 + + + + + + dehydrogenase beta subunit precursor (encodingmitochondrial protein) NADH dehydrogenase 1 U53468.1 + + + + + +(ubiquinone) 1 alpha subcomplex, 5 (13 kD, B13) (NDUFA5) NADHdehydrogenase 1 AF047181 + + + + + (ubiquinone) 1 beta subcomplex, 5 (16kD, SGDH) (NDUFB5) NADH dehydrogenase 1 AF050640 + + + + + (ubiquinone)Fe—S protein 2 (49 kD) (NADH-coenzyme Q eductase) (NDUFS2) NADHdehydrogenase 1 M22538 + + + + (ubiquinone) flavoprotein 2 (24 kD)(NDUFV2) NADH: ubiquinone 2 AF053070 + + + + + + dehydrogenase 51 kDasubunit (NDUFV1) NADH-CYTOCHROME B5 1 P00387 REDUCTASE (B5R) (50% aa)NADH-UBIQUINONE 1 P03886 OXIDOREDUCTASE CHAIN 1 Nardilysin (N-arginine 2U64898 + + + + + dibasic convertase) (NRD1) nascent-polypeptide- 5X80909 + + + + associated complex alpha polypeptide (NACA) naturalkiller cell group 7 8 S69115 + + sequence (NKG7) natural killer celltranscript 19 M32011 + 4 (NK4) natural killer-associated 1 U30274 +blood only transcript 3 (NKAT3) natural killer-associated 1 AF022045 +blood only transcript 5 (NKAT5) natural killer-tumor 1 L04288 B + + +recognition sequence (NKTR) N-deacetylase/N- 2 AF042084 + + + +sulfotransferase (heparan glucosaminyl) 2 (NDST2) Ndr protein kinase 3Z35102 + Nedd-4-like ubiquitin- 1 U96113 protein ligase WWP1 nel(chicken)-like 2 3 D83018 + + (NELL2) N-ethylmaleimide-sensitive 1U39412 + + factor attachment protein, alpha (NAPA)N-ethylmaleimide-sensitive 1 U78107 + + + factor attachment protein,gamma (NAPG) neural precursor cell 3 X92544 + + + + + high in testisexpressed, developmentally down- regulated 5 (NEDD5) neural precursorcell 1 D23662 + + + + + + expressed, developmentally down- regulated 8(NEDD8) neuregulin 1 (NRG1) 1 U02330 + + + neuroblastoma RAS viral 4AB020692 + + + + + (v-ras) oncogene homolog (NRAS) Neuroblastoma RASviral 1 X68286 (v-ras) oncogene homolog (NRAS) (low match) Neurofibromin2 (bilateral 1 S73853 + + acoustic neuroma) (NF2) neuronal apoptosis 2U19251 + + + + inhibitory protein (NAIP) neuronal cell adhesion 1AB002341 + + + + molecule (NRCAM) neuropathy target esterase 1AJ004832 + + + + (NTE) neuropeptide Y3 receptor, 1 D28433 5′UTR (lowscore) neurotrophic tyrosine 14 X03541 + + + + + + kinase, receptor,type 1 (NTRK1) neutrophil cytosolic factor 4 2 U50720 (40 kD) NG31 1AF129756 NGAL (=X83006) 1 X99133 nibrin (NBS) 1 AF051334 NIK 1AB014587 + + + + Ninjurin 1; nerve injury- 1 U72661 + + + + inducedprotein-1 nitrilase 1 (NIT1) 1 AF069987 (=AF069984) NKG2-D (low match)(non- 1 X54870 exact, 58%) Nmi 1 U32849 N-myristoyltransferase 1 1AF043324 + + + + + (NMT1) No arches-like (zebrafish) 1 U79569 + + + +zinc finger protein (NAR) non-histone chromosome 1 D50420 + + + + + +protein 2 (S. cerevisiae)- like 1 (NHP2L1) non-muscle (fibroblast) 1tropomyosin non-muscle alpha-actinin 1 U48734 non-muscle myosin alkali 3M22918 + + + + + + High in fetal adrenal light chain (Hs.77385) glandand BPH stroma non-neuronal enolase (EC 1 X16289 4.2.1.11) non-receptortyrosine 1 M33689 phosphatase 1 normal keratinocyte 3 X53778 + + + + + +high in many libraries substraction library mRNA, clone H22a notch groupprotein (N) 3 M99437 novel protein 1 X99961 novel T-cell activation 1X94232 + + + + protein N-ras protein NRU 1 A60196 N-sulfoglucosamine 1U60111 + + sulfohydrolase (sulfamidase) (SGSH) nsulin induced gene 1 1U96876 + + + + + + (INSIG1) ntegrin, alpha 4 (antigen 3 L12002 + +CD49D, alpha 4 subunit of VLA-4 receptor) (ITGA14) nterferon,gamma-inducible 1 M63838 + + + + + protein 16 (IFI16) nterleukin 1, beta(IL1RB) 1 M15330 nuclear antigen H731-like 2 U83908 + + + + proteinnuclear antigen Sp100 4 U36501 + + + + (SP100) Nuclear antigen Sp100 1P23497 (SP100) (85% aa) Nuclear antigen Sp100 1 P23497 (SP100) (89% aa)nuclear autoantigenic 1 M97856 + + sperm protein (histone- binding)(NASP) nuclear corepressor KAP-1 1 U78773 (KAP-1) (=U95040; X97548TIF1beta zinc finger protein) Nuclear domain 10 protein 4U22897 + + + + + + (NDP52) Nuclear factor (erythroid- 1 S74017 + + + + +derived 2)-like 2 (NFE2L2) Nuclear factor of kappa 2 M58603 + + + +light polypeptide gene enhancer in B-cells 1 (p105) (NFKB1) nuclearfactor of kappa 3 M69043 + + + + light polypeptide gene enhancer inB-cells inhibitor, alpha (NFKBIA) nuclear factor related to 1U08191 + + + + kappa B binding protein (NFRKB) nuclear mitotic apparatus3 Z11583 + + + + + + protein 1 (NUMA1) nuclear receptor 1 X97674coactivator 2 (GRIP1) nuclear receptor 2 AF010227 + + + + coactivator 3(AIB3) nuclear receptor 22 X77548 + + + + + coactivator 4 (ELE1) nuclearreceptor interacting 1 X84373 + + + protein 1 (NRIP1) nuclearrespiratory factor 1 1 U02683 B + + (NRF1) nuclear RNA helicase, 4U90426 + + + + + DECD variant of DEAD box family (DDXL) nucleartranscription factor 1 X59711 B Y, alpha (NFYA) nuclear transcriptionfactor, 3 U15306 + + + X-box binding 1 (NFX1) nuclear transport factor 21 X07315 + + + + + (placental protein 15) (PP15) nucleobindin (=M96824)1 U31336 nucleobindin 1 (NUCB1) 2 M96824 + + + + + nucleolarphosphoprotein 1 Z34289 + + p130 (P130) nucleolar protein (KKE/D 1Y12065 + + + + + repeat) (NOP56) nucleolar protein (MSP58) 1 AF015308nucleolar protein 1 (120 kD) 1 M32110 + + (NOL1) nucleolar protein p40 1U86602 + + + + + nucleolin (NCL) 2 M60858 + + + + + nucleophosmin(nucleolar 14 M28699 + + + + + phosphoprotein B23, numatrin) (NPM1)nucleophosmin-retinoic 1 U41742 acid receptor alpha fusion proteinNPM-RAR long form nucleoporin (NUP358) 2 L41840 (=D42063 RanBP2 (Ran-binding protein 2)) nucleoporin 153 kD 1 Z25535 (NUP153) nucleoporin 98kD (NUP98) 1 U41815 nucleosome assembly 1 D28430 protein nucleosomeassembly 1 M86667 + + + + protein 1-like 1 (NAP1L1) nucleosome assembly2 U77456 + + + + + protein 1-like 4 (NAP1L4) nucleosome assembly 1D28430 protein, 5′UTR olfactory receptor (OR7- 1 U86281 141) OLFACTORYRECEPTOR- 1 P34982 LIKE PROTEIN HGMP07E (OR17-4) (non-exact 65%)oligodendrocyte myelin 7 L05367 + glycoprotein (OMG) O-linked N- 1U77413 + + + + + acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine: polypeptide- N-acetylglucosaminyl transferase) (OGT)oncofetal trophoblast 1 A53531 glycoprotein 5T4 precursor (non-exact55%) Oncogene TIM (TIM) (non- 1 U02082 exact 84%) ORF (Hs.77868) 1M68864 + + + + + + ORF1; MER37; putative 1 U49973 transposase similar topogo element Length = 454 origin recognition complex, 2 U27459 + subunit2 (yeast homolog)- like (ORC2L) origin recognition complex, 1 AF022108subunit 4 (yeast homolog)- like (ORC4L) (low match) ornithineaminotransferase 2 M23204 + + + (gyrate atrophy) (OAT) ornithinedecarboxylase 1 M20372 (ODC) ornithine decarboxylase 11D78361 + + + + + + High in pancreas, antizyme, ORF 1 and ORF 2 andactivated T cells orphan receptor 2 U07132 + + + + + (Hs.100221) OS-9precurosor 6 AB002806 + + + + + + osteonectin (=X82259 BM- 1 D28381 40)ovel centrosomal protein 1 AB008515 + + + + RanBPM (RANBPM)over-expressed breast 1 L34839 tumor protein oviductal glycoprotein 1, 1U09550 + + + 120 kD (OVGP1) oxidase (cytochrome c) 1 X80695 + + + + +assembly 1-like (OXAIL) oxoglutarate 4 D10523 T + + + + dehydrogenase(lipoamide) (OGDH) oxysterol binding protein 1 M86917 + + + (OSBP) OZF 1X70394 + + + + OZF (non-exact zinc finger) 1 X70394p21/Cdc42/Rac1-activated 2 U51120 + + + kinase 1 (yeast Ste20- related)(PAK1) P35-related protein (= 1 D63392 S80990 ficolin) p40 1 U93569p40phox (=U50720) 1 X77094 P47 LBC oncogene 4 U03634 p53-induced protein1 AF010315 + + + + (PIG11) p54nrb (low match) 1 Y11287 p62 nucleoporin 1X58521 p63 mRNA for 1 X69910 + + + + + transmembrane protein PAC cloneDJ0701O16 1 Q07108 from 7q33-q36 (non-exact 54%) palmitoyl-protein 10U44772 + + + + thioesterase (ceroid- lipofuscinosis, neuronal 1,infantile; Haltia-Santavuori disease) (PPT) papillary renal cell 1X99720 + + + + + + carcinoma (translocation- associated) (PRCC) PARprotein 1 AF115850 + + partial EST (clone c-1gh04) 1 Z43627PAX3/forkhead 1 U02368 transcription factor gene fusion paxillin (PXN) 4D86862 + + + + PBK1 protein 2 AJ007398 + + + + + PBS-EST (nz92e01.s1 1AA732534 NCI_CGAP_GCB1 clone IMAGE: 1302936) (low score) PDZ domainprotein 1 AJ224747 + + + (Drosophila inaD-like) (INALD) PEBP2aC Runtdomain 1 Z38108 encoding gene (=Z35728) peptidase D (PEPD) 1 J04605peptidylprolyl isomerase A 3 Y00052 + + + + + high in many libraries(cyclophilin A) (PPIA) peptidylprolyl isomerase D 2 L11667 T + + + +(cyclophilin D) (PPID) peptidylprolyl isomerase E 1 AF042386 + + + +(cyclophilin E) (PPIE) PERB11.1 (=U56942 MHC 1 U69630 class Ichain-related protein A) perforin 1 (preforming 14 M28393 protein)(PRF1) peroxisomal acyl-CoA 2 X86032 thioesterase (PTE1) Peroxisomalacyl- 1 X71440 + + + + + coenzyme A oxidase peroxisomal farnesylated 1X75535 + + + + + protein (PXF) phorbol-12-myristate-13- 1 D90070 B, Wacetate-induced protein (PMAIP1) phosphate carrier 1 X77337(mitochondrial gene?) Phosphate carrier, 3 X60036 + + + + +mitochondrial (PHC) phosphate 1 L28957 T + + cytidylyltransferase 1,choline, alpha isoform (PCYT1A) PHOSPHATIDATE 1 Q92903CYTIDYLYLTRANSFERASE (CDP-DIGLYCERIDE) phosphatidylinositol 3- 2 U57843kinase delta catalytic subunit phosphatidylinositol 4- 3AB005910 + + + + + kinase, catalytic, beta polypeptide (PIK4CB)phosphatidylinositol glycan, 1 L19783 + + + + + class H (PIGH)phosphatidylinositol 2 D30037 transfer protein (PI-TPbeta)phosphatidylinositol 2 X98654 B, T + transfer protein, lymphomamembrane-associated (PITPNM) phosphatidylinositol 1 X98654 transferprotein, membrane-associated (PITPNM) (non-exact 64%)phosphatidylinositol-4- 1 U14957 + + phosphate 5-kinase, type II, alpha(PIP5K2A) phosphatidylinositol-4- 1 U85245 + + + + phosphate 5-kinase,type II, beta (PIP5K2B) phosphodiesterase 7A 1 L12052 B, W + + + (PDE7A)phosphodiesterase IB 1 U56976 ONLY (PDES1B) phosphoglucomutase 1 2M83088 + + + + (PGM1) phosphogluconate 1 U30255 + dehydrogenase (PGD)phosphoglycerate kinase 1 12 V00572 (PGK1) phosphoglycerate mutase 3J04173 + + + + + + 1 (brain) (PGAM1) phosphoglycerate mutase 1M55673 + + + 2 (muscle) (PGAM2) phosphoinositide-3-kinase, 1Z29090 + + + catalytic, alpha polypeptide (PIK3CA)phosphoinositide-3-kinase, 4 U86453 + + + + catalytic, delta polypeptide(PIK3CD) phosphoinositide-3-kinase, 1 X83368 catalytic, gammapolypeptide (PIK3CG) phospholipase C 1 X14034 phospholipase C, delta 1 2U09117 + + + + (PLCD1) phospholipase C, gamma 1 1 M34667 + + + + +(formerly subtype 148) (PLCG1) phospholipid scramblase 1 AF008445phosphoribosyl 1 D61391 + + + pyrophosphate synthetase- associatedprotein 1 (PRPSAP1) phosphoribosylglycinamide 3 X54199 + + + + +formyltransferase, phosphoribosylglycinamide synthetase,phosphoribosylaminoimidazole synthetase (GART) phosphorylase kinase, 3D38616 + + + + + alpha 2 (liver), glycogen storage disease IX (PHKA2)phosphorylase, glycogen; 1 U47025 + + + + brain (PYGB) phosphorylase,glycogen; 1 U47025 brain (PYGB) (low match, non-exact, 75%)phosphorylase, glycogen; 1 Y15233 + + + + liver (Hers disease, lycogenstorage disease type VI) (PYGL) phosphorylation regulatory 2 proteinHP-10 phosphotidylinositol 1 D30036 + + + + + transfer protein (PITPN)pigment epithelium-derived 1 U29953 + + + + + + factor (PEDF) pim-1oncogene (PIM1) 1 M24779 + + + + pinin, desmosome 1 U77718 B, associatedprotein (PNN) monocyte, T lymphoma placenta (Diff33) 5 U49188 + + + +placenta (Diff33) (non- 1 U49188 exact, 69%) placenta (Diff48) 18U49187 + placenta (Diff48) (low 1 U49187 match) placenta (Diff48) (low 1U49187 match) plasminogen activator, 1 X74039 + + + urokinase receptor(PLAUR) platelet factor 4 (PF4) 1 M25897 + + platelet/endothelial cell 8M37780 + + + + + adhesion molecule (CD31 ntigen) (PECAM1)platelet-activating factor 4 U89386 + + + acetylhydrolase 2 (40 kD)(PAFAH2) platelet-activating factor 1 U72342 + + + + + +acetylhydrolase, isoform lb, alpha subunit (45 kD) (PAFAH1B1)platelet-activating factor 1 D10202 + + receptor (PTAFR) pleckstrin(PLEK) 10 X07743 + + + pleckstrin (PLEK) (low 1 X07743 match) pleckstrinhomology, Sec7 4 M85169 + + + + and coiled/coil domains 1(cytohesin 1)(PSCD1) pleckstrin homology, Sec7 4 L06633 + + and coiled/coil domains,binding protein (PSCDBP) pM5 protein 1 X57398 + + + + + PMP69 2 Y14322poly (ADP-ribose) 1 X56140 polymerase (NAD (+) ADP- ribosyltransferase)(=X16674) poly(A) polymerase (PAP) 1 X76770 + + + + + poly(A)-bindingprotein-like 19 Y00345 + + + + + + 1 (PABPL1) poly(rC)-binding protein 13 X78137 + + + + + + (PCBP1) polyadenylate binding 1 U75686 proteinpolycystic kidney disease 1 5 U24498 (autosomal dominant) (PKD1)polymerase (DNA 1 D29013 + + + directed), beta (POLB) polymerase (DNA 6D84103 directed), gamma (POLG) polymerase (RNA) II (DNA 1X63564 + + + + + + directed) polypeptide A (220 kD) (POLR2A)polymyositis/scleroderma 1 L01457 + + + + + + autoantigen 2 (100 kD)(PMSCL2) polypyrimidine tract binding 1 X65372 + + + + + + protein(heterogeneous nuclear ribonucleoprotein I) (PTB) positive regulator of3 U13021 + programmed cell death ICH-1L (Ich-1) postmeiotic segregation1 M16514 + + + + + increased 2-like 12 (PMS2L12) postmeiotic segregation1 U38964 + + + + + increased 2-like 8 (PMS2L8) potassium inwardly- 1D87291 + + rectifying channel, subfamily J, member 15 (KCNJ15) potassiumvoltage-gated 1 AF051426 + + + + channel, KQT-like subfamily, member 1(KCNQ1) POU domain, class 2, 1 Z49194 + associating factor 1 (POU2AF1)POU domain, class 2, 2 X13403 + + transcription factor 1 (POU2F1) PPARbinding protein 1 Y13467 + + + + + (PPARBP) PPAR gamma2 1 D83233pre-B-cell colony- 8 U02020 enhancing factor (PBEF) prefoldin 1 (PFDN1)1 Y17392 + + + + + + prefoldin 5 (PRFLD5) 3 D89667 B + + + prefoldinsubunit 3 1 Y17394 (=U96759 von Hippel- Lindau binding protein (VBP-1))pregnancy-associated 1 U28727 + + high in placenta plasma protein A(PAPPA) pre-mRNA splicing factor 1 U08815 + + + + + SF3a (60 kD),similar to S. cerevisiae PRP9 (spliceosome-associated protein 61)(SF3A60) pre-mRNA splicing factor 1 U08815 SF3a (60 kD), similar to S.cerevisiae PRP9 (spliceosome-associated protein 61) (SF3A60) (low score)pre-mRNA splicing factor 2 D28423 SRp20, 5′UTR preprotein translocase 3X97544 + + + + + (TIM17) prion protein 1 X82545 prion protein (p27-30) 1M13899 + + + + (Creutzfeld-Jakob disease, Gerstmann-Strausler- Scheinkersyndrome, fatal familial insomnia) (PRNP) pristanoyl-CoA oxidase 1Y11411 (low match) pristanoyl-CoA oxidase 1 Y11411 (low score)procollagen-lysine, 2- 1 M98252 + + + + oxoglutarate 5-dioxygenase(lysine hydroxylase, Ehlers- Danlos syndrome type VI) (PLOD)procollagen-proline, 2- 1 M24486 + + + + + + oxoglutarate 4-dioxygenase(proline 4-hydroxylase), alpha polypeptide 1 (P4HA1)procollagen-proline, 2- 4 X05130 + + + + + + oxoglutarate 4-dioxygenase(proline 4-hydroxylase), beta polypeptide (protein disulfide isomerase;thyroid hormone binding protein p55) (P4HB) profilin 1 (PFN1) 1J03191 + + + + + + progesterone receptor- 2 U28918 + associated p48protein (P48) prohibitin (PHB) 1 S85655 + + + + + proliferating cellnuclear 3 J04718 + + + + + antigen (PCNA) proliferation-associated 4L19184 + + + + + + gene A (natural iller- enhancing factor A) (PAGA)proline-rich protein BstNI 1 S62936 subfamily 2 (PRB2) (non- exact, 43%aa) proline-serine-threonine 1 U94778 phosphatase interacting protein 1(PSTPIP1) prolyl endopeptidase 2 X74496 + + + (PREP)prolylcarboxypeptidase 5 L13977 + + + + + (angiotensinase C) (PRCP)promyelocytic leukemia 1 M80185 + + + + + (PML) properdin P factor, 4X57748 + complement (PFC) pro-platelet basic protein 1 M54995 + + +(includes platelet basic protein, beta- thromboglobulin, connectivetissue-activating peptide III, neutrophil-activating peptide-2) (PPBP)pro-platelet basic protein 7 M54995 + + + (includes platelet basicprotein, beta- thromboglobulin, connective tissue-activating peptideIII, neutrophil- activating peptide-2) (PPBP) proprotein convertase 4U40623 subtilisin/kexin type 7 (PCSK7) prosaposin (variant 89D00422 + + + + + + Gaucher disease and variant metachromaticleukodystrophy) (PSAP) prostaglandin- 1 U63846 B + + + endoperoxidesynthase 1 (prostaglandin G/H synthase and cyclooxygenase) (PTGS1)prostaglandin- 2 L15326 endoperoxide synthase 2 (prostaglandin G/Hsynthase and cyclooxygenase) (PTGS2) prostaglandin- 1 D64068endoperoxide synthase-1 (=L08404; U84208) (all promoters) prostatecarcinoma tumor 2 L78132 antigen (pcta-1) protease inhibitor 1 (anti- 17K02212 + + + + + high in many libraries elastase), alpha-1- antitrypsin(PI) protease inhibitor 2 (anti- 1 M93056 + + elastase),monocyte/neutrophil (ELANH2) (low match) proteasome (prosome, 3 L02426B + + + macropain) 26S subunit, ATPase, 1 (PSMC1) proteasome (prosome, 1M34079 + + + + + macropain) 26S subunit, ATPase, 3 (PSMC3) proteasome(prosome, 2 AF020736 macropain) 26S subunit, ATPase, 4 (PSMC4)proteasome (prosome, 5 L38810 + + + + + + macropain) 26S subunit,ATPase, 5 (PSMC5) proteasome (prosome, 2 D78275 + + + + + macropain) 26Ssubunit, ATPase, 6 (PMSC6) proteasome (prosome, 1 AF001212 T + +macropain) 26S subunit, non-ATPase, 11 (PSMD11) proteasome (prosome, 2D78151 + + + macropain) 26S subunit, non-ATPase, 2 (PSMD2) proteasome(prosome, 1 S79862 T + + + macropain) 26S subunit, non-ATPase, 5 (PSMD5)proteasome (prosome, 1 D50063 + + + + high in many libraries macropain)26S subunit, non-ATPase, 7 (Mov34 homolog) (PMSD7) proteasome (prosome,1 AB003103 + + + + macropain) 26S subunit, on-ATPase, 12 (PMSD12)proteasome (prosome, 3 L07633 + + + + + macropain) activator subunit 1(PA28 alpha) (PSME1) proteasome (prosome, 2 D00762 + + + + macropain)subunit, alpha type, 3 (PSMA3) proteasome (prosome, 3 X61970 + + + + +macropain) subunit, alpha type, 5 (PSMA5) proteasome (prosome, 3AF054185 + + + + + macropain) subunit, alpha type, 7 (PSMA7) proteasome(prosome, 1 AF022815 macropain) subunit, alpha type, 7 (PSMA7) (lowmatch) proteasome (prosome, 1 D00761 + + + + + + macropain) subunit,beta type, 1 (PSMB1) proteasome (prosome, 1 X71874 + + + + + macropain)subunit, beta type, 10 (PSMB10) proteasome (prosome, 1 D29012 + + + +macropain) subunit, beta type, 6 (PMSB6) proteasome (prosome, 1U17497 + + + + + macropain) subunit, beta type, 8 (large multifunctionalprotease 7) (PSMB8) proteasome (prosome, 3 Z14977 + + + macropain)subunit, beta type, 9 (large multifunctional protease 2) (PSMB9)proteasome (prosome, 1 D38048 + + + + + + macropain) subunit, beta type,7 (PSMB7) protective protein for beta- 3 M22960 + + + + + +galactosidase (galactosialidosis) (PPGB) protein A alternatively 1U47925 + spliced form 2 (A-2) protein activator of the 1AF072860 + + + + high in testis interferon-induced protein kinase (PACT)protein disulfide isomerase- 2 D49489 + + + + + + related protein (P5)protein 1 L25441 + + + geranylgeranyltransferase type I, beta subunit(PGGT1B) protein homologous to 20 M24194 + + + + + + high in manylibraries chicken B complex protein, guanine nucleotide binding (H12.3)protein kinase A anchoring 1 AF037439 + protein protein kinase Csubstrate 2 U50317 + + + + + 80K-H (PRKCSH) protein kinase C, beta 1 6X06318 + + + + + (PRKCB1) protein kinase C, delta 1 D10495 + + + + +(PRKCD) protein kinase C, eta 1 M55284 + + (PRKCH) protein kinase C, mu1 X75756 (PRKCM) (non-exact 78%) Protein kinase C-like 1 2D26181 + + + + + (PRKCL1) protein kinase, AMP- 1 U42412 B, T + +activated, gamma 1 non- lymphoma catalytic subunit (PRKAG1) proteinkinase, cAMP- 4 M18468 + + + + + dependent, regulatory, type I, alpha(tissue specific extinguisher 1) (PRKAR1A) protein kinase, DNA- 1U47077 + + + + activated, catalytic polypeptide (PRKDC) protein kinase,mitogen- 1 Z11695 B + + activated 1 (MAP kinase 1; p40, p41) (PRKM1)protein kinase, mitogen- 1 L77964 + + + + activated 6 (extracellularsignal-regulated kinase, p97) (PRKM6) protein kinase, mitogen- 1U66839 + + + + + activated, kinase 3 (MAP kinase kinase 3) (PRKMK3)protein phosphatase 1, 5 M63960 + + + + + + catalytic subunit, alphaisoform (PPP1CA) protein phosphatase 1, 3 Y13247 + + + + regulatorysubunit 10 (PPPR10) protein phosphatase 1, 2 Z50749 + + + + + +regulatory subunit 7 (PPP1R7) protein phosphatase 2 1 X12656 + + + + + +(formerly 2A), catalytic subunit, beta isoform (PPP2CB) proteinphosphatase 2 1 L07590 + + + (formerly 2A), regulatory subunit B″ (PR72), alpha isoform and (PR 130), beta isoform (PPP2R3) proteinphosphatase 2, 2 L42373 + + + + + regulatory subunit B (B56), alphaisoform (PPP2R5A) protein phosphatase 2, 3 D78360 + + + + regulatorysubunit B (B56), delta isoform (PPP2R5D) protein phosphatase 2, 1D26445 + + + + + regulatory subunit B (B56), gamma isoform (PPP2R5C)protein phosphatase 2A 5 J02902 + + + + + regulatory subunit alpha-isotype (alpha-PR65) protein phosphatase 4 2 AF097996 + + + + +(formerly X), catalytic subunit (PPP4C) protein tyrosine kinase 2 4L49207 + + + beta (PTK2B) protein tyrosine 1 X54134 phosphatase epsilonprotein tyrosine 2 L48723 + + + + + phosphatase type IVA, member 2(PTP4A2) protein tyrosine 1 M31724 + + + + phosphatase, non-receptortype 1 (PTPN1) protein tyrosine 1 M93425 + + + + high in testisphosphatase, non-receptor type 12 (PTPN12) protein tyrosine 1 M93425phosphatase, non-receptor type 12 (PTPN12) (non- exact, 70%) proteintyrosine 2 M25393 + + + + phosphatase, non-receptor type 2 (PTPN2)protein tyrosine 1 M68941 + + + phosphatase, non-receptor type 4(megakaryocyte) (PTPN4) protein tyrosine 7 M74903 + + + + + phosphatase,non-receptor type 6 (PTPN6) protein tyrosine 1 D11327 + + + phosphatase,non-receptor type 7 (PTPN7) protein tyrosine 1 M34668 + + + + +phosphatase, receptor type, alpha polypeptide (PTPRA) protein tyrosine44 Y00638 + + + + phosphatase, receptor type, c polypeptide (PTPRC)protein tyrosine 1 X58288 + + + + phosphatase, receptor type, M (PTPRM)protein tyrosine 2 U81561 + + + phosphatase, receptor type, Npolypeptide 2 (PTPRN2) protein with polyglutamine 1 U94836 + + + + +repeat (ERPROT213-21) protein-kinase, interferon- 1 U28424 + + + + +inducible double stranded RNA dependent inhibitor (PRKRI)protein-L-isoaspartate (D- 4 D13892 + + aspartate) O- methyltransferase(PCMT1) proteoglycan 1, secretory 7 J03223 + + + granule (PRG1)prothymosin, alpha (gene 12 M14483 + + + + + + sequence 28) (PTMA)prp28, U5 snRNP 100 kd 7 AF026402 + + + + + protein (U5-100K)PRP4/STK/WD splicing 1 AF001687 + + + + factor (HPRP4P) PTK7 proteintyrosine 1 U40271 + + + + kinase 7 (PTK7) purinergic receptor P2X, 3AF000234 + + + + ligand-gated ion channel, 4 (P2RX4) purinergic receptorP2X, 1 Y12851 + macrophage only ligand-gated ion channel, 7 (P2RX7)puromycin-sensitive 1 Y07701 + + + aminopeptidase (PSA) putativeATP(GTP)-binding 2 AJ010842 + + protein putative brain nuclearly- 1AB018308 + + + + + targeted protein (KIAA0765) putative chemokine 1D10923 + receptor; GTP-binding protein (HM74) putative dienoyl-CoA 1AF030249 isomerase (ECH1) putative G-binding protein 1 AF065393 Putativehuman HLA class 1 U73477 B + + II associated protein I (PHAP1) PutativeL-type neutral 1 AB007896 amino acid transporter (KIAA0436) putativemitochondrial 1 AF050198 space protein 32.1 PUTATIVE MUCIN CORE 1 Q04900PROTEIN PRECURSOR 24 (MULTI- GLYCOSYLATED CORE PROTEIN 24) (MGC-24)(MUC-24) putative nucleic acid 2 X76302 + + + + + binding proteinputative outer 1 U58970 + + + + mitochondrial membrane 34 kDatranslocase Htom34 putative p150 (non-exact 1 U93568 88%) putativetranslation 1 L26247 + + + + + + High in moderately initiation factor(SUI1) differentiated colon adenocarcinoma putative tumor suppressor 1AF061836 + + + + protein (123F2) pyrroline 5-carboxylate 1M77836 + + + + + reductase pyruvate dehydrogenase 1 D90084 + + + + +(lipoamide) alpha 1 (PDHA1) pyruvate dehydrogenase 2 J03576 + + + + +(lipoamide) beta (PDHB) Pyruvate dehydrogenase 3 Y13145 + + complex,lipoyl-containing component X; E3-binding protein (PDX1) pyruvatekinase, muscle 11 M23725 + (PKM2) RAB, member of RAS 1 U18420 + + + +oncogene family-like (RABL) RAB1, member RAS 3 M28209 + + + + oncogenefamily (RAB1) RAB11A, member RAS 2 X56740 + + + + + high in spleenoncogene family (RAB11A) RAB11B, member RAS 1 D45418 + + oncogene family(Rab11B) RAB27A, member RAS 3 U38654 + oncogene family (RAB27A) RAB5B,member RAS 1 X54871 + + + + oncogene family (RAB5B) RAB6, member RAS 1M28212 + + oncogene family (RAB6) RAB7, member RAS 1 X93499 + + + + +oncogene family (RAB7) RAB7, member RAS 2 D84488 + + + + oncogenefamily-like 1 (RAB7L1) RAB9, member RAS 1 U44103 oncogene family (RAB9)RAD50 (S. cerevisiae) 2 U63139 + + + homolog (RAD50) RAD51 (S.cerevisiae) 1 AF029669 + + + + homolog C (RAD51C) Radin blood group (RD)2 L03411 + + + + RAE1 (RNA export 1, 3 U84720 + + + + + S. pombe)homolog (RAE1) ralA-binding protein 2 L42542 + + + + (RLIP76) RANbinding protein 2-like 2 AF012086 1 (RANBP2L1) Ran GTPase activating 3X82260 + + + + + protein 1 (RANGAP1) RAN, member RAS 1 M31469 oncogenefamily (RAN) (low match) RanBP2 (Ran-binding 1 D42063 protein 2)(=U19248; L41840 sapiens nucleoporin (NUP358)) ransforming growthfactor, 4 D50683 + + + + + beta receptor II (70-80 kD) (TGFBR2) RAP1A,member of RAS 10 M22995 + + + + + + oncogene family (RAP1A) RAR-relatedorphan 1 U16997 + receptor C (RORC) RAS guanyl releasing 1 Y12336 + +protein 2 (calcium and DAG-regulated) ras homolog gene family, 12X05026 + + + + + + high in ovary member A (ARHA) ras homolog genefamily, 1 X61587 + + + + member G (rho G) (ARHG) ras homolog genefamily, 2 Z35227 + + + + member H (ARHH) ras inhibitor (RIN1) 2 M37191 +Ras-GTPase activating 2 AF053535 + + + + + protein SH3 domain- bindingprotein 2 (KIAA0660) Ras-GTPase-activating 3 U32519 + + + + + proteinSH3-domain- binding protein (G3BP) ras-related C3 botulinum 11M29871 + + toxin substrate 2 (rho family, small GTP binding proteinRac2) (RAC2) RAS-RELATED PROTEIN 1 P09526 RAP-1B (GTP-BINDING PROTEINSMG P21B) RBQ-1 1 X85133 + + + rearranged T cell receptor 1 L06891 betavariable region (TCRB) (=X58810) regulator of Fas-induced 1 AF057557 B +apoptosis (TOSO) regulator of G protein 1 AF073920 + signalling 6 (RGS6)regulator of G-protein 2 AF037195 + + + + signalling 14 (RGS14)regulator of G-protein 6 L13391 + + + + + signalling 2, 24 kD (RGS2)regulator of G-protein 1 O15539 signalling 5 (RGS5) (49% aa) regulatoryfactor X, 4 1 M69297 + + (influences HLA class II expression) (RFX4)regulatory factor X, 5 2 X85786 T + + + (influences HLA class IIexpression (RFX5) replication protein A1 1 M63488 + + + + + (RPA1)replication protein A3 1 L07493 (14 kD) (RPA3) (low match) reproduction8 (D8S2298E) 1 D83767 + + + requiem, apoptosis 2 U94585 + + + + +response zinc finger gene (REQ) requiem, apoptosis 1 U94585 responsezinc finger gene (REQ) (=AF001433) (low match) restin (Reed-Steinbergcell- 1 M97501 B, T + + expressed intermediate filament-associatedprotein) (RSN) retinoblastoma 1 (including 3 L11910 + + + +osteosarcoma) (RB1) retinoblastoma binding 1 AF087481 protein 2 homolog1 (RBBP2H1) retinoblastoma-binding 1 S66427 + + protein 1 (RBBP1)retinoblastoma-binding 5 S66431 + + + + + protein 2 (RBBP2)retinoblastoma-binding 1 X71810 + + + + protein 4 (RBBP4)retinoblastoma-binding 1 X74262 + + + + protein 4 (RBBP4)retinoblastoma-binding 1 U35143 protein 7 (RBBP7) retinoblastoma-like 21 X76061 + + + + (p130) (RBL2) retinoic acid receptor 1 AF060228 + + + +responder (tazarotene nduced) 3 (RARRES3) retinoic acid receptor, 1X06538 + + + alpha (RARA) retinoic acid responsive 1 U50383 + + +(NN8-4AG) retinoid X receptor beta 2 X66424 + + + + (RXR-beta) REV3(yeast homolog)-like, 1 AF035537 catalytic subunit of DNA polymerasezeta (REV3L) Rho GDP dissociation 23 L07916 + + + + + + inhibitor (GDI)beta (ARHGDIB) Rho GTPase activating 2 X78817 + + protein 4 (ARHGAP4)Rho GTPase activating 1 P98171 protein 4 (ARHGAP4) (low match)Rho-associated, coiled-coil 1 AB014519 containing protein kinase 2(ROCK2) ribonuclease 6 precursor 2 U85625 + + + + + + (RNASE6PL)ribonuclease 6 precursor 1 U85625 (RNASE6PL) (low match) ribonuclease,RNase A 1 X55988 + family, 2 (liver, eosinophil- derived neurotoxin)(RNASE2) ribonuclease/angiogenin 3 M36717 + + + + + inhibitor (RNH)ribonucleoside diphosphate 1 X65708 reductase M1 subunit ribonucleotidereductase 1 P31350 M2 polypeptide (non-exact 91%) ribophorin I (RPN1) 1Y00281 + + + + + ribophorin II (RPN2) 1 Y00282 + + + + + + ribosomal 18SrRNA 3 M10098 ribosomal 28S RNA 1 M11167 ribosomal phosphoprotein 1D28418 P0, 5′UTR (low match) Ribosomal protein 1 ribosomal protein L1030 L25899 + + + + + + high in many libraries (RPL10) RIBOSOMAL PROTEIN 2P53025 L10A (CSA-19) ribosomal protein L11 4 X79234 + + + + + + Alveolar(RPL11) rhabdomyosarcoma ribosomal protein L12 2 L06505 + + + + + +(RPL19) ribosomal protein L13 1 P26373 + + + + + + high in manylibraries (PRL13) ribosomal protein L14 4 D87735 + + + + + + high inmany libraries (RPL14) ribosomal protein L17 4 X53777 + blood only(RPL17) ribosomal protein L18 10 L11566 + + + + + (RPL18) ribosomalprotein L18a 5 L05093 + + + + + High in fetal adrenal (RPL18A) gland andskin ribosomal protein L18a 2 X80821 + homologue ribosomal protein L1915 X63527 + + + + + + (RPL19) ribosomal protein L21 6 U14967 + + + + + +(RPL21) ribosomal protein L22 3 D17652 + + + + + (RPL22) ribosomalprotein L23 2 X55954 + + + + + + high in many libraries (RPL23)ribosomal protein L23a 5 U37230 + + + + + + high in many libraries(RPL23A) ribosomal protein L26 8 X69392 + + + + + + (RPL26) ribosomalprotein L27 6 L05094 + + + + + (RPL27) ribosomal protein L27a 10U14968 + + + + + + (RPL27A) ribosomal protein L28 6 U14969 + + + + +(RPL28) ribosomal protein L29 6 U10248 + + + + + + (RPL29) ribosomalprotein L3 81 + + + + + + high in many libraries (RPL3) ribosomalprotein L3 81 X06323 homologue ribosomal protein L30 6X79238 + + + + + + high in lymphoma (RPL30) ribosomal protein L30 1X79238 (RPL30) (low score) ribosomal protein L31 10 X15940 + + + + + +High in alveolar (RPL31) rhabdomyosarcoma ribosomal protein L32 3X03342 + + + + + + (RPL32) ribosomal protein L33-like 1 AF047440 + + + +(RPL33L) ribosomal protein L34 5 L38941 + + + + + (RPL34) ribosomalprotein L34 1 L38941 (RPL34) (low match) ribosomal protein L37 5D23661 + + + + + + high in barstead (RPL37) prostate ribosomal proteinL37a 4 X66699 + + + + + + high in many libraries ribosomal protein L38 1Z26876 + + + + + + high in many libraries (PRL38) ribosomal protein L427 D23660 + + + + + + high in many libraries (RPL4) ribosomal proteinL41 4 AF026844 + + + + + + high in many libraries (RPL41) ribosomalprotein L5 14 U14966 + + + + + + High in alveolar (RPL5)rhabdomyosarcoma ribosomal protein L5 1 U14966 (RPL5) (low match)ribosomal protein L6 7 X69391 + + + + + + high in many libraries (RPL6)ribosomal protein L7 14 X52967 + + + + + + high in conorm (RPL7)ribosomal protein L7a 15 M36072 + + + + + + High in uterus, and (RPL7A)seminoma ribosomal protein L8 5 Z28407 + + + + + + high in ovary (RPL8)ribosomal protein L9 10 U09953 + + + + + (RPL9) ribosomal protein S10 5U14972 + + + + + + high in many libraries (RPS10) ribosomal protein S114 X06617 + + + + + + high in many libraries (RPS11) ribosomal proteinS11 1 AB007152 (RPS11) (low match) ribosomal protein S12 3X53505 + + + + + + high in many libraries (RPS12) ribosomal protein S132 L01124 + + + + + (RPS13) ribosomal protein S14 12 M13934 + + + + + +(RPS14) ribosomal protein S15 2 M32405 + + + + + + (RPS15) ribosomalprotein S16 3 M60854 + + + + + + High in prostate (RPS16) invasive tumorribosomal protein S17 2 M13932 + + + + + + high in many libraries(RPS17) ribosomal protein S18 8 X69150 ribosomal protein S19 7M81757 + + + + + + high in many libraries (RPS19) ribosomal protein S2 4X17206 + + + + + + high in many libraries (RPS2) RIBOSOMAL PROTEIN S2 2P15880 (RPS4) ribosomal protein S20 7 L06498 + + + + + + high in manylibraries (RPS20) ribosomal protein S21 3 L04483 + + + + + + high inCD34+/CD38− (RPS21) hematopoietic cells and skin tumor ribosomal proteinS23 3 D14530 + + + + (RPS23) ribosomal protein S24 7 M31520 + + + + + +high in uterus (RPS24) ribosomal protein S25 3 M64716 + + + + + + highin barstead (RPS25) prostate ribosomal protein S26 2 X69654 + + + + +(RPS26) ribosomal protein S27 5 U57847 + + + + + +((metallopanstimulin 1) (RPS27) ribosomal protein S28 3 U58682 + + + + +(RPS28) ribosomal protein S29 2 U14973 + + + + + + (RPS29) ribosomalprotein S3 9 X55715 + + + + + + high in many libraries (RPS3) ribosomalprotein S3 1 U14990 (RPS3) (low match) ribosomal protein S3A 21Z83334 + + + + + high in many libraries (RPS3A) ribosomal protein S3A 1M77234 (RPS3A) (low score) ribosomal protein S4, X- 9 M58458 + + + + +high in ovary and linked (RPS4X) Synovial sarcoma ribosomal protein S4,Y- 2 M58459 + + + + + + linked (RPS4Y) ribosomal protein S5 4U14970 + + + + + + high in lymphoma (RPS5) RIBOSOMAL PROTEIN S6 1 P10660(PHOSPHOPROTEIN NP33) ribosomal protein S6 22 M20020 + + + + + + (RPS6)ribosomal protein S6 1 M77232 (RPS6) (non-exact 86%) ribosomal proteinS6 3 L07597 + + + + + kinase, 90 kD, polypeptide 1 (RPS6KA1) ribosomalprotein S6 1 X85106 kinase, 90 kD, polypeptide 2 (RPS6KA2) ribosomalprotein S7 4 Z25749 + + + + + (RPS7) ribosomal protein S8 6X67247 + + + + + (RPS8) ribosomal protein S9 8 U14971 colon tumor (RPS9)ribosomal protein, large, P0 18 M17885 T + + (RPLP0) ribosomal protein,large, P1 12 M17886 T + + + (RPLP1) ribosomal RNA 18S 11 X03205(=M10098; K03432) (=polyadenylating sequence) ribosomal RNA 28S 2 M11167ribosomal RNA, 16S 1 U25123 ring finger protein (non- 1 AJ001019 exact58%) ring finger protein 3 (RNF3) 1 AJ001019 ring finger protein 4(RNF4) 3 AB000468 + + + + ring zinc-finger protein 3 U41315 + + + +(ZNF127-Xp) RNA (guanine-7-) 1 AB007858 + + + + methyltransferase (RNMT)RNA binding motif protein 5 4 U23946 + + + + + (RBM5) RNA binding motif,single 1 D28483 + + + stranded interacting protein 2 (RBMS2) RNAhelicase (putative), 1 X98743 + + + + + (Myc-regulated DEAD box protein)(MRD8) RNA helicase-related 1 AF083255 + + + + protein RNA pol IIlargest subunit 2 X74872 RNA polymerase I subunit 1 AF008442 + + +(RPA40) RTVP-1 protein 2 X91911 + + + + + S100 calcium-binding 2M81457 + + + protein A10 (annexin II ligand, calpactin I, lightpolypeptide (p11)) (S100A10) S100 calcium-binding 1 X80201 + + + +protein A11 (calgizzarin) (S100A11) S100 calcium-binding 3 M80563 B + +protein A4 (calcium protein, calvasculin, metastasin, murine placentalhomolog)(S100A4) S100 calcium-binding 7 M21005 + + + high in bone marrowprotein A8 (calgranulin A) (S100A8) S100 calcium-binding 14 X06233 + +high in invasive protein A9 (calgranulin B) larynx squamous cell(S100A9) carcinoma S164 gene 1 AF109907 S-adenosylmethionine 3M88003 + + + + + decarboxylase 1 (AMD1) SB classII 5 M27487 + + + + +histocompatibility antigen alpha-chain SC35-interacting protein 1 5AF030234 + + + + + + (SRRP129) scaffold attachment factor 1U72355 + + + + + B (SAFB) scaffold attachment factor 1 U72355 B (SAFB)(non-exact 78%) scRNA molecule, 1 L13713 transcribed from Alu repeatSEC14 (S. cerevisiae)-like 4 D67029 + + + + (SEC14L) SEC23-like proteinB 2 X97065 + + + + + (SEC23B) SEC63 (SEC63) 1 AF100141 + + + secretedprotein, acidic, 7 M25746 + + + + + high in bone marrow cysteine-rich(osteonectin) stroma (SPARC) secretory carrier 1 AF038966 + + membraneprotein 1 (SCAMP1) secretory carrier 1 AF005038 + + + + + + membraneprotein 2 (SCAMP2) secretory carrier 1 AF005039 membrane protein 3(SCAMP3) secretory granule 1 M33649 proteoglycan core (cloneslambda-PG[6,7,8]) selectin L (lymphocyte 43 X17519 + + + adhesionmolecule 1) (SELL) selectin P ligand (SELPLG) 13 U02297 + + sema domain,2 U60800 + + + immunoglobulin domain (Ig), transmembrane domain (TM) andshort cytoplasmic domain, (semaphorin) 4D (SEMA4D) Ser/Arg-relatednuclear 4 AF048977 + + + + + matrix protein (plenty of prolines101-like) (SRM160) serine palmitoyltransferase 1 Y08685 + + + + subunitI (SPTI) serine palmitoyltransferase, 1 AB011098 + + + + + subunit II(LCB2) serine protease 1 J02907 serine protease inhibitor, 1U78095 + + + + + Kunitz type, 2 (SPINT2) serine/threonine kinase 10 1AB015718 + + + + + (STK10) serine/threonine kinase 19 1 L26260 + + + +(STK19) serine/threonine kinase 4 1 U18297 + + (STK4) serine/threonineprotein 1 X66358 + + + + kinase KKIALRE (KKIALRE) serine/threonineprotein- 1 Y10256 + + + kinase (NIK) SERINE/THREONINE- 1 P37023 PROTEINKINASE RECEPTOR R3 PRECURSOR (SKR3) serologically defined colon 2AF039694 cancer antigen 16 (NY-CO- 16) serologically defined colon 1AF039698 B, T + + + cancer antigen 33 (SDCCAG33) serologically definedcolon 1 AF039698 cancer antigen 33 (SDCCAG33) (low score) serologicallydefined colon 1 AF039698 cancer antigen 33 (SDCCAG33) (low score) serumdeprivation 1 AF085481.1 response (phosphatidylserine-binding protein)(SDPR) (=S67386) serum/glucocorticoid 2 Y10032 + + + + + regulatedkinase (SGK) SET domain, bifurcated 1 2 D31891 + + + + (SETDB1) SH2domain protein 1A, 1 AF073019 T + Duncan's disease lymphoproliferativesyndrome) (SH2D1A) SH3 binding protein (SAB) 2 AB005047 + + + + + SH3domain protein 1B 4 U61167 + + + (SH3D1B) SH3BGR PROTEIN (=21- 1 P55822GLUTAMIC ACID-RICH PROTEIN; 21-GARP) (non- exact 82% aa) SH3-bindingdomain 1 AF042081 + + + + + glutamic acid-rich protein like (SH3BGRL)SH3-domain GRB2-like 1 1 U65999 + + + + + (SH3GL1) SHC (Src homology 2 2X68148 + + + + domain-containing) transforming protein 1 (SHC1) siahbinding protein 1 2 U51586 + + + + (SiahBP1) siah binding protein 1 1U51586 (SiahBP1) (non-exact, 69%) Sialomucin CD164 9 D14043 (CD164)sialophorin (gpL115, 2 J04536 leukosialin, CD43) (SNP) sialyltransferase(STHM) 1 U14550 + + + sialyltransferase 1 (beta- 2 X17247 + + + + + +galactoside alpha-2,6- sialytransferase) (SIAT1) sialyltransferase 4A(beta- 1 AF059321 B + + + + galactosidase alpha-2,3- sialytransferase)(SIAT4A) sialyltransferase 8 (alpha- 1 L41680 +2,8-polysialytransferase) D (SIAT8D) signal peptidase 25 kDa 1 L38950subunit signal recognition particle 1 X73459 + + + + + + 14 kD(homologous Alu RNA-binding protein) (SRP14) signal recognition particle1 U51920 + + + 54 kD (SRP54) signal recognition particle 2U20998 + + + + + 9 kD (SRP9) signal recognition particle 5 X06272receptor (‘docking protein’) SRPR signal regulatory protein, 5Y10376 + + beta, 1 (SIRP-BETA-1) signal sequence receptor, 2 Z12830 + +alpha (translocon- associated protein alpha) (SSR1) signal sequencereceptor, 2 X74104 + + + + + beta (translocon- associated protein beta)(SSR2) signal transducer and 4 L41142 + + + + + + activator oftranscription (STAT5A) signal transducer and 1 U18671 + activator oftranscription 2, 113 KD (STAT2) signal transducer and 3 L29277 activatorof transcription 3 (acute-phase response factor) (STAT3) signaltransducer and 2 U48730 + + + + + + activator of transcription 5A(STAT5A) signal transducing adaptor 1 U43899 molecule (SH3 domain andITAM motif) 1 (STAM) silencing mediator of 1 U37146 retinoid and thyroidhormone action (SMRT) similar to beta-transducin 1 U02609 + + + +superfamily proteins (SAZD) similar to S. cerevisiae 1 AB011169 + + + +SSM4 (TEB4) similar to yeast pre-mRNA 1 AF026031 + + + + + splicingfactors, Prp1/Zer1 and Prp6 SIT protein 1 AJ010059.1 Sjogren syndromeantigen 2 M62800 + A1 (52 kD, ribonucleoprotein autoantigen SS-A/Ro)(SSA1) Sjogren syndrome antigen 1 M62800 A1 (52 kD, ribonucleoproteinautoantigen SS-A/Ro) (SSA1) (non-exact 63%) (match to zinc finger)SKAP55 homologue 1 AJ004886 + + + + (SKAP-HOM) skb1 (S. pombe) homolog 2AF015913 + + + + + (SKB1) skeletal muscle abundant 1 X87613 + + + + +protein SMA3 (SMA3) 1 X83300 + + + + small acidic protein 3U51678 + + + + + small EDRK-rich factor 2 2 Y10351 + + + + + + high infetal lung (SERF2) small inducible cytokine A5 2 M21121 + + + + + + highin many libraries (RANTES) (SCYA5) small inducible cytokine 1 D63789subfamily C, member 2 (SCYC2) small nuclear 2 M15841 + + + +ribonucleoprotein polypeptide B″ (SNRPB2) small nuclear 4J04615 + + + + + + ribonucleoprotein polypeptide N (SNRPN) small nuclear2 J04564 + + + + + ribonucleoprotein polypeptides B and B1 (SNRPB) smallnuclear RNA 1 AF093593 + + + + + activating complex, polypeptide 5, 19kD (SNAPC5) smallest subunit of 1 D55636 + + + + + + high in fetal lungubiquinol-cytochrome c reductase SMC (mouse) homolog, X 1L25270 + + + + + chromosome (SMCX) SMT3B protein (2) 2X99585 + + + + + + SNARE protein (YKT6) (low 1 U95735 match) SNC19 1U20428 SNC73 protein (SNC73) 2 J00220 + + + + + high in many librariessolute carrier family 1 2 U53347 + + + (neutral amino acid transporter),member 5 (SLC1A5) Solute carrier family 11 7 D50403 + (proton-coupleddivalent metal ion transporters), member 1 (SLC11A1) solute carrierfamily 17 1 U90545 + (sodium phosphate), member 3 (SLC17A3) solutecarrier family 19 1 U17566 B, + + (folate transporter), lymphoma member1 (SLC19A1) solute carrier family 2 1 K03195 + + + + + + (facilitatedglucose transporter), member 1 (SLC2A1) solute carrier family 23 3D87075 + + + + (nucleobase transporters), member 2 (SLC23A2) solutecarrier family 25 1 AF070548 B, T + + + + (mitochondrial carrier;oxoglutarate carrier), member 11 (SLC25A11) solute carrier family 31 3U83461 + + (copper transporters), member 2 (SLC31A2) solute carrierfamily 4, 1 X62137 + + + anion exchanger, member 2 (erythrocyte membraneprotein band 3-like 1) (SLC4A2) solute carrier family 4, 1 AB018282 +sodium bicarbonate cotransporter, member 8 (SLC4A8) solute carrierfamily 7 2 M80244 T, W + + + (cationic amino acid transporter, y+system), member 5 (SLC7A5) solute carrier family 7 3 D87432 + + + +(cationic amino acid transporter, y+ system), member 6 (SLC7A6) solutecarrier family 7 1 D87432 (cationic amino acid transporter, y+ system),member 6 (SLC7A6) (non- exact 77%) solute carrier family 9 1AF030409 + + + + (sodium/hydrogen exchanger), isoform 6 (SLC9A6) somaticcytochrome c 2 M22877 (HCS) SON DNA binding protein 2 X63753 + + + +(SON) son of sevenless 1 L13858 + + + (Drosophila) homolog 1 (SOS1)sorcin (SRI) 1 M32886 sortilin 1 (SORT1) 2 X98248 + + + sortilin-relatedreceptor, 6 Y08110 L(DLR class) A repeats- containing (SORL1) sortingnexin 1 (SNX1) 3 U53225 + + + + + sorting nexin 2 (SNX2) 2 AF043453sorting nexin 6 (SNX6) 1 AF121856.1 (=U83194.1 TRAF4- associated factor2) Sp3 transcription factor 1 X68560 + + + + + (SP3) Sp3 transcriptionfactor 4 M97191 + + + + + (SP3) special AT-rich sequence 1 M97287binding protein 1 (binds to nuclear matrix/scaffold- associating DNA's)(SATB1) speckle-type POZ protein 4 AJ000644 (SPOP) speckle-type POZprotein 1 AJ000644 (SPOP) (non-exact) spectrin SH3 domain 6U87166 + + + + binding protein 1 (SSH3BP1) Spectrin, alpha, non- 2J05243 + + + erythrocytic 1 (alpha-fodrin) (SPTAN1) spermidine/spermineN1- 11 M55580 acetyltransferase (SAT) spermidine/spermine N1- 1 U40369acetyltransferase (SAT) (non-exact, 84%) spermine synthase (SMS) 1AD001528 + + + + + SPF31 (SPF31) 1 AF083190 + + + + + sphingomyelin 1X52679 + + + phosphodiesterase 1, acid lysosomal (acid sphingomyelinase)(SMPD1) SPINDLIN HOMOLOG 1 Q99865 (PROTEIN DXF34) spinocerebellar ataxia1 3 X79204 B + + (olivopontocerebellar ataxia 1, autosomal dominant,ataxin 1) (SCA1) spinocerebellar ataxia 2 1 U70323 B +(olivopontocerebellar ataxia 2, autosomal dominant, ataxin 2) (SCA2)spinocerebellar ataxia 7 2 AJ000517 + (olivopontocerebellar atrophy withretinal degeneration) (SCA7) spliceosome associated 3 U41371 + + + + +protein (SAP 145) splicing factor (CC1.3) 2 L10910 + + + + + + (CC1.3)splicing factor SRp40-1 7 U30826 + + + + + + (SRp40) splicing factor, 3M74002 B + + + + arginine/serine-rich 11 (SFRS11) splicing factor, 4L41887 + + + + arginine/serine-rich 7 (35 kD) (SFRS7) Src-like adapterprotein 1 U30473 (non-exact, 76% aa) Src-like-adapter (SLA) 6D89077 + + + + Src-like-adapter (SLA) (low 1 D89077 match)Src-like-adapter (SLA) (low 1 U44403 score) stannin (SNN) 2AF030196 + + + + + STAT induced STAT 1 AB004904 + inhibitor 3 (SSI-3)STE20-like kinase 3 (MST- 2 AF024636 + + + + + 3) step II splicingfactor SLU7 1 AF101074 + + + + (SLU7) steroid sulfatase 1 M17591 steroidsulfatase 1 J04964 + + + (microsomal), arylsulfatase C, isozyme S (STS)sterol carrier protein 2 1 M55421 + + + + + (SCP2) sterolO-acyltransferase 1 AF059202 + (acyl-Coenzyme A: cholesterolacyltransferase) 1 (SOAT1) stimulated trans-acting 6 X82200 + + + factor(50 kDa) (STAF50) Striatin, calmodulin-binding 1 U17989 protein (STRN)(low match, 71% aa) Stromal antigen 2 (STAG2) 2 Z75331 + + + + stromalinteraction 3 U52426 + + + + + molecule 1 (STIM1) structure specific 1M86737 + + + + recognition protein 1 (SSRP1) succinate dehydrogenase 5L21936 + complex, subunit A, flavoprotein (Fp) (SDHA) succinatedehydrogenase 1 U17248 + + + + + complex, subunit B, iron sulfur (Ip)(SDHB) succinate dehydrogenase 1 U57877 + + + + + complex, subunit C,integral membrane protein, 15 kD (SDHC) succinate dehydrogenase 3AB006202 + + + complex, subunit D, Integral membrane protein (SDHD)succinate-CoA ligase, 1 AF058954 + + + + + GDP-forming, beta subunit(SUCLG2) succinyl CoA synthetase 1 Z68204 sudD (suppressor of 2AF013591 + + + bimD6, Aspergillus nidulans) homolog (SUDD)sulfotransferase family 1A, 1 L19999 + + + phenol-preferring, member 1(SULT1A1) sulfotransferase family 1A, 1 U37686 phenol-preferring, member3 (SULT1A3) (non-exact 67%) superoxide dismutase 1, 4 X02317 + + + +soluble (amyotrophic lateral sclerosis 1 (adult)) (SOD1) superoxidedismutase 2, 5 Y00985 + + + + + mitochondrial (SOD2) supervillin (SVIL)2 AF051851 + + + suppression of 2 U15131 + + + tumorigenicity 5 (ST5)suppression of 1 U15779 tumorigenicity 5 (ST5) (non-exact 82%)suppressor of K+ transport 1 AF038960 + + defect 1 (SKD1) suppressor ofTy 1 AF064804 + + + + + (S. cerevisiae) 3 homolog (SUPT3H) suppressor ofTy 2 U38817 + + + + + (S. cerevisiae) 4 homolog 1 (SUPT4H1) suppressorof Ty 2 U56402 + + (S. cerevisiae) 5 homolog (SUPT5H) suppressor of Ty 2U46691 + + + + + + (S. cerevisiae) 6 homolog (SUPT6H) suppressor ofvariegation 1 AF019968 + + + 3-9 (Drosophila) homolog 1 (SUV39H1)survival of motor neuron 1, 1 U18423 telomeric (SMN1) SWI/SNF related,matrix 1 M88163 + + + associated, actin dependent regulator ofchromatin, subfamily a, member 1 (SMARCA1) (non-exact, 75%) SWI/SNFrelated, matrix 2 D26155 + associated, actin dependent regulator ofchromatin, subfamily a, member 2 (SMARCA2) SWI/SNF related, matrix 1D26156 + + + + + + associated, actin dependent regulator of chromatin,subfamily a, member 4 (SMARCA4) SWI/SNF related, matrix 4U66616 + + + + + + associated, actin dependent regulator of chromatin,subfamily c, member 2 (SMARCC2) SWI/SNF related, matrix 2 AF035262 B,W + + + + associated, actin dependent regulator of chromatin, subfamilye, member 1 (SMARCE1) synaptobrevin-like 1 1 X95803 + + + + (SYBL1)synaptosomal-associated 2 AJ011915 + + + + protein, 23 kD (SNAP23)syndecan binding protein 15 AF006636 + + + + + (syntenin) (SDCBP)synovial sarcoma, 2 X79201 + translocated to X chromosome (SSXT)syntaxin 16 1 AF038897 syntaxin 3A (STX3A) 2 U32315 + + + syntaxin 6(STX6) 1 AJ002078.1 SYNTAXIN BINDING 1 O00186 PROTEIN 3 (UNC-18 HOMOLOG3) (UNC-18C) syntaxin-16C 1 AF008937 SYT interacting protein 1AF080561 + + + + (SIP) T cell activation, increased 4 M88282 + lateexpression (TACTILE) T cell receptor V alpha 2 X58744 gene segmentV-alpha-7 (clone IGRa11) T cell receptor V alpha 1 X58740 gene segmentV-alpha-w27 T3 receptor-associating 5 S83390 + + + + + + cofactor-1tafazzin (cardiomyopathy, 1 X92763 + + + + dilated 3A (X-linked);endocardial fibroelastosis 2; Barth syndrome) (TAZ) TAFII100 protein(non- 1 U80191 exact 53%) tankyrase, TRF1- 1 AF082556 + + + +interacting ankyrin-related ADP-ribose polymerase (TNKS) TAP1, TAP2,LMP2, LMP7 1 X66401 and DOB TAR DNA-binding protein- 6 U23731 + + + + +43 Tat interactive protein 2 U40989 + + + + + (60 kD) (TIP60) TATA boxbinding protein 1 O00268 (TBP)-associated factor, RNA polymerase II, C1,130 kD (TAF2C1) (non- exact, 55%) TATA box binding protein 4X97999 + + + + + (TBP)-associated factor, RNA polymerase II, F, 55 kD(TAF2F) TATA box binding protein 2 U21858 + + + + + (TBP)-associatedfactor, RNA polymerase II, G, 32 kD (TAF2G) TATA box binding protein 1D63705 + + + + + (TBP)-associated factor, RNA polymerase II, I, 28 kD(TAF2I) Tax1 (human T-cell 1 U33821 + + + + + leukemia virus type I)binding protein 1 (TAX1BP1) T-box 2 (TBX2) (non-exact 1 U28049 + + +77%) TBP-associated factor 172 1 AJ001017 + + + (TAF-172) T-celldeath-associated 1 U95218 + gene 8 (TDAG8) T-cell leukemia/lymphoma 1X82240 + 1A (TCL1A) T-cell leukemia/lymphoma 1 X82240 1A (TCL1A) (lowmatch) T-cell receptor (delta D2- 1 M22197 J1-region) (clone K3B) T-cellreceptor (V beta 5.1, 1 M97705 J beta 1.5, C beta 1) (low match) T-cellreceptor alpha delta 2 AE000662 (=M94081) T-cell receptor alpha 1 B39625enhancer-binding protein, short form (=X58636 Mouse LEF1 lymphoidenhancer binding factor 1 (=D16503)) T-cell receptor delta gene 1 M22197D2-J1-region, clone K3B T-cell receptor germline 1 M11955 beta chaingene V-region (V) V-beta-MT1-1 T-cell receptor germline 1 M14159 + onlyin blood beta-chain gene J2.1 exon T-cell receptor germline 2 M22152delta-chain D-J region T-cell receptor interacting 2 AJ224878 + molecule(TRIM) protein T-cell receptor rearranged 1 M21784 delta-chain, V-region(V- delta 3-J) T-cell receptor, alpha 3 AE000660 + + + + + (V, D, J, C)(TCRA) T-cell receptor, beta cluster 3 L34740 + + + + + + high inpancreas (TCRB) T-cell receptor, delta 2 X73617 + + + (V, D, J, C)(TCRD) T-cell, immune regulator 1 3 U45285 only found in tumor (TCIRG1)TCF-1 mRNA for T cell 1 X59870 factor 1 TCF-1 mRNA for T cell 1 X59870factor 1 (splice form B) (low match) T-COMPLEX PROTEIN 1, 1 Q99832 ETASUBUNIT (TCP-1- ETA) (CCT-ETA) (HIV-1 NEF INTERACTING PROTEIN) T-COMPLEXPROTEIN 1, 1 P50990 THETA SUBUNIT (TCP-1- THETA) (CCT-THETA) (KIAA0002)TCR eta = T cell 1 S94421 receptor(eta-exon) TCR V Beta 13.2 1 X75419TERA 1 AC004472 testis enhanced gene 33 X75861 + + + + + + transcript(TEGT) tetracycline transporter-like 2 L11669 + + + + protein (TETRAN)tetratricopeptide repeat 1 U46570 + + + + + domain 1 (TTC1)tetratricopeptide repeat 1 U46571 + + + domain 2 (TTC2)tetratricopeptide repeat 1 D84296 + + + + + domain 3 (TTC3)TGFB1-induced anti- 1 D86970 + + + + + apoptotic factor 1 (TIAF1)thioredoxin reductase 1 3 S79851 + + + + (TXNRD1) THIOREDOXIN- 1 P30048DEPENDENT PEROXIDE REDUCTASE PRECURSOR, mitochondrial (ANTI- OXIDANTPROTEIN 1) (AOP-1) threonyl-tRNA synthetase 1 M63180 + + + + (TARS)thrombin inhibitor 1 Z22658 thrombospondin 1 (THBS1) 2 X04665 + + + + +thromboxane A synthase 1 1 M80647 + + + + (platelet, cytochrome P450,subfamily V) (TBXAZ1) thymidine kinase 2, 2 X76104 + + + mitochondrial(TK2) thymidylate kinase (CDC8) 1 L16991 + + + + thymine-DNA glycosylase2 U51166 + + + + + (TDG) Thymosin, beta 10 2 M20259 + + + + + + (TMSB10)thymosin, beta 4, X 29 M17733 + + + + chromosome (TMSB4X) thyroidautoantigen 70 kD 7 J04611 (Ku antigen) (G22P1) thyroid hormone receptor1 AF016270 + + + coactivating protein (SMAP) thyroid hormone receptor 2L40357 + + + + interactor 7 (TRIP7) thyroid hormone receptor 4 L40411 +interactor 8r (TRIP8) thyroid hormone receptor- 1 D83783 associatedprotein, 230 kDa subunit (TRAP230) thyroid receptor interacting 2L40388 + + + + protein 15 (TRIP15) TI-227H 1 D50525 TIA1 cytotoxicgranule- 1 M77142 + + + + associated RNA-binding protein (TIA1) tissueinhibitor of 1 X02598 + + + + + + metalloproteinase 1 (erythroidpotentiating activity, collagenase inhibitor) (TIMP1) tissue inhibitorof 1 M32304 + + + + + high in placenta metalloproteinase 2 (TIMP2)tissue specific 1 U58766 + + + + + transplantation antigen P35B (TSTA3)titin (TTN) 1 X64697 + + + + + high in muscle TNF receptor-associated 1U12597 + + + + factor 2 (TRAF2) TNF receptor-associated 1 AF110908.1 +factor 3 (TRAF3) TNF receptor-associated 1 U78798 factor 6 (TRAF6) (lowmatch) toll-like receptor 1 (TLR1) 1 U88540 + toll-like receptor 2(TLR2) 1 U88878 + + + + toll-like receptor 4 (TLR4) 1 U88880 + +toll-like receptor 5 (TILR5) 1 AF051151 + + topoisomerase (DNA) I 1J03250 + + + (TOP1) topoisomerase (DNA) II 2 X68060 + + + + + beta (180kD) (TOP2B) topoisomerase (DNA) III 3 D87012 + beta (TOP3B) TR3beta 1D85245 + TRAF family member- 3 U63830 + + + + + + associated NF-kBactivator (TANK) TRANSALDOLASE 1 P37837 transaldolase 1 (TALDO1) 4L19437 + + + + + transaldolase-related 1 AF010398 protein transcobalaminII (TCII) 1 AF047576 transcription elongation 2 Z47087 + + + + + factorB (SIII), polypeptide 1-like (TCEB1L) transcription elongation 1L47345 + + + + + + factor B (SIII), polypeptide 3 (110 kD, elongin A)(TCEB3) transcription factor 12 1 M83233 + + + + + (HTF4,helix-loop-helix transcription factors 4) (TCF12) transcription factor17 2 D89928 + + (TCF17) transcription factor 4 2 X52079 + + + + (TCR4)transcription factor 6-like 1 2 M62810 + + + + (mitochondrialtranscription factor 1-like) (TCF6L1) transcription factor 7-like 2 1Y11306 + + + + (T-cell specific, HMG-box) (TCF7L2) transcription factorbinding 1 X96717 + + + + + to IGHM enhancer 3 (TFE3 transcription factorIL-4 7 AF067575 + + + + + + Stat transcription factor IL-4 1 U16031 Stat(low match) transcription factor ISGF-3 4 M97935 (=M97936) transcriptionfactor REST 1 A56138 transcription factor TFIID 1 Z22828 transcriptionaladaptor 2 1 AF064094 (ADA2, yeast, homolog)- like (TADA2L)transcriptional intermediary 1 AF009353 factor 1 (TIF1) (non-exact 72%)transducin (beta)-like 1 1 Y12781 + + + + + (TBL1) transducin-likeenhancer of 1 M99438 + + split 3, homolog of Drosophila E(sp1) (TLE3)Transformation/transcription 1 AF076974 + + + + + domain-associatedprotein (TRRAP) transformation-sensitive, 2 M86752 + + + + similar toSaccharomyces cerevisiae STI1 (STI1L) transforming growth factor 1AB009356 beta-activated kinase 1 (TAK1) (non-exact 78%) transforminggrowth factor 3 AJ222700 + + + + + beta-stimulated protein TSC-22(TSC22) transforming growth factor, 1 L07594 + + + + beta receptor III(betaglycan, 300 kD) (TGFBR3) transforming growth factor, 24507466 + + + + + + beta-induced, 68 kD (TGFBI) TRANSFORMING 2 Q15582GROWTH FACTOR-BETA INDUCED PROTEIN IG-H3 PRECURSOR (BETA IG- H3)transforming, acidic coiled- 1 AF049910 coil containing protein 1(TACC1) (non-exact 70%) transgelin 2 (TAGLN2) 14 D21261 + + + + + +transgelin 2 (TAGLN2) 1 D21261 (non-exact) trans-Golgi network protein 2AF029316 + + (46, 48, 51 kD isoforms) (TGN51) transient receptorpotential 1 X89066 + + + + channel 1 (TRPC1) transketolase (Wernicke- 7L12711 + + + + Korsakoff syndrome) (TKT) translation factor sui1 1AF064607 + + + + + homolog (GC20) translin (TSN) 3 X78627 + + + + +translin-associated factor X 1 X95073 + + + + (TSNAX) transmembrane 1U79725 glycoprotein (A33) transmembrane protein 1 X69910 + + + + + (63kD), endoplasmic reticulum/Golgi intermediate compartment (P63)transmembrane protein 1 1 AB001523 + + + (TMEM2) TRANSMEMBRANE 1 P51805PROTEIN SEX PRECURSOR (non-exact 65%) transmembrane trafficking 2X97442 + + + + + + protein (TMP21) transporter 1, ABC (ATP 3L21208 + + + + + binding cassette) (TAP1) Treacher Collins- 2U40847 + + + + + high in many libraries Franceschetti syndrome 1 (TCOF1)triosephosphate isomerase 2 X69723 + + + + + + 1 (TPI1) tropomyosin 2X04201 + + + + tropomyosin 4 (TPM4) 2 X05276 + + + + + TRPM-2 protein 2M63376 tryptase I precursor (non- 1 A35863 exact 64%)(=P20231)tryptophan rich basic 1 Y12478 protein (WRB) tryptophanyl-tRNA 1X59892 + + + + + + synthetase (WARS) Ts translation elongation 1L37936 + + + + factor, mitochondrial (TSFM) ttopoisomerase (DNA) II 1Z15115 + + + beta (180 kD) Tu translation elongation 4 L38995 factor,mitochondrial (TUFM) tuberous sclerosis 1 1 AF013168 + + + + (TSC1)tuberous sclerosis 2 1 X75621 + + + + (TSC2) tubulin, alpha 1 (testis 1X06956 + + specific) (TUBA1) tubulin, alpha, ubiquitous 11K00558 + + + + + + high in many libraries (K-ALPHA-1) tubulin, alpha,ubiquitous 1 K00558 (K-ALPHA-1) (low match) tubulin-specific chaperone 1U61234 + + + + c (TBCC) tumor necrosis factor 7 U37518 + + + + (ligand)superfamily, member 10 (TNFSF10) tumor necrosis factor 1AF046888 + + + + (ligand) superfamily, member 13 (TNFSF13) tumornecrosis factor 1 AF036581 (ligand) superfamily, member 14 (TNFSF14)tumor necrosis factor 1 D38122 + Found only in library (ligand)superfamily, 386: T-cell lymphoma member 6 (TNFSF6) tumor necrosisfactor 1 L09753 B only (ligand) superfamily, member 8 (TNFSF8) tumornecrosis factor 1 AF061034 + + + + alpha-inducible cellular proteincontaining leucine zipper domains (FIP2) Tumor necrosis factor 2M63928 + + receptor superfamily member 7 (TNFRSF7) tumor necrosis factor1 AF016266 + + + + + receptor superfamily, member 10b (TNFRSF10B) tumornecrosis factor 3 AF012629 + receptor superfamily, member 10c, decoywithout an intracellular domain (TNFRSF10C) tumor necrosis factor 1AF023849 found only in prostate receptor superfamily, member 10d, decoywith truncated death domain (TNFRSF10D) (non-exact 84%) tumor necrosisfactor 1 U94508 + + + + + receptor superfamily, member 12 (translocatingchain-association membrane protein) (TNFRSF12) tumor necrosis factor 1U70321 + + + + + receptor superfamily, member 14 (herpesvirus entrymediator) (TNFRSF14) tumor necrosis factor 5 U52165 + + + + + receptorsuperfamily, member 1B (TNFRSF1B) tumor necrosis factor 1 X63717 B, W +receptor superfamily, member 6 (TNFRSF6) tumor necrosis factor 1M63928 + + receptor superfamily, member 7 (TNFRSF7) tumor necrosisfactor, 8 M92357 + + + alpha-induced protein 2 (TNFAIP2) tumor necrosisfactor, 2 M59465 alpha-induced protein 3 (TNFAIP3) tumor protein53-binding 1 AF078776 + + + + protein, 1 (TP53BP1) tumor protein p53(Li- 1 M14695 + + + Fraumeni syndrome) (TP53) Tumor protein p53-binding1 U82939 + + + protein (TP53BPL) tumor protein, 35 X16064translationally-controlled 1 (TPT1) tumor protein, 1 X16064translationally-controlled 1 (TPT1) (low score) tumor rejection antigen9 X15187 + + + + + + (gp96) 1 (TRA1) tumorous imaginal discs 2AF061749 + (Drosophila) homolog (TID1) TXK tyrosine kinase (TXK) 2L27071 type II integral membrane 1 AJ001685 + found only in fetalprotein (NKG2-E) liver/spleen TYRO protein tyrosine 3 AF019562 + kinasebinding protein (TYROBP) tyrosine 3- 1 X57346 + + + + + high in ecnormmonooxygenase/tryptophan 5-monooxygenase activation protein, betapolypeptide (YWHAB) tyrosine 3- 1 M86400 monooxygenase/tryptophan5-monooxygenase activation protein, zeta polypeptide (YWHAZ) tyrosine 3-1 M86400 monooxygenase/tryptophan 5-monooxygenase activation protein,zeta polypeptide (YWHAZ) Tyrosine kinase 2 (TYK2) 3 X54637 + + + +TYROSINE-PROTEIN 2 P43403 KINASE ZAP-70 (70 KD ZETA-ASSOCIATED PROTEIN)(SYK-RELATED TYROSINE KINASE) tyrosyl-tRNA synthetase 1 U89436 + + + + +(YARS) U1 small nuclear RNA 1 M14387 U19H snoRNA (=M63485 1 AJ224166 R.norvegicus matrin 3) U2(RNU2) small nuclear 1 M96982 + + + + RNAauxiliary factor 1 (non- standard symbol) (U2AF1) U22 snoRNA host gene 2U40580 (UHG) U4/U6-associated RNA 4 AF016370 + + + + splicing factor(HPRP3P) U49 small nuclear RNA 1 X96649 U5 snRNP-specific protein 1AB007510 + + + + + (220 kD), ortholog of S. cerevisiae Prp8p (PRP8) U5snRNP-specific protein, 4 D21163 + + + + + 116 kD (U5-116 KD) U5snRNP-specific protein, 3 Z70200 200 kDa (DEXH RNA helicase family)(U5-200- KD) Uba80 mRNA for ubiquitin 4 S79522 + + + + + + high in ovaryubiquinol-cytochrome c 1 D55636 + + + + + + high in fetal lung reductase(6.4 kD) subunit (UQCR) UBIQUINOL- 1 P47985 CYTOCHROME C REDUCTASE IRON-SULFUR SUBUNIT PRECURSOR (RIESKE IRON-SULFUR PROTEIN) (RISP) (low match)ubiquitin A-52 residue 2 X56999 ribosomal protein fusion product 1(UBA52) ubiquitin activating enzyme 1 AF094516 + + + E1-like protein(GSA7) ubiquitin C (UBC) 5 AB009010 + + + + + high in ovary ubiquitincarboxyl-terminal 1 M30496 + + + + + esterase L3 (ubiquitinthiolesterase) (UCHL3) ubiquitin fusion degradation 1 U64444 + + + + +1-like (UFD1L) ubiquitin protein ligase E3A 1 U84404 B + + + (humanpapilloma virus E6- associated protein, Angelman syndrome) (UBE3A)ubiquitin specific protease 4 D80012 + + + + + 10 (USP10) ubiquitinspecific protease 1 U44839 + + + + + + 11 (USP11) ubiquitin specificprotease 3 AB011101 + + + + + 15 (USP15) ubiquitin specific protease 1AB020698 + 19 (USP19) ubiquitin specific protease 1 AF017305 B + + + + 4(proto-oncogene) (USP4) ubiquitin specific protease 1 AF017306 4(proto-oncogene) (USP4) (non-exact, 66%) ubiquitin specific protease 1Z72499 + + + + 7 (herpes virus-associated) (USP7) ubiquitin specificprotease 5 D29956 + + + + 8 (USP8) UBIQUITIN-ACTIVATING 1 P22314 ENZYMEE1 (A1S9 PROTEIN) (56%) ubiquitin-activating enzyme 1 M58028 + + + + +E1 (A1S9T and BN75 temperature sensitivity complementing) (UBE1)ubiquitin-activating enzyme 1 L34170 + + + + E1, like (UBE1L)UBIQUITIN-BINDING 1 U41806 + + PROTEIN P62; phosphotyrosine independentligand for the Lck SH2 domain p62 (P62) ubiquitin-conjugating 2U49278 + + + + + + enzyme E2 variant 1 (UBE2V1) ubiquitin-conjugating 1X98091 enzyme E2 variant 2 (UBE2V2) UBIQUITIN- 1 Q16781 CONJUGATINGENZYME E2-17 KD (UBIQUITIN- PROTEIN LIGASE) ubiquitin-conjugating 1M74525 + + + + + enzyme E2B (RAD6 homolog) (UBE2B) ubiquitin-conjugating1 AF032456 + + + + + enzyme E2G 2 (homologous to yeast UBC7) (UBE2G2)ubiquitin-conjugating 1 Z29328 + + + + + enzyme E2H (homologous to yeastUBC8) (UBE2H) ubiquitin-conjugating 1 X92962 + + + enzyme E2L 1 (UBE2L1)ubiquitin-conjugating 3 AJ000519 + + + + enzyme E2L 3 (UBE2L3)ubiquitin-conjugating 4 AF031141 + + + + + enzyme E2L 6 (UBE2L6)ubiquitin-like 1 (sentrin) 2 U61397 + + + + + (UBL1)UDP-N-acetyl-alpha-D- 2 X85019 galactosamine: polypeptide N-acetylgalactosaminyltransferase 2 (GalNAc-T2) (GALNT2)UDP-N-acetyl-alpha-D- 1 X92689 galactosamine: polypeptide N-acetylgalactosaminyltransferase 3 (GalNAc-T3) (GALNT3) (non-exact 65%)unactive progesterone 2 L24804 + + + + receptor, 23 Kd (P23)unconventional myosin-ID 3 U57053 (MYO1F) uncoupling protein 1 U94592homolog (UCPH) uncoupling protein 1 U94592 homolog (UCPH) (low match67%) Unknown gene product 1 AC002310 unknown mRNA (clone 1 AF07054224514) unknown protein (clone 2 Z70223 ICRFp507L0677) unknown protein 1AF070626 + + + + + + (Hs.93832) unknown protein IT14 1 AF040966uppressor of Ty 1 D79984 + + + + + + (S. cerevisiae) 6 homologupregulated by 1,25- 74 S73591 + + + + + high in heart dihydroxyvitaminD-3 (VDUP1) upregulated by 1,25- 1 S73591 dihydroxyvitamin D-3 (VDUP1)(low match) upregulated by 1,25- 1 S73591 dihydroxyvitamin D-3 (VDUP1)(low match) upregulated by 1,25- 1 S73591 dihydroxyvitamin D-3 (VDUP1)(low score) upstream binding factor 1 X53461 + + + + (hUBF) UV radiationresistance 2 X99050 + + + + associated gene (UVRAG) vacuolarproton-ATPase, 4 X71490 + + + + + subunit D; V-ATPase, subunit D(ATP6DV) v-akt murine thymoma viral 1 M63167 + + + + + oncogene homolog1 (AKT1) Vanin 2 (VNN2) 3 AJ132100 vasodilator-stimulated 3Z46389 + + + + phosphoprotein (VASP) vav 1 oncogene (VAV1) 1 M59834 +vav 2 oncogene (VAV2) 1 S76992 + + v-crk avian sarcoma virus 1 D10656W + + + CT10 oncogene homolog (CRK) v-erb-b2 avian 1 M29366 +erythroblastic leukemia viral oncogene homolog 3 (ERBB3) VERSICAN CORE 1P13611 PROTEIN PRECURSOR Vesicle-associated 1 M36196 + + + + membraneprotein 1 (synaptobrevin 1) (VAMP1) vesicle-associated 1 U64520 membraneprotein 3 (cellubrevin) (VAMP3) v-fos FBJ murine 26 K00650 + + + + +high in aorta osteosarcoma viral oncogene homolog (FOS) v-fos FBJ murine1 K00650 osteosarcoma viral oncogene homolog (FOS) (low match) villin 2(ezrin) (VIL2) 1 X51521 + + + + + villin-like protein 1 D88154 vimentin(VIM) 12 X56134 + + + + + high in many libraries vinculin (VCL) 4M33308 + + + + vitamin A responsive; 6 AF070523 + + + + cytoskeletonrelated (JWA) v-jun avian sarcoma virus 2 U65928 + + + + + 17 oncogenehomolog (JUN) v-myb avian myeloblastosis 1 M15024 + + viral oncogenehomolog (MYB) voltage-dependent anion 1 L06132 + + + + + channel 1(VDAC1) voltage-dependent anion 4 U90943 + + + + channel 3 (VDAC3) vonHippel-Lindau 1 L15409 + + + + syndrome (VHL) von Willebrand factor 1X06828 (vWF) (low matched) v-raf murine sarcoma 3611 2 L24038 + + + +viral oncogene homolog 1 (ARAF1) v-raf-1 murine leukemia 1X03484 + + + + + viral oncogene homolog 1 (RAF1) v-ral simian leukemiaviral 3 M35416 oncogene homolog B (ras related; GTP binding protein)(RALB) V-rel avian 1 L19067 + + + + reticuloendotheliosis viral oncogenehomolog A (nuclear factor of kappa light polypeptide gene enhancer inB-cells 3 (p65)) (RELA) v-yes-1 Yamaguchi 2 M16038 + + + + sarcoma viralrelated oncogene homolog (LYN) WD repeat domain 1 1 AB010427 + + + + + +(WDR1) WDR1 (=AF020260) 1 AF020056 WD-repeat protein 2 U94747 + + +(HAN11) Williams-Beuren syndrome 12 AF045555 + + + + + + chromosomeregion 1 (WBSCR1) Wiskott-Aldrich syndrome 4 X86019 + + + + proteininteracting protein (WASPIP) X (inactive)-specific 2 M97168 transcript(XIST) xeroderma pigmentosum, 3 D21089 + + + + complementation group C(XPC) XIAP associated factor-1 2 X99699 + XIB 1 X90392 + + + + X-linkedanhidroitic 1 AF003528 ectodermal dysplasia X-ray repair 1M30938 + + + + + high in spleen complementing defective repair inChinese hamster cells 5 (double-strand- break rejoining; Ku autoantigen,80 kD) (XRCC5) XRP2 protein 1 AJ007590 yeloid differentiation 1U84408 + + + + primary response gene (88) (MYD88) zeta-chain (TCR) 1L05148 + + associated protein kinase (70 kD) (ZAP70) zeta-chain (TCR) 1L05148 associated protein kinase (70 kD) (ZAP70) (low match) zinc fingerprotein 2 U69274 + + + + + (Hs.47371) zinc finger protein 1U69645 + + + + + (Hs.78765) zinc finger protein 10 (KOX 1 X78933 + 1)(ZNF10) only ZINC FINGER PROTEIN 1 Q15973 124 (HZF-16) (non-exact 51%)zinc finger protein 124 1 S54641 (HZF-16) (ZNF124) (non- exact, 78%)ZINC FINGER PROTEIN 1 P52736 133 zinc finger protein 136 1 U09367 + +(clone pHZ-20) (ZNF136) zinc finger protein 140 1 U09368 + + + (clonepHZ-39) (ZNF140) zinc finger protein 140 1 AF060865 (clone pHZ-39)(ZNF140) (non-exact 59%) zinc finger protein 140 1 U09368 (clone pHZ-39)(ZNF140) (non-exact 73%) zinc finger protein 140 1 S66508 (clone pHZ-39)(ZNF140) (non-exact 73% aa) zinc finger protein 140 1 U09368 (clonepHZ-39) (ZNF140) (non-exact, 80%) zinc finger protein 143 2U09850 + + + + + + (clone pHZ-1) (ZNF143) zinc finger protein 143 1U09850 (clone pHZ-1) (ZNF143) (low match) zinc finger protein 148 1AF039019 + (pHZ-52) (ZNF148) ZINC FINGER PROTEIN 1 Q13105 151 (MIZ-1PROTEIN) (low match) zinc finger protein 173 1 U09825 B, T + + +(ZNF173) zinc finger protein 192 1 U57796 (ZNF192) (non-exact, 66%) zincfinger protein 198 1 AJ224901 + + + (ZNF198) zinc finger protein 2(ZNF2) 1 X60152 (low match) zinc finger protein 200 1 AF060866 + +(ZNF200) zinc finger protein 207 6 AF046001 + + + + + + high in prostate(ZNF207) zinc finger protein 216 2 AF062072 + + + + + (ZNF216) zincfinger protein 217 1 AF041259 T activated + (ZNF217) ZINC FINGER PROTEIN1 P17026 22 (ZINC FINGER PROTEIN KOX15) (non- exact 58%) zinc fingerprotein 230 1 U95044 + (ZNF230) Zinc finger protein 239 1 L26914 + +(ANF239) zinc finger protein 261 1 AB002383 + + + + (ZNF261) zinc fingerprotein 262 1 AB007885 + + + + (ANF262) zinc finger protein 263 1 D88827(ZNF263) zinc finger protein 264 1 AB007872 + + + (ZNF264) ZINC FINGERPROTEIN 1 Q06730 33A (ZINC FINGER PROTEIN KOX31) (KIAA0065) (HA0946)zinc finger protein 42 1 M58297 + + + + + (myeloid-specific retinoiccid-responsive) (ZNF42) zinc finger protein 43 1 X59244 (HTF6) (ZNF43)(low match) zinc finger protein 43 1 X59244 (HTF6) (ZNF43) (non- exact,54%) zinc finger protein 43 1 X59244 (HTF6) (ZNF43) (non- exact, 71%)ZINC FINGER PROTEIN 1 P28160 43 (ZINC PROTEIN HTF6) (non-exact 67%) zincfinger protein 45 (a 1 L75847 only found in testis Kruppel-associatedbox (KRAB) domain polypeptide) (ZNF45) ZINC FINGER PROTEIN 1 P24278 46(ZINC FINGER PROTEIN KUP) (non-exact 62%) zinc finger protein 6 1X56465 + + + + (CMPX1) (ZNF6) zinc finger protein 74 1 X71623 (Cos52)(ZNF74) (non- exact, 67%) zinc finger protein 76 1 M91592 + + + +(expressed in testis) (ZNF76) ZINC FINGER PROTEIN 1 P51522 83 (ZINCFINGER PROTEIN HPF1) (non- exact 65%) zinc finger protein 84 1 M27878 Tactivated + + + (HPF2) (ZNF84) zinc finger protein 85 2 U35376 + + +(ZNF85)) zinc finger protein 9 (ZNF9) 5 M28372 + + + + + ZINC FINGERPROTEIN 1 P35789 93 (=ZINC FINGER PROTEIN HTF34) (non- exact 70%) zincfinger protein C2H2-25 3 U38904 + + + (ZNF25) zinc finger protein clone1 AF024706 L3-4 zinc finger protein 4 M92843 + blood only homologous toZfp-36 in mouse (ZFP36) ZINC FINGER PROTEIN 1 Q03164 HRX (ALL-1) (71%a.a.) zinc finger protein HZF4 1 X78927 zinc finger protein RIZ 1D45132 + + + + + zinc finger protein, 1 U40462 + subfamily 1A, 1(Ikaros) (LYF1) zinc finger protein, 1 U40462 subfamily 1A, 1 (Ikaros)(LYF1) (low match) zinc finger transcriptional 1 M92844 regulator(GOS24) zinc-finger helicase (hZFH) 2 U91543 + + + + + Zn-15 relatedzinc finger 1 U22377 + + + protein (rlf) Zn-15 related zinc finger 1U22377 protein (rlf) (non-exact 56%) ZNF80-linked ERV9 long 1 X83497terminal repeat ZW10 (Drosophila) 2 U54996 + homolog,centromere/kinetochore protein (ZW10) zyxin (ZYX) 4 X95735 Column 1:List of unique genes derived from 6,283 known ESTs from blood cells.Column 2: Number of genes found in randomly sequenced ESTs from bloodcells. Column 3: Accession number. Column 4: “+” indicates the presenceof the unique gene in publicly available cDNA libraries of blood (Bl),brain (Br), heart (H), kidney (K), liver (Li) and lung (Lu).**Comparison to previously identified tissue-specific genes wasdetermined using the GenBank of the National Centre of BiotechnologyInformation (NCBI) Database.

Discussion

Every cell and tissue comprising the human body share the necessarygenetic information required to maintain cellular homeostasis. These“housekeeping” genes function in basic cellular maintenance, includingenergy metabolism and cellular structure in all cell types. However, incertain situations, even the housekeeping genes show altered expression.Thus, it is necessary to define the use of these genes as internalcontrols from one investigation to another. Current results from thehuman blood cell EST database indicate that over 50% of the transcriptsare widely expressed throughout the human body. Most of the cell ortissue specific genes are also detectable in blood cells by RT-PCRanalysis.

For example, isoformic myosin heavy chain genes are known to begenerally expressed in cardiac muscle tissue. In the rodent, the βMyHCgene is only highly expressed in the fetus and in diseased states suchas overt cardiac hypertrophy, heart failure and diabetes; the βMyHC geneis highly expressed shortly after birth and continues to be expressed inthe adult heart. In the human, however, βMyHC is highly expressed in theventricles from the fetal stage through adulthood. This highly expressedβMyHC, which harbours several mutations, has been demonstrated to beinvolved in familial hypertrophic cardiomyopathy (Geisterfer-Lowrance etal. 1990). It was reported that mutations of βMyHC can be detected byPCR using blood lymphocyte DNA (Ferrie et al., 1992). Most recently, itwas also demonstrated that mutations of the myosin-binding protein C infamilial hypertrophic cardiomyopathy can be detected in the DNAextracted from lymphocytes (Niimura et al., 1998).

Similarly, APP and APC, which are known to be tissue specific andpredominantly expressed in the brain and intestinal tract, are alsodetectable in the transcripts of blood. These cell- or tissue-specifictranscripts are not detectable by Northern blot analysis. However, thelow number of transcript copies can be detected by RT-PCR analysis.These findings strongly demonstrate that genes preferentially expressedin specific tissues can be detected by a highly sensitive RT-PCR assay.In recent years, evidence has been obtained to indicate that expressionof cell or tissue-restricted genes can be detected in the peripheralblood of patients with metastatic transitional cell carcinoma (Yuasa etal. 1998) and patients with prostate cancer (Gala et al. 1998).

Atrial natriuretic factor (ANF) and zinc finger protein (ZFP), which areknown to be highly expressed in heart tissue biopsies and in the plasmaof heart failure patients, are also detectable in the transcripts ofblood. Differential expression of zinc finger protein among the normal,diabetic and asymptomatic preclinical subjects may have additional valueas a prophylactic “early warning system”. On a related note, there isnow more attention/discussion in the cardiovascular disease field beingfocused on Syndrome X, loosely defined as a continuum of hypertension,increasing sugar levels, diabetes, kidney failure, culminating in heartfailure, with the possibility of stroke and heart attack at any time inthe continuum. The early identification of patients at risk of organfailure has been a challenge to the medical community for some time andthe present method has the potential of resolving or, at least,ameliorating this challenge.

The present invention demonstrates that a simple drop of blood may beused to determine the quantitative expression of various mRNAs thatreflect the health/disease state of the subject through the use ofRT-PCR analysis. This entire process takes about three hours or less.The single drop of blood may also be used for multiple RT-PCR analyses.There is no need for large samples and/or costly and time-consumingseparation of cell types within the blood for this method as compared tothe methods described by Kimoto (1998) and Chelly et al. (1989; 1988).It is believed that the present finding can potentially revolutionizethe way that diseases are detected, diagnosed and monitored because itprovides a non-invasive, simple, highly sensitive and quick screeningfor tissue-specific transcripts. The transcripts detected in whole bloodhave potential as prognostic or diagnostic markers of disease, as theyreflect disturbances in homeostasis in the human body. Delineation ofthe sequences and/or quantitation of the expression levels of thesemarker genes by RT-PCR will allow for an immediate and accuratediagnostic/prognostic test for disease or to assess the efficacy andmonitor a particular therapeutic.

In addition to RT-PCR, other methods of amplifying may also be used forthe purpose of measuring/quantitating tissue-specific transcripts inhuman blood. For example, mass spectrometry may be used to quantify thetranscripts (Koster et al., 1996; Fu et al., 1998). The application ofpresently disclosed method for detecting tissue-specific transcripts inblood does not restrict to subjects undergoing course of therapy ortreatment, it may also be used for monitoring a patient for the onset ofovert symptoms of a disease. Furthermore, the present method may be usedfor detecting any gene transcripts in blood. A kit for diagnosing,prognosing or even predicting a disease may be designed usinggene-specific primers or probes derived from a whole blood sample for aspecific disease and applied directly to a drop of blood. A cDNA libraryspecific for a disease may be generated from whole blood samples andused for diagnosis, prognosis or even predicting a disease.

The following references were cited herein:

-   Claudio J O et al. (1998). Genomics 50:44-52.-   Chelly J et al. (1989). Proc. Nat. Acad. Sci. USA. 86:2617-2621.-   Chelly J et al. (1988). Nature 333:858-860.-   Drews J & Ryser S (1997). Nature Biotech. 15:1318-9.-   Ferrie R M et al. (1992). Am. J. Hum. Genet. 51:251-62.-   Fu D-J et al. (1998). Nat. Biotech 16: 381-4.-   Gala J L et al. (1998). Clin. Chem. 44(3):472-81.-   Geisterfer-Lowrance A A T et al. (1990). Cell 62:999-1006.-   Groden J et al. (1991). Cell 66:589-600.-   Hwang D M et al. (1997). Circulation 96:4146-4203.-   Jandreski M A & Liew C C (1987). Hum. Genet. 76:47-53.-   Jin O et al. (1990). Circulation 82:8-16-   Kimoto Y (1998). Mol. Gen. Genet 258:233-239.-   Koster M et al. (1996). Nat. Biotech 14: 1123-8.-   Liew & Jandreski (1986). Proc. Nat. Acad. Sci. USA. 83:3175-3179-   Liew C C et al. (1990). Nucleic Acids Res. 18:3647-3651.-   Liew C C (1993). J Mol. Cell. Cardiol. 25:891-894-   Liew C C et al. (1994). Proc. Natl. Acad. Sci. USA. 91:10645-10649.-   Liew et al. (1997). Mol. and Cell. Biochem. 172:81-87.-   Niimura H et al. (1998). New Eng. J. Med. 338:1248-1257.-   Ogawa M (1993). Blood 81:2844-2853.-   Santoro I M & Groden J (1997). Cancer Res. 57:488-494.-   Yuasa T et al. (1998). Japanese J. Cancer Res. 89:879-882.

Any patents or publications mentioned in this specification areindicative of the levels of those skilled in the art to which theinvention pertains. Further, these patents and publications areincorporated by reference herein to the same extent as if eachindividual publication was specifically and individually indicated to beincorporated by reference.

One skilled in the art will appreciate readily that the presentinvention is well adapted to carry out the objects and obtain the endsand advantages mentioned, as well as those objects, ends and advantagesinherent herein. The present examples, along with the methods,procedures, treatments, molecules, and specific compounds describedherein are presently representative of preferred embodiments, areexemplary, and are not intended as limitations on the scope of theinvention. Changes therein and other uses will occur to those skilled inthe art which are encompassed within the spirit of the invention asdefined by the scope of the claims.

1. A method of identifying at least one potential marker of prostatecancer, the method comprising: for each gene of a set of genes, (a)determining a level of RNA encoded by the gene in blood samples of humansubjects having prostate cancer, and a level of RNA encoded by the genein blood samples of human subjects not having prostate cancer; and (b)comparing the levels with each other, wherein a determination, resultingfrom step (b), of a significant difference between the levels identifiesthe gene as a potential marker of prostate cancer, and wherein the setcomprises the genes identified as: 100 kDa coactivator; 10 kD protein(BC10); 14-3-3 epsilon; 14-3-3 protein; 15 kDa selenoprotein (SEP15);1-phosphatidylinositol-4-phosphate 5-kinase isoform C; 23 kD highlybasic protein; 2-5A-dependent RNase; 2′-5′oligoadenylate synthetase 2(OAS2); 26S proteasome subunit 11; 36 kDa phosphothyrosine protein;3-phosphoglycerate dehydrogenase (PGAD); 3-prime-phosphoadenosine5-prime-phosphosulfate synthase 1 (PAPSS1);5-aminoimidazole-4-carboxamide ribonucleotide transformylase;5′-nucleotidase; 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4(PFKFB4); 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PF2K);71 kd heat shock cognate protein hsc70; 76 kDa membrane protein (P76);8-oxoguanine DNA glycosylase (OGG1); a disintegrin and metalloproteasedomain 10 (ADAM10); a disintegrin and metalloprotease domain 8 (ADAM8);A kinase anchor protein 95 (AKAP95); A kinase anchor protein, 149 kD(AKAP149); Absent in melanoma 1 (AIM1); accessory proteins BAP31/BAP29(DXS1357E); acetyl-Coenzyme A acyltransferase (peroxisomal3-oxoacyl-Coenzyme A thiolase) (ACAA); acetyl-Coenzyme A transporter(ACATN); acidic 82 kDa protein; acidic protein rich in leucines (SSP29);Aconitase 2, mitochondrial (ACO2); actin binding protein MAYVEN; actin,beta (ACTB); actin, gamma 1 (ACTG1); actin-binding LIM protein (ABLIM);Actinin, alpha 1 (ACTN1); actinin, alpha 4 (ACTN4); activated p21cdc42Hskinase (ACK); activated RNA polymerase II transcription cofactor 4(PC4); activating transcription factor 1 (ATF1); activatingtranscription factor 2 (ATF2); activating transcription factor 4(tax-responsive enhancer element B67) (ATF4); active BCR-related gene(ABR); acyl-CoA oxidase (AOX); acyl-Coenzyme A dehydrogenase, C-4 toC-12 straight chain (ACADM); acyl-Coenzyme A dehydrogenase, very longchain (ACADVL); acyloxyacyl hydrolase (neutrophil) (AOAH); adaptin,delta (ADTD); adaptin, gamma (ADTG); adaptor complex sigma3B (AP3S3);adaptor protein p150; adducin 1 (alpha) (ADD1); adducin 1 (alpha)(addl); adducin 3 (gamma) (ADD3); adenine nucleotide translocator 2(fibroblast) (ANT2); adenine nucleotide translocator 3 (liver) (ANT3);adenomatous polyposis-coli protein (APC); adenosine deaminase,RNA-specific (ADAR); adenylate cyclase 3 (ADCY3); adenylate cyclase 7(ADCY7); adenylate kinase 2 (AK2); adenylyl cyclase-associated protein(CAP); adipose differentiation-related protein; adipophilin (ADFP);ADP-ribosylation factor 1 (ARF1); ADP-ribosylation factor 3 (ARF3);ADP-ribosylation factor 4 (ARF4); ADP-ribosylation factor 5 (ARF5);ADP-ribosylation factor domain protein 1, 64 kD (ARFD1);ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase) (ADPRT);adrenergic, beta, receptor kinase 1 (ADRBK1); adrenoleukodystrophy-like1 (ALDL1); AF-17; A-gamma-globin; A-gamma-globin (chromosome 11 allele);agammaglobulinaemia tyrosine kinase (ATK); AHNAK nucleoprotein(desmoyokin) (AHNAK); alanyl (membrane) aminopeptidase (aminopeptidaseN, aminopeptidase M, microsomal aminopeptidase, CD13, p150) (ANPEP);alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5); aldehydedehydrogenase 1, soluble (ALDH1); aldehyde dehydrogenase 10 (fattyaldehyde dehydrogenase) (ALDH10); aldehyde reductase 1 (low Km aldosereductase) (ALDR1); aldo-keto reductase family 1, member A1 (aldehydereductase) (AKR1A1); aldo-keto reductase family 1, member C3 (3-alphahydroxysteroid dehydrogenase, type II) (AKR1C3); aldo-keto reductasefamily 7, member A2 (aflatoxin aldehyde reductase) (AKR7A2); aldolase A,fructose-bisphosphate (ALDOA); aldolase C, fructose-bisphosphate(ALDOC); alkaline phosphatase, liver/bone/kidney (ALPL); alphamannosidase II isozyme; alpha thalassemia/mental retardation syndromeX-linked (ATRX); alpha-2 macroglobulin; alpha-2-globin;alpha-2-macroglobulin receptor/lipoprotein receptor protein (A2MR/LRP);alpha-polypeptide of N-acetyl-alpha-glucosaminidase (HEXA);alpha-spectrin; alpha-subunit of Gi2 a (GTP-binding signal transductionprotein); aminin receptor 1 (67 kD); Ribosomal protein SA (LAMR1);aminolevulinate, delta-, dehydratase (ALAD); amino-terminal enhancer ofsplit (AES); amino-terminal enhancer of split (AES); AMP deaminaseisoform L (AMPD2); amphiphysin (Stiff-Mann syndrome with breast cancer128 kD autoantigen) (AMPH); amphiphysin II; amphiphysin-like (AMPHL);AMY-1; amyloid beta (A4) precursor protein-binding, family B, member 1(Fe65) (APBB1); amyloid beta (A4) precursor-like protein 2 (APLP2);amyloid precursor protein (APP); annexin I (lipocortin I) (ANX1);annexin II; annexin II (lipocortin II; calpactin I, heavy polypeptide)(ANX2); annexin IV (placental anticoagulant protein II) (ANX4); annexinV (endonexin II) (ANX5); annexin V (endonexin II) (ANXV); annexin VI(p68) (ANX6); annexin VII (synexin) (ANX7); antigen identified bymonoclonal antibodies 12E7, F21 and O13 (MIC2); antigen identified bymonoclonal antibodies 4F2, TRA1.10, TROP4, and T43 (MDU1); anti-oxidantprotein 2 (non-selenium glutathione peroxidase, acidiccalcium-independent phospholipase A2) (KIAA0106); APEX nuclease(multifunctional DNA repair enzyme) (APEX); apoptosis inhibitor 1(API1); apoptosis inhibitor 4 (survivin) (API4); apoptosis inhibitor 5(APIS); apoptosis specific protein (ASP); apoptotic protease activatingfactor (APAF1); aquaporin 3 (AQP3); aquaporin 9 (AQP9); arachidonate12-lipoxygenase (ALOX12); arachidonate 5-lipoxygenase-activating protein(ALOX5AP); ariadne homolog (ARI); ariadne-2 (D. melanogaster) homolog(all-trans retinoic acid inducible RING finger) (ARI2); ARP1(actin-related protein 1, yeast) homolog A (centractin alpha) (ACTR1A);ARP2 (actin-related protein 2, yeast) homolog (ACTR2); ARP2/3 proteincompex subunit 34 (ARC34); Arp2/3 protein compex subunit p41 (ARC41);Arp2/3 protein complex subunit p16 (ARC16); Arp2/3 protein complexsubunit p20 (ARC20); Arp2/3 protein complex subunit p21(ARC21); ARP3(actin-related protein 3, yeast) homolog (ACTR3); arrestin, beta 2(ARRB2); arsA (bacterial) arsenite transporter, ATP-binding, homolog 1(ASNA1); aryl hydrocarbon receptor nuclear translocator-like (ARNTL);aryl hydrocarbon receptor-interacting protein (AIP); arylsulfatase A(ARSA); asialoglycoprotein receptor 2 (ASGR2); asparaginyl-tRNAsynthetase (NARS); aspartyl-tRNA synthetase (DARS); ataxiatelangiectasia mutated (includes complementation groups A, C and D)(ATM); ataxin-2-like protein A2LP (A2LG); ATF6; ATP synthase (F1-ATPase)alpha subunit, mitochondrial; ATP synthase beta subunit gene; ATPsynthase, H+ transporting, mitochondrial F0 complex, subunit b, isoform1 (ATP5F1); ATP synthase, H+ transporting, mitochondrial F0 complex,subunit c (subunit 9), isoform 1 (ATP5G1); ATP synthase, H+transporting, mitochondrial F1 complex, alpha subunit, isoform 1,cardiac muscle (ATP5A1); ATP synthase, H+ transporting, mitochondrial F1complex, beta polypeptide (ATP5B); ATP synthase, H+ transporting,mitochondrial F1 complex, gamma polypeptide 1 (ATP5C1); ATP synthase, H+transporting, mitochondrial F1F0, subunit g (ATP5JG); ATP/GTP-bindingprotein (HEAB); ATPase, Ca++ transporting, ubiquitous (ATP2A3); ATPase,H+ transporting, lysosomal (vacuolar proton pump) 21 kD (ATP6F); ATPase,H+ transporting, lysosomal (vacuolar proton pump) 31 kD (ATP6E); ATPase,H+ transporting, lysosomal (vacuolar proton pump) 42 kD; Vacuolarproton-ATPase, subunit C; V-ATPase, subunit C (ATP6D); ATPase, H+transporting, lysosomal (vacuolar proton pump), alpha polypeptide, 70kD, isoform 1 (ATP6A1); ATPase, H+ transporting, lysosomal (vacuolarproton pump), beta polypeptide, 56/58 kD, isoform 2 (ATP6B2); ATPase, H+transporting, lysosomal (vacuolar proton pump), member J (ATP6J);ATPase, H+ transporting, lysosomal (vacuolar proton pump), subunit 1(ATP6S1); ATP-binding cassette 50 (TNF-alpha stimulated) (ABC50);ATP-binding cassette protein M-ABC1 (mitochondrial); ATP-dependent RNAhelicase; atrial natriuretic factor (ANF); autoantigen (Hs.75528);autoantigen (Hs.75682); autoantigen La/SS-B; axin (AXIN1); axonemaldynein heavy chain (DNAH17); basement membrane-induced gene (ICB1);basic leucine zipper nuclear factor 1 (JEM-1) (BLZF1); basictranscription factor 3 (BTF3); basigin (BSG); BC-2; B-cell CLL/lymphoma6 (zinc finger protein 51) (BCL6); B-cell translocation gene 1,anti-proliferative (BTG); BCL2/adenovirus E1B 19 kD-interacting protein2 (BNIP2); BCL2/adenovirus E1B 19 kD-interacting protein 3-like(BNIP3L); beclin 1 (coiled-coil, myosin-like BCL2-interacting protein)(BECN1); beta-1,2-N-acetylglucosaminyltransferase II (MGAT2);beta-2-microglobulin (B2M); beta-hexosaminidase alpha chain (HEXA);beta-tubulin; BING4; biphenyl hydrolase-like (serine hydrolase) (BPHL);bone marrow stromal cell antigen 1 (BST1); box-dependent myc-interactingprotein isoform BIN1-10 (BIN1); brain my047 protein; branched chain ketoacid dehydrogenase E1, alpha polypeptide (maple syrup urine disease)(BCKDHA); BRCA1 associated protein-1 (ubiquitin carboxy-terminalhydrolase) (BAP1); breakpoint cluster region protein, uterine leiomyoma,1; barrier to autointegration factor (BCRP1); breakpoint cluster regionprotein, uterine leiomyoma, (BCRP2); bromodomain-containing protein, 140kD (peregrin) (BR140); Bruton's agammaglobulinemia tyrosine kinase(Btk); Bruton's tyrosine kinase (BTK); BS4; BTG2 (BTG2); BTK regionclone ftp; BTK region clone ftp-3; BUB3 (budding uninhibited bybenzimidazoles 3, yeast) homolog (BUB3); butyrate response factor 1(EGF-response factor 1) (BRF1); butyrophilin (BTF1); butyrophilin likereceptor; CAG repeat containing (CTG4A); CAGH32;calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma(CAMK2G); calcium/calmodulin-dependent protein kinase kinase (KIAA0787);calmodulin 1 (phosphorylase kinase, delta) (CALM1); calnexin (CANX);calpain, large polypeptide L1 (CAPN1); calpain, large polypeptide L2(CANP2); calpain, small polypeptide (CAPN4); calpastatin (CAST);Calponin 2; calponin 2 (CNN2); calumenin (CALU); cAMP responseelement-binding protein CRE-Bpa (H_GS165L15.1); cAMP-dependent proteinkinase type II (Ht31); canicular multispecific organic anion transporter(CMOAT2); capping protein (actin filament) muscle Z-line, alpha 1(CAPZA1); capping protein (actin filament) muscle Z-line, alpha 2(CAPZA2); capping protein (actin filament) muscle Z-line, beta (CAPZB);capping protein (actin filament), gelsolin-like (CAPG);carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, anddihydroorotase (CAD); carbonic anhydrase V, mitochondrial (CA5);carboxypeptidase D (CPD); cardiac beta-myosin heavy chain;carnitine/acylcarnitine translocase (CACT); Cas-Br-M (murine) ecotropicretroviral transforming sequence (cbl); casein kinase 1, alpha 1(CSNK1A1); casein kinase 2, alpha 1 polypeptide (CSNK2A1); casein kinaseI gamma 3L (CSNK1G3L); CASP8 and FADD-like apoptosis regulator (CFLAR);caspase 1, apoptosis-related cysteine protease (interleukin 1, beta,convertase) (CASP1); caspase 10, apoptosis-related cysteine proteas(CASP10); caspase 3, apoptosis-related cysteine protease (CASP3);caspase 4, apoptosis-related cysteine protease (CASP4); caspase 5,apoptosis-related cysteine protease (CASP5); caspase 8,apoptosis-related cysteine protease (CASP8); caspase 9,apoptosis-related cysteine protease (CASP9); catalase (CAT);catechol-O-methyltransferase (COMT); catenin (cadherin-associatedprotein), alpha 1 (102 kD) (CTNNA1); cathelicidin antimicrobial peptide(CAMP); cathepsin B (CTSB); cathepsin C (CTSC); cathepsin D (lysosomalaspartyl protease) (CTSD); cathepsin E (CTSE); cathepsin G (CTSG);cathepsin S (CTSS); cathepsin W (lymphopain) (CTSW); CCAAT/enhancerbinding protein (C/EBP), alpha (CEBPA); CCAAT/enhancer binding protein(C/EBP), delta (CEBPB); CCAAT-box-binding transcription factor (CBF2);CD14 antigen (CD14); CD1C antigen, c polypeptide (CD1C); CD2 antigen(cytoplasmic tail)-binding protein 2 (CD2BP2); CD2 antigen (p50), sheepred blood cell receptor (CD2); CD2 cytoplasmic tail-binding protein 1(CD2BP1); CD20 antigen (CD20); CD20 receptor (S7); CD22 antigen (CD22);CD24 signal transducer; CD33 antigen (gp67) (CD33); CD33 antigen-like 2;CD36 antigen (collagen type I receptor, thrombospondin receptor) (CD36);CD37 antigen (CD37); CD38 alt; CD39 antigen (CD39); CD3D antigen, deltapolypeptide (TiT3 complex) (CD3D); CD3E antigen, epsilon polypeptide(TiT3 complex) (CD3E); CD3G antigen, gamma polypeptide (TiT3 complex)(CD3G); CD3Z antigen, zeta polypeptide (TiT3 complex) (CD3Z); CD3-zeta(clone pBS NK1); CD4 antigen (p55) (CD4); CD44 antigen (homing functionand Indian blood group system (CD44); CD48 antigen (B-cell membraneprotein) (CD48); CD53 antigen (CD53); CD63 antigen (melanoma 1 antigen)(CD63); CD68 antigen (CD68); CD74 antigen (invariant polypeptide ofmajor histocompatibility complex, class II antigen-associated) (CD74);CD79A antigen (immunoglobulin-associated alpha) (CD79A); CD79B antigen(immunoglobulin-associated beta) (CD79B); CD8 antigen, alpha polypeptide(p32) (CD8A); CD8 antigen, beta polypeptide 1 (p37) (CD8B1); CD81antigen (target of antiproliferative antibody 1 (CD81); CD84 antigen(leukocyte antigen) (CD84); CD86 antigen; CD9 antigen (p24) (CD9); CD97antigen (CD97); CDC23 (cell division cycle 23, yeast, homolog) (CDC23);CDC37 homolog; Cdc42 effector protein 3 (CEP3); CDC-like kinase (CLK);CDC-like kinase 2 (CLK2); CDW52 antigen (CAMPATH-1 antigen) (CDW52);cell cycle progression restoration 8 protein (CPR8); cell division cycle10 (homologous to CDC10 of S. cerevisiae) (CDC10); cell division cycle20, S. cerevisiae homolog (CDC20); cell division cycle 25B (CDC25B);cell division cycle 42 (GTP-binding protein, 25 kD) (CDC42); centromereprotein B (80 kD) (CENPB); cep250 centrosome associated protein;ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowskydisease) (CLN2); CGI-19 protein; chaperonin containing TCP1, subunit 3(gamma) (CCT3); chaperonin containing TCP1, subunit 4 (delta) (CCT4);chaperonin containing TCP1, subunit 6A (zeta 1) (CCT6A); chaperonincontaining TCP1, subunit 7 (eta) (CCT7); Chediak-Higashi syndrome 1(CHS1); chemokine (C-C motif) receptor 2 (CCR2); chemokine (C-C motif)receptor 7 (CCR7); chemokine (C-X3-C) receptor 1 (CX3CR1); chemokine(C-X-C motif), receptor 4 (fusin) (CXCR4); chitinase 3-like 1 (cartilageglycoprotein-39) (CHI3L1); chitinase 3-like 2 (CHI3L2); chloride channel6 (CLCN6); Chloride intracellular channel 1 (CLIC1); chondroitin sulfateproteoglycan 2 (versican) (CSPG2); chondroitin sulfate proteoglycan coreprotein; chromodomain helicase DNA binding protein 1 (CHD1);chromodomain helicase DNA binding protein 1-like (CHD1L); chromodomainhelicase DNA binding protein 2 (CHD2); chromodomain helicase DNA bindingprotein 3 (CHD3); chromodomain helicase DNA binding protein 4 (CHD4);chromosome 1 open reading frame 7 (C1ORF7); chromosome 1 specifictranscript KIAA0493; chromosome 17 open reading frame 1B (C17ORF1B);chromosome 4 open reading frame 1 (C4ORF1); chromosome condensation1-like (CHC1L); chromosome X open reading frame 5 (CXORF5);chromosome-associated polypeptide C(CAP-C); cig42; cig5; citratesynthase (CS); class I major histocompatibility antigen (HLA-Cw3);clathrin assembly protein lymphoid myeloid leukemia (CALM); clathrinheavy chain; clathrin, heavy polypeptide-like 2 (CLTCL2);clathrin-associated/assembly/adaptor protein, medium 1 (CLAPM1);cleavage stimulation factor, 3′ pre-RNA, subunit 3, 77 kD (CSTF3); clk3;clone 23815 (Hs.82845); clone 24592 mRNA sequence; Clq/MBL/SPA receptorC1qR(p); clusterin (complement lysis inhibitor, SP-40,40, sulfatedglycoprotein 2, testosterone-repressed prostate message 2,apolipoprotein J) (CLU); CMP-sialic acid transporter (CMPST); CMRF35;c-myc oncogene containing coxIII; coagulation factor II (thrombin)receptor (F2R); coagulation factor V (proaccelerin, labile factor) (F5);coagulation factor XIII a subunit; coagulation factor XIII, Alpolypeptide (F13A1); coated vesicle membrane protein (RNP24); coatomerprotein complex, subunit alpha (COPA); Cofilin 1 (non-muscle) (CFL1);cold inducible RNA-binding protein (CIRBP); cold shock domain protein A(CSDA); collagen, type IX, alpha 2 (COL9A2); colony stimulating factor 1receptor, formerly McDonough feline sarcoma viral (v-fms) oncogenehomolog (CSF1R); colony stimulating factor 2 receptor, beta,low-affinity (granulocyte-macrophage) (CSF2RB); colony stimulatingfactor 3 receptor (granulocyte) (CSF3R); complement component 5 receptor1 (C5a ligand) (C5R1); conserved gene amplified in osteosarcoma (0S4);COP9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 3(COPS3); COP9 homolog (HCOP9); COPII protein, homolog of s. cerevisiaeSEC23p (SEC23A); copine I (CPNE1); coproporphyrinogen oxidase(coproporphyria, harderoporphyria) (CPO); core-binding factor, betasubunit (CBFB); coronin; cot (cancer Osaka thyroid) oncogene (COT);cryptochrome 1 (photolyase-like) (CRY1); CTD (carboxy-terminal domain,RNA polymerase II, polypeptide A) phosphatase, subunit 1 (CTDP1);C-terminal binding protein 1 (CTBP1); C-terminal binding protein 2(CTBP2); CUG triplet repeat, RNA-binding protein 1 (CUGBP1); cullin 1(CUL1); cullin 3 (CUL3); cut (Drosophila)-like 1 (CCAAT displacementprotein) (CUTL1); cyclin D2 (CCND2); cyclin D3 (CCND3); cyclin G1(CNNG1); cyclin I; cyclin T2 (CNNT2); cyclin-dependent kinase 2 (CDK2);cyclin-dependent kinase inhibitor (p27Kip1); cyclin-dependent kinaseinhibitor 1A (p21, Cip1) (CDKN1A); cystatin B (stefin B) (CSTB);cysteine and glycine-rich protein 3 (cardiac LIM protein) (CSRP3);cytidine deaminase (CDA); cytochrome b(-245) beta chain N-terminalregion (X-linked granulomatous disease gene); cytochrome b-245, betapolypeptide (chronic granulomatous disease) (CYBB); cytochrome c oxidasesubunit IV (COX4); cytochrome c oxidase subunit Vb (COX5B); cytochrome coxidase subunit VII-related protein (COX7RP); cytokine suppressiveanti-inflammatory drug binding protein 1 (p38 MAP kinase) (CSBP1);Cytoplasmic antiproteinase=38 kda intracellular serine proteinaseinhibitor; cytotoxic granule-associated RNA-binding protein p40-TIA-1;D123 (D123); D2-2; D38; damage-specific DNA binding protein 1 (127 kD)(DDB1); DEAD/H (Asp-Glu-Ala-Asp/His) box binding protein 1 (DDXBP1);DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide (72 KD) (P72); DEAD/H(Asp-Glu-Ala-Asp/His) box polypeptide 1 (DDX1); DEAD/H(Asp-Glu-Ala-Asp/His) box polypeptide 15 (DDX15); DEAD/H(Asp-Glu-Ala-Asp/His) box polypeptide 16 (DDX16); DEAD/H(Asp-Glu-Ala-Asp/His) box polypeptide 3 (DDX3); DEAD/H(Asp-Glu-Ala-Asp/His) box polypeptide 5 (RNA helicase, 68 kD) (DDX5);DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 6 (RNA helicase, 54 kD)(DDX6); DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 8 (RNA helicase, 54kD) (DDX8); DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 9 (RNA helicaseA, nuclear DNA helicase II; leukophysin) (DDX9); DEAD/H(Asp-Glu-Ala-Asp/His) box polypeptide, Y chromosome (DBY); Deathassociated protein 3 (DAP3); death effector domain-containing protein(DEDD); death-associated protein 6 (DAXX); dedicator of cyto-kinesis 2(DOCK2); defender against cell death 1 (DAD1); Defensin, alpha 1,myeloid-related sequence (DEFA1); DEK gene (D6S231E); delta sleepinducing peptide, immunoreactor (DSIPI); dendritic cell protein (GA17);deoxycytidine kinase (DCK); deoxyribonuclease II, lysosomal (DNASE2);DGS-I; diacylglycerol kinase; diacylglycerol kinase alpha (DAGK1) (clone24); diaphanous (Drosophila, homolog) 1 (DIAPH1); diaphorase (NADH)(cytochrome b-5 reductase) (DIA1); differentiated Embryo Chondrocyteexpressed gene 1 (DEC1); differentiation antigen CD20; DiGeorge syndromecritical region gene 2 (DGCR2); dihydrolipoamide dehydrogenase (E3component of pyruvate dehydrogenase complex, 2-oxo-glutarate complex,branched chain keto acid dehydrogenase complex) (DLD); dihydrolipoamideS-acetyltransferase (E2 component of pyruvate dehydrogenase complex)(DLAT); dihydropyrimidinase-like 2 (DPYSL2); dinG gene; diptheria toxinresistance protein required for diphthamide biosynthesis(Saccharomyces)-like 2 (DPH2L2); DJ-1 protein; Dmx-like 1 (DMXL1); DNA(cytosine-5-)-methyltransferase 1 (DNMT1); DNA fragmentation factor, 40kD, beta subunit (DFFB); DNA fragmentation factor, 45 kD, alpha subunit(DFFA); DNA mismatch repair protein (hMLH1); DNA segment on chromosome X(unique) 648 expressed sequence; DNA segment, single copy probeLNS-CAI/LNS-CAII (deleted in polyposis (D5S346); DnaJ protein; dockingprotein 2, 56 kD (DOK2); dolichyl-diphosphooligosaccharide-proteinglycosyltransferase (DDOST); dolichyl-phosphate mannosyltransferasepolypeptide 1, catalytic subunit (DPMI); down-regulated by activation(immunoglobulin superfamily) (DORA); D-type cyclin-interacting protein 1(DIP1); dual specificity phosphatase 1 (DUSP1); dual specificityphosphatase 11 (RNA/RNP complex 1-interacting) (dusp11); dualspecificity phosphatase 3 (vaccinia virus phosphatase VH1-related)(DUSP3); dual specificity phosphatase 6 (DUSP6); dynactin 1 (p150, Glued(Drosophila) homolog) (DYTN1); dynamin 2 (DNM2); dynein, cytoplasmic,light intermediate polypeptide 2 (DNCLI2); dyskeratosis congenita 1,dyskerin (DKC1); dystonia 1, torsion (autosomal dominant) (DYT1);dystrobrevin, beta (DTNB); dystrophia myotonica-containing WD repeatmotif (DMWD); dystrophia myotonica-protein kinase (DMPK); E1B-55kDa-associated protein; E2F transcription factor 3 (E2F3); E2Ftranscription factor 4, p107/p130-binding (E2F4); E2F transcriptionfactor 5, p130-binding (E2F5); E74-like factor 1 (ets domaintranscription factor) (ELF1); E74-like factor 4 (ets domaintranscription factor) (ELF4); early development regulator 2 (homolog ofpolyhomeotic 2) (EDR2); EBV induced G-protein coupled receptor (EBI2);ecotropic viral integration site 2B (EVI2B); ectin, galactoside-binding,soluble, 1 (galectin 1) (LGALS1); EGF-like-domain, multiple 4 (EGFL4);eIF-2-associated p67 homolog; elav-type RNA-binding protein (ETR-3);electron-transfer-flavoprotein, alpha polypeptide (glutaric aciduria II)(ETFA); ELK3, ETS-domain protein (SRF accessory protein 2) (ELK3);elongation factor 1-beta; elongation factor Ts (mitochondrial protein);elongation factor Tu-nuclear encoded mitochondrial; eMDC II protein;ems1 sequence (mammary tumor and squamous cell carcinoma-associated(p80/85 src substrate) (EMS1); endogenous retroviral element HC2;endosulfine alpha (ENSA); endothelial differentiation, sphingolipidG-protein-coupled receptor, 1 (EDG1); eendothelial monocyte-activatingpolypeptide (EMAPII); enolase 1, (alpha) (ENO1); enolase 2, (gamma,neuronal) (ENO2); enolase-alpha; enoyl Coenzyme A hydratase 1,peroxisomal (ECH1); enoyl Coenzyme A hydratase, short chain, 1,mitochondrial (ECHS1); epidermal growth factor receptor pathwaysubstrate 15 (EPS15); epithelial membrane protein 3 (EM[P3); Epoxidehydrolase 1, microsomal (xenobiotic) (EPHX1); ERF-2; ERp28 protein;erythrocyte membrane protein; erythroleukemic cells K562; EST(Hs.189509); estrogen receptor-related protein (hERRa1); ET bindingfactor 1 (SBF1); ets domain protein ERF; eukaryotic translationelongation factor 1 alpha 1 (EEF1A1); eukaryotic translation elongationfactor 1 beta 2 (EEF1B2); eukaryotic translation elongation factor 1delta (guanine nucleotide exchange protein) (EEF1D); eukaryotictranslation elongation factor 1 gamma (EEF1G); eukaryotic translationelongation factor 2 (EEF2); eukaryotic translation initiation factor 2,subunit 1 (alpha, 35 kD) (EIF2S1); eukaryotic translation initiationfactor 2, subunit 2 (beta, 38 kD) (EIF2S2); eukaryotic translationinitiation factor 2, subunit 3 (gamma, 52 kD) (EIF2S3); eukaryotictranslation initiation factor 3, subunit 10 (theta, 150/170 kD)(EIF3S10); eukaryotic translation initiation factor 3, subunit 2 (beta,36 kD) (EIF3S2); eukaryotic translation initiation factor 3, subunit 3(gamma, 40 kD) (EIF3S3); eukaryotic translation initiation factor 3,subunit 4 (delta, 44 kD) (EIF3S4); eukaryotic translation initiationfactor 3, subunit 6 (48 kD) (EIF3S6); eukaryotic translation initiationfactor 3, subunit 6 (EIF3S6); eukaryotic translation initiation factor3, subunit 7 (zeta, 66/67 kD) (EIF3S7); eukaryotic translationinitiation factor 3, subunit 8, 110 KD (EIF3S8); eukaryotic translationinitiation factor 4 gamma, 1 (EIF4G); eukaryotic translation initiationfactor 4 gamma, 1 (EIF4G1); eukaryotic translation initiation factor 4gamma, 2 (EIF4G2); eukaryotic translation initiation factor 4 gamma, 2(EIFG2); eukaryotic translation initiation factor 4A, isoform 1(EIF4A1); eukaryotic translation initiation factor 4A, isoform 2(EIF4A2); eukaryotic translation initiation factor 4B (EIF4B);Eukaryotic translation initiation factor 4E binding protein 2(EIF4EBP2); eukaryotic translation initiation factor 5 (EIF5);eukaryotic translation termination factor 1 (ETF1); EV12 protein; Ewingsarcoma breakpoint region 1 (EWSR1); EWS/FLI1 activated transcript 2homolog (EAT-2); EWS-E1A-F chimeric protein; excision repaircross-complementing rodent repair deficiency, complementation group 1(includes overlapping antisense sequence) (ERCC1); excision repaircross-complementing rodent repair deficiency, complementation group 5(xeroderma pigmentosum, complementation group G (Cockayne syndrome))(ERCC5); exostoses (multiple)-like 3 (EXTL3); F11; F1-ATPase betasubunit (F-1 beta); Fanconi anaemia group A; Fanconi anemia,complementation group A (FANCA); far upstream element (FUSE) bindingprotein 1 (FUBP1); farnesyl diphosphate synthase (farnesyl pyrophosphatesynthetase, dimethylallyltranstransferase, geranyltranstransferase)(FDPS); farnesyl-diphosphate farnesyltransferase 1 (FDFT1);farnesyltransferase, CAAX box, beta (FNTB); Fas-ligand associated factor1; fatty-acid-Coenzyme A ligase, long-chain 1 (FACL1); Fc fragment ofIgA, receptor for (FCAR); Fc fragment of IgE, high affinity I, receptorfor; gamma polypeptide (FCER1G); Fc fragment of IgE, low affinity II,receptor for (CD23A) (FCER2); Fc fragment of IgG, low affinity IIa,receptor for (CD32); Fc fragment of IgG, low affinity IIa, receptor for(CD32) (FCGR2A); Fc fragment of IgG, low affinity Ma, receptor for(CD16) (FCGR3A); Fc fragment of IgG, receptor, transporter, alpha(FCGRT); fc-fgr; Fc-gamma-receptorIIIB (FCGR3B); feline sarcoma(Snyder-Theilen) viral (v-fes)/Fujinami avian sarcoma (PRCII) viral(v-fps) oncogene homolog(FES) c-fes/fps); female sterilehomeotic-related gene 1 (mouse homolog) (FSRG1); ferritin L-chain;ferritin, heavy polypeptide 1 (FTH1); fetal Alzheimer antigen (FALZ);fetal Ig heavy chain variable region; fibrillarin (FBL); fibrinogen-likeprotein 2 (T49); ficolin (collagen/fibrinogen domain-containing) 1(FCN1); filamin A, alpha (actin-binding protein-280) (FLNA); filamin B,beta (actin-binding protein-278) (FLNB); Finkel-Biskis-Reilly murinesarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived); ribosomalprotein S30 (FAU); FK-506 binding protein; FK506-binding protein 1A (12kD) (FKBP1A); FK506-binding protein 1B (12.6 kD) (FKBP1B); FK506-bindingprotein 5 (FKBP5); Flightless I (Drosophila) homolog (FLI1); FLN29(FLN29); flotillin 2 (FLOT2); folate receptor 2 (fetal) (FOLR2);forkhead (Drosophila) homolog (rhabdomyosarcoma) like 1 (FKHRL1); Formylpeptide receptor 1 (FPR1); formyl peptide receptor-like 1 (FPRL1);fragile X mental retardation 1 (FMR1); fragile X mental retardation,autosomal homolog 1 (FXR1); Friend leukemia virus integration 1 (FLI1);fructose-bisphosphatase 1 (FBP1); FSHD-associated repeat DNA, proximalregion; fucose-1-phosphate guanylyltransferase (FPGT); full lengthinsert cDNA clone ZA78A09; full length insert cDNA YPO7G10; fumaratehydratase (FH); FYN-binding protein (FYB-120/130) (FYB); G protein betasubunit-like protein 12.3; G protein-coupled receptor kinase 6 (GPRK6);G1 to S phase transition 1 (GSPT1); GA-binding protein transcriptionfactor, beta subunit 2 (47 kD) (GABPB2); galactose-1-phosphateuridylyltransferase (GALT); galactosidase, beta 1 (GLB1); galectin-9isoform; gamma2-adaptin (G2AD); gamma-actin; gamma-aminobutyric acid(GABA) B receptor 1 (GABBR1); GATA-binding protein 2 (GATA2);GATA-binding protein 3 (GATA3); GCN5 (general control of amino-acidsynthesis, yeast, homolog)-like 1 (GCN5L1); GDP dissociation inhibitor 1(GDI1); GDP dissociation inhibitor 2 (GCl2); GDS-related protein(HKE1.5); gelsolin (amyloidosis, Finnish type) (GSN); generaltranscription factor II, I (GTF2I); general transcription factor II, i,pseudogene 1 (GTF2IP1); general transcription factor IIF, polypeptide 1(74 kD subunit) (GTF2F1); general transcription factor IIH, polypeptide3 (34 kD subunit) (GTF2H3); general transcription factor IIH,polypeptide 4 (52 kD subunit) (GTF2H4); general transcription factorIIIA (GTF3A); general transcription factor IIIC, polypeptide 1 (alphasubunit, 220 kD) (GTF3C1); general transcription factor IIIC,polypeptide 2 (beta subunit, 110 kD) (GTF3C2); germline immunoglobulinheavy chain (IGHV@); germline immunoglobulin heavy chain, variablregion; germline immunoglobulin heavy chain, variable region, (21-2);GLE1 (yeast homolog)-like, RNA export mediator (GLE1L); glia maturationfactor, beta (GMFB); glioma-associated oncogene homolog (zinc fingerprotein) (GLI); globin, alpha 2; glucocorticoid receptor (GRL); glucosphosphate isomerase (CONTAINS LARGE REPEAT); glucosamine(N-acetyl)-6-sulfatase (Sanfilippo disease IIID) (GNS); glucosetransporter-like protein-III (GLUT3); glucosidase, alpha; acid (Pompedisease, glycogen storage disease type II) (GAA); glucosidase, beta;acid (includes glucosylceramidase) (GBA); glutamate dehydrogenase 1(GLUD1); glutamate-ammonia ligase (glutamine synthase) (GLUL);glutamate-cysteine ligase (gamma-glutamylcysteine synthetase), catalytic(72.8 kD) (GLCLC); glutamine cyclotransferase;glutamine-fructose-6-phosphate transaminase 1 (GFPT1); glutaminyl-tRNAsynthetase; glutaminyl-tRNA synthetase (QARS); glutamyl-prolyl-tRNAsynthetase (EPRS); glutathione peroxidase 1 (GPX1); glutathioneperoxidase 4 (phospholipid hydroperoxidase) (GPX4); glutathioneS-transferase pi (GSTP1); glutathione S-transferase subunit 13 homolog;glyceraldehyde-3-phosphate dehydrogenase (GAPD); glycogenin (GYG);glycophorin C (Gerbich blood group) (GYPC); glycoprotein M6B (GPM6B);glycyl-tRNA synthetase (GARS); glyoxalase I (lactoyl glutathione lyase)(GLYI); golgi autoantigen, golgin subfamily a, 1 (GOLGA1); golgiautoantigen, golgin subfamily a, 4 (GOLGA4); golgi autoantigen, golginsubfamily b, macrogolgin (with transmembrane signal), 1 (GOLGB1); gp25L2protein; grancalcin; granulin (GRN); Granulysin (NKG5); granzyme A(granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3)(GZMA); GRB2-related adaptor protein (GRAP); Grb2-related adaptorprotein 2 (GRAP2); GRO1 oncogene (melanoma growth stimulating activity,alpha) (GRO1); growth arrest and DNA-damage-inducible gene (GADD153);growth arrest-specific 7 (GAS7); growth factor receptor-bound protein 2(GRB2); GS1 (protein of unknown function); GS3955; GTP binding protein 1(GTPBP1); GTPase activating protein-like (GAPL); Gu protein (GURDB);guanine nucleotide binding protein (G protein), alpha inhibitingactivity polypeptide 2 (GNAI2); guanine nucleotide binding protein (Gprotein), alpha inhibiting activity polypeptide 3 (GNAI3); guaninenucleotide binding protein (G protein), alpha stimulating activitypolypeptide 1 (GNAS1); guanine nucleotide binding protein (G protein),alpha transducing activity polypeptide 2 (GNAT2); guanine nucleotidebinding protein (G protein), beta 5 (GNB5); guanine nucleotide bindingprotein (G protein), beta polypeptide 1 (GNB1); guanine nucleotidebinding protein (G protein), q polypeptide (GNAQ); guanine nucleotidebinding protein-like 1 (GNL1); guanine nucleotide exchange factor;guanine nucleotide regulatory factor (LFP40); GUANINE-MONOPHOSPHATESYNTHETASE (GMPS); guanosine-diphosphatase like protein; guanylatebinding protein 1, interferon-inducible, 67 kD (GBP1); guanylate bindingprotein 2, interferon-inducible (GBP2); H2A histone family, member C(H2AFC); H2A histone family, member Y (H2AY); H2B histone family, memberL (H2BFL); h2-calponin; H-2K binding factor-2; H3 histone family, memberK (H3FK); H3 histone, family 3A (H3F3A); H3 histone, family 3B (H3.3B)(H3F3B); hbc647; heat shock 27 kD protein 1 (HSPB1); heat shock 40 kDprotein 1 (HSPF1); heat shock 60 kD protein 1 (chaperonin) (HSPD1); heatshock 70 kD protein 1 (HSPA1A); heat shock 70 kD protein 5(glucose-regulated protein, 78 kD) (HSPA5); heat shock 70 kD protein 6(HSP70B′) (HSPA6); heat shock 70 kD protein 9B (mortalin-2) (HSPA9B);heat shock factor binding protein 1 (HSBP1); heat shock protein 90; heatshock protein, DNAJ-like 2 (HSJ2); Hect (homologous to the E6-AP (UBE3A)carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 (HERC1);hect domain and RLD 2 (HERC2); helicase-like protein (HLP);helix-loop-helix protein HE47 (E2A); hematopoietic cell-specific Lynsubstrate 1 (HCLS1); heme oxygenase (decycling) 1 (HMOX1); hemoglobinbeta (beta globin); hemoglobin, alpha 1 (HBA1); hemoglobin, beta (HBB);emokine (C-X-C motif), receptor 4 (fusin) (CXCR4); hemopoietic cellkinase (HCK); hepatitis C-associated microtubular aggregate protein p44;hepatoma-derived growth factor; Hermansky-Pudlak syndrome (HPS);heterogeneous nuclear ribonucleoprotein (C1/C2) (HNRPC); heterogeneousnuclear ribonucleoprotein A/B (HNRPAB); heterogeneous nuclearribonucleoprotein Al (HNRPA1); heterogeneous nuclear ribonucleoproteinA2/B1 (HNRPA2B1); heterogeneous nuclear ribonucleoprotein D (hnRNP D);heterogeneous nuclear ribonucleoprotein D-like (HNRPDL); heterogeneousnuclear ribonucleoprotein F (HNRPF); heterogeneous nuclearribonucleoprotein G (HNRPG); heterogeneous nuclear ribonucleoprotein H1(H) (HNRPH1); heterogeneous nuclear ribonucleoprotein K (HNRPK);heterogeneous nuclear ribonucleoprotein R (HNRPR); heterogeneous nuclearribonucleoprotein U (scaffold attachment factor A) (HNRPU); hexokinase 1(HK1); hexokinase 2 (HK2); hexokinase 3 (HK3); hexosaminidase A (alphapolypeptide) (HEXA; HGMPO7I gene for olfactory receptor; High densitylipoprotein binding protein (HDLBP); high-mobility group (nonhistonechromosomal) protein 1 (HMG1); High-mobility group (nonhistonechromosomal) protein 17 (HMG17); high-mobility group (nonhistonechromosomal) protein 2 (HMG2); high-mobility group (nonhistonechromosomal) protein isoforms I and Y; histidine ammonia-lyase (HAL);histidyl-tRNA synthetase (HARS); histocompatibility antigen (HLA-Cw3),class I; histone deacetylase 1 (HDAC); histone deacetylase 1 (HDAC1);histone deacetylase 5 (NY-CO-9); HK2 gene for hexokinase II; HL9monocyte inhibitory receptor precursor; HLA class I heavy chain(HLA-Cw*1701); HLA class I locus C heavy chain; HLA class II SB 4-betachain; HLA class III region containing NOTCH4 gene; HLA-A; HLA-A*7402;HLA-A11; HLA-B; HLA-B associated transcript-1 (D6S81E); HLA-B associatedtranscript-2 (D6S51E); HLA-B*1529; HLA-Bw72 antigen; HLA-C gene(HLA-Cw*0701 allele); HLA-Cw*0701; HLA-Cw*0801; HLA-Cw*1203; HLA-DRalpha-chain; HLA-F (leukocyte antigen F); HMG box containing protein 1;Hmob33; HMT1 (hnRNP methyltransferase, S. cerevisiae)-like 1 (HRMT1L1);homeodomain-interacting protein kinase 3 (HIPK3); homolog of Drosophilapast (PAST); homolog of yeast (S. cerevisiae) ufd2 (UFD2); HPV16 E1protein binding protein; HRIHFB2157; hsc70 gene for 71 kd heat shockcognate protein; HSPC012; HSPC021; HsPex13p; htra2-beta-2; HU-K4;hunc18b2; HUNKI; huntingtin-interacting protein HYPA/FBP11 (HYPA);hVps41p (HVPS41); hydroxyacyl-Coenzyme Adehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase(trifunctional protein), alpha subunit (HADHA); hydroxyacyl-Coenzyme Adehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase(trifunctional protein), beta subunit (HADHB); hydroxysteroid (17-beta)dehydrogenase 1 (HSD17B1); hypoxia-inducible factor 1, alpha subunit(basic helix-loop-helix transcription factor) (HIF1A); Ia-associatedinvariant gamma-chain (clones lambda-y (1,2,3)); iduronate 2-sulfatase(Hunter syndrome) (IDS); Ig heavy chain variable region; Ig heavy chainvariable region (VH4DJ) (clone T14.4); Ig heavy chain variable region(VH4DJ) (clone T22.18); Ig J chain; Ig kappa; IG kappa light chainvariable region A20; Ig lambda light chain variable region(26-34ITIIIF120); Ig mu-chain VDJ4-region; Ig rearranged anti-myelinkappa-chain (V-J4-region, hybridoma AE6-5); Ig rearranged H-chain mRNAV-region; IgG Fc binding protein (FC(GAMMA)BP); IgG heavy chain variableregion (vH26); IgM heavy chain (C mu, membrane exons); IkB kinase-beta(IKK-beta); IL-1 receptor type II; IL2-inducible T-cell kinase (ITK);immediate early protein (ETR101); immunogloblin light chain (lambda);Immunoglobulin (CD79A) binding protein 1 (IGBP1); immunoglobulin G Fcreceptor IIIB; immunoglobulin gamma 3 (Gm marker) (IGHG3);immunoglobulin heavy chain (VI-3B); immunoglobulin heavy chain J region;immunoglobulin heavy chain J region, B1 haplotype; immunoglobulin heavychain variable region (IGH) (clone 21u-48); immunoglobulin heavy chainvariable region (IGH) (clone 23u-1); immunoglobulin heavy chain variableregion V3-43 (IGHV @); immunoglobulin heavy chain variable region V3-7(IGHV @); immunoglobulin IgH heavy chain Fd fragment; immunoglobulinkappa light chain; immunoglobulin kappa light chain V-segment A27;immunoglobulin light chain; immunoglobulin light chain variable region(lambda IIIb subgroup) from IgM rheumatoid factor; immunoglobulin Mheavy chain V region=anti-lipid A antibody; immunoglobulin mu (IGHM);immunoglobulin mu binding protein 2 (IGHMBP2); immunoglobulinsuperfamily, member 2 (IGSF2); imogen 38 (IMOGEN38); IMP (inosinemonophosphate) dehydrogenase 1 (IMPDH1); IMP (inosine monophosphate)dehydrogenase 2 (IMPDH2); inc finger protein 151 (pHZ-67) (ZNF151); incfinger protein, C2H2, rapidly turned over (ZNF20); induciblepoly(A)-binding protein (IPABP); inducible protein (Hs.80313); inhibitorof DNA binding 2, dominant negative helix-loop-helix protein (ID2);inhibitor of kappa light polypeptide gene enhancer in B-cells, kinasecomplex-associated protein (IKBKAP); inositol 1,3,4-trisphosphate5/6-kinase; inositol 1,4,5 trisphosphate receptor type 1 (ITPR1);inositol 1,4,5-trisphosphate 3-kinase B (ITPKB); inositolmonophosphatase; inositol polyphosphate-5-phosphatase, 145 kD (INPP5D);Ins(1,3,4,5)P4-binding protein; insulin (INS); insulin-like growthfactor 2 receptor (IGF2R); integral membrane protein 1 (ITM1); integralmembrane protein 2C (ITM2C); integral membrane protein Tmp21-I (p23);integrin beta 4 binding protein (ITGB4BP); integrin, alpha 2b (plateletglycoprotein IIb of IIb/IIIa complex, antigen CD41B) (ITGA2B); integrin,alpha 5 (fibronectin receptor, alpha polypeptide) (ITGA5); integrin,alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1;alpha polypeptide) (ITGAL); integrin, alpha M (complementcomponentreceptor 3, alpha; also known as CD11b (p170), macrophageantigen alpha polypeptide) (ITGAM); integrin, alpha X (antigen CD11C(p150), alpha polypeptide) (ITGAX); integrin, beta 1 (fibronectinreceptor, beta polypeptide, antigen CD29 includes MDF2 MSK12) (ITGB1);integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associatedantigen 1; macrophage antigen 1 (mac-1) beta subunit) (ITGB2); integrin,beta 7 (ITGB7); Integrin-linked kinase (ILK); intercellular adhesionmolecule 1 (CD54), human rhinovirus receptor (ICAM1); intercellularadhesion molecule 2 (ICAM2); intercellular adhesion molecule 3 (ICAM3);intercellular adhesion molecule 4, Landsteiner-Wiener blood group(ICAM4); Interferon consensus sequence binding protein 1 (ICSBP1);interferon regulatory factor 2 (IRF2); interferon regulatory factor1(IRF1); interferon regulatory factor5 (IRF5); interferon,gamma-inducible protein 16 (IFI16); interferon, gamma-inducible protein30 (IFI30); interferon-induced protein 17 (IFI17); interferon-inducedprotein 54 (IF154); interferon-inducible (1-8D); interferon-inducible(1-8U); interferon-related developmental regulator 1 (IFRD1);interferon-stimulated transcription factor 3, gamma (48 kD) (ISGF3G);interleukin 1 receptor, type II (IL1R2); Interleukin 10 receptor, beta(I.10RB); interleukin 12 receptor, beta 1 (IL12RB1); interleukin 13receptor, alpha 1 (IL13RA1); interleukin 16 (lymphocyte chemoattractantfactor) (IL16); interleukin 18 receptor 1 (IL18R1); interleukin 2receptor, beta (IL2RB); interleukin 2 receptor, gamma (severe combinedimmunodeficiency) (IL2RG); interleukin 4 receptor (IL4R); interleukin 6receptor (IL6R); interleukin 6 signal transducer (gp130, oncostatin Mreceptor) (IL6ST); interleukin 7 receptor (IL7R); interleukin 8 (IL8);interleukin 8 receptor alpha (IL8RA); interleukin 8 receptor, beta(IL8RB); interleukin enhancer binding factor 2, 45 kD (ILF2);interleukin enhancer binding factor 3, 90 kD (ILF3); interleukin-1receptor-associated kinase 1 (IRAK1); interleukin-10 receptor, alpha(IL10RA); interleukin-11 receptor, alpha (IL11RA); intestinalcarboxylesterase; IQ motif containing GTPase activating protein 1(IQGAP1); IQ motif containing GTPase activating protein 2 (IQGAP2);isocitrate dehydrogenase 1 (NADP+), soluble (IDH1); isocitratedehydrogenase 2 (NADP+), mitochondrial (IDH2); isocitrate dehydrogenase3 (NAD+) alpha (IDH3A); isocitrate dehydrogenase 3 (NAD+) gamma (IDH3G);isolate TzCCR5-179 CCR5 receptor (CCR5); isopentenyl-diphosphate deltaisomerase (IDI1); Janus kinase 1 (a protein tyrosine kinase) (JAK1);Janus kinase 2 (a protein tyrosine kinase) (JAK2); Jk-recombinationsignal binding protein (RBPJK); JM1 protein; jumonji (mouse) homolog(JMJ); jun D proto-oncogene (JUND); jun dimerization protein; junctionplakoglobin (JUP); kangai 1 (suppression of tumorigenicity 6, prostate;CD82 antigen (R2 leukocyte antigen, antigen detected by monoclonal andantibody IA4)) (KAI1); karyopherin (importin) beta 1 (KPNB1);karyopherin (importin) beta 2 (KPNB2); karyopherin alpha 1 (importinalpha 5) (KPNA1); karyopherin alpha 2 (RAG cohort 1, importin alpha 1)(DPNA2); karyopherin alpha 3 (importin alpha 4) (KPNA3); karyopherinalpha 4 (KPNA4); Katanin (80 kDa) (KAT); KE03 protein; Keratin 8 (KRT8);ketohexokinase (fructokinase) (KHK); KIAA0002 (KIAA0002); KIAA0005(KIAA0005); KIAA0010 (KIAA0010); KIAA0016 (KIAA0016); KIAA0017(KIAA0017); KIAA0022 (KIAA0022); KIAA0023 (KIAA0023); KIAA0024(KIAA0024); KIAA0025 (KIAA0025); KIAA0026 (KIAA0026); KIAA0027; KIAA0032(KIAA0032); KIAA0040 (KIAA0040); KIAA0050 (KIAA0050); KIAA0053(KIAA0053); KIAA0057 (KIAA0057); KIAA0058 (KIAA0058); KIAA0063(KIAA0063); KIAA0064 (KIAA0064); KIAA0066; KIAA0068; KIAA0073; KIAA0081;KIAA0084; KIAA0085; KIAA0088; KIAA0090; KIAA0092 (KIAA0092); KIAA0094;KIAA0095 (KIAA0095); KIAA0096; KIAA0097 (KIAA0097); KIAA0099 (KIAA0099);KIAA0102 (KIAA0102); KIAA0105; KIAA0121 (KIAA0121); KIAA0123; KIAA0128;KIAA0129 (KIAA0129); KIAA0130 (KIAA0130); KIAA0136; KIAA0137 (KIAA0137);KIAA0140 (KIAA0140); KIAA0141 (KIAA0141); KIAA0144 (KIAA0144); KIAA0146;KIAA0148 (KIAA0148); KIAA0154; KIAA0156; KIAA0160; KIAA0161 (KIAA0161);KIAA0164 (KIAA0164); KIAA0167 (KIAA0167); KIAA0168 (KIAA0168); KIAA0169;KIAA0171 (KIAA0171); KIAA0174 (KIAA0174); KIAA0179; KIAA0181; KIAA0183;KIAA0184; KIAA0193 (KIAA0193); KIAA0200 (KIAA0200); KIAA0210 (KIAA0210);KIAA0217; KIAA0219; KIAA0222 (KIAA0222); KIAA0223; KIAA0229; KIAA0232(KIAA0232); KIAA0233 (KIAA0233); KIAA0235; KIAA0239; KIAA0240; KIAA0242;KIAA0248; KIAA0249 (KIAA0249); KIAA0253; KIAA0254 (KIAA0254);KIAA0255(KIAA0255); KIAA0262 (KIAA0262); KIAA0263 (KIAA0263); KIAA0264;KIAA0268; KIAA0275 (KIAA0275); KIAA0304 (KIAA0304); KIAA0308; KIAA0310(KIAA0310); KIAA0315 (KIAA0315); KIAA0329 (KIAA0329); KIAA0330;KIAA0332; KIAA0333; KIAA0336 (KIAA0336); KIAA0342 (KIAA0342); KIAA0344(KIAA0344); KIAA0354 (KIAA0354); KIAA0365 (KIAA0365); KIAA0370; KIAA0372(KIAA0372); KIAA0373 (KIAA0373); KIAA0375 (KIAA0375); KIAA0377(KIAA0377); KIAA0379; KIAA0380 (KIAA0380); KIAA0382 (KIAA0382);KIAA0383; KIAA0386 (KIAA0386); KIAA0392; KIAA0397 (KIAA0397); KIAA0403;KIAA0404; KIAA0409; KIAA0421; KIAA0428 (KIAA0428); KIAA0429 (KIAA0429);KIAA0430 (KIAA0430); KIAA0432 (KIAA0432); KIAA0435 (KIAA0435); KIAA0438(KIAA0438); KIAA0447 (KIAA0447); KIAA0449; KIAA0456; KIAA0458(KIAA0458); KIAA0462; KIAA0465; KIAA0476 (KIAA0476); KIAA0489; KIAA0494(KIAA0494); KIAA0515; KIAA0521; KIAA0525; KIAA0530; KIAA0532; KIAA0537(KIAA0537); KIAA0540; KIAA0543; KIAA0544; KIAA0549; KIAA0551; KIAA0554;KIAA0561; KIAA0562 (KIAA0562); KIAA0563 (KIAA0563); KIAA0569 (KIAA0569);KIAA0571 (KIAA0571); KIAA0573; KIAA0576; KIAA0580; KIAA0584; KIAA0592;KIAA0596; KIAA0598 (KIAA0598); KIAA0608; KIAA0614; KIAA0615 (KIAA0615);KIAA0621; KIAA0648; KIAA0652 (KIAA0652); KIAA0668; KIAA0669; KIAA0671(KIAA0671); KIAA0675 (KIAA0675); KIAA0676; KIAA0677 (KIAA0677);KIAA0678; KIAA0679; KIAA0680 (KIAA0680); KIAA0692; KIAA0697; KIAA0699;KIAA0700; KIAA0737 (KIAA0737); KIAA0748 (KIAA0748); KIAA0763 (KIAA0763);KIAA0769 (KIAA0769); KIAA0782; KIAA0796; KIAA0798 (KIAA0798); KIAA0823;KIAA0854; KIAA0856; KIAA0860; KIAA0862; KIAA0873; KIAA0892; KIAA0906;KIAA0991; killer cell lectin-like receptor subfamily B, member 1(KLRB1); killer cell lectin-like receptor subfamily C, member 4 (KLRC4);kinectin 1 (kinesin receptor) (KTN1); kinesin family member 5B (KIF5B);kinesin-like DNA binding protein; Kruppel related gene (clone pHKR1RS);Kruppel-like zinc finger protein Zf9; kruppel-type zinc finger protein,ZK1; L apoferritin; lactate dehydrogenase A (LDHA); lactatedehydrogenase B (LDHB); lactotransferrin (LTF); laminin receptor 1 (67kD); Ribosomal protein SA (LAMR1); laminin receptor homolog {3′ region};laminin, gamma 1 (formerly LAMB2) (LAMC1); latent transforming growthfactor beta binding protein 1 (LTBP1); LDLC; lectin,galactoside-binding, soluble, 2 (galectin 2) (LGALS2); lectin,galactoside-binding, soluble, 3 binding protein (galectin 6 bindingprotein) (LGALS3BP); leucine rich repeat (in FLIT) interacting protein 1(LRRFIP1); leucocyte immunoglobulin-like receptor-5 (LIR-5); leucocyteimmunoglobulin-like receptor-6a (LIR-6); leucocyte immunoglobulin-likereceptor-7 (LIR-7); leukemia virus receptor 1 (GLVR1); leukocyteadhesion protein p150,95 alpha subunit; leukocyte antigen, HLA-A2;leukocyte immunoglobulin-like receptor (MIR-10); leukocyte tyrosinekinase (LTK); leukocyte-associated Ig-like receptor 1 (LIAR1);leukotriene A4 hydrolase (LTA4H); leupaxin (LDPL); ligase I, DNA,ATP-dependent (LIG1); LIM and SH3 protein 1 (LASP1); LIM domain kinase 2(LIMK2); Line-1 repeat mRNA with 2 open reading frames; Line-1 repeatwith 2 open reading frames; lipase A, lysosomal acid, cholesterolesterase (Wolman disease) (LIPA); lipase, hormone-sensitive (LIPE);LMP7; Lon protease-like protein (LONP); low density lipoprotein-relatedprotein 1 (alpha-2-macroglobulin receptor) (LRP1); low densitylipoprotein-related protein-associated protein 1 (alpha-2-macroglobulinreceptor-associated protein 1) (LRPAP1); low-affinity Fc-gamma receptorIIA; LPS-induced TNF-alpha factor (PIG7); Lst-1; L-type amino acidtransporter subunit LAT1; lung resistance-related protein (LRP);Lymphocyte antigen 75 (LY75); lymphocyte antigen 9 (LY9); lymphocyteantigen HLA-B*4402 and HLA-B*5101; lymphocyte cytosolic protein 1(L-plastin) (LCP1); lymphocyte cytosolic protein 2 (SH2domain-containing leukocyte protein of 76 kD) (LCP2); lymphocyteglycoprotein T1/Leu-1; lymphocyte-specific protein 1 (LSP1);lymphocyte-specific protein tyrosine kinase (LCK); lymphoid phosphataseLyP1; lymphoid-restricted membrane protein (LRMP); lymphoid-specificSP100 homolog (LYSP100-A); lymphoma proprotein convertase (LPC);lysosomal-associated membrane protein 1 (LAMP1); Lysosomal-associatedmembrane protein 2 (LAMP2); lysozyme (renal amyloidosis) (LYZ);lysyl-tRNA synthetase (KARS); M phase phosphoprotein 10 (U3 smallnucleolar ribonucleoprotein) (MPP-10); M1-type and M2-type pyruvatekinase; m6A methyltransferase (MT-A70); mab-21 (C. elegans)-like 1(MAB21L1); MacMarcks; macrophage-associated antigen (MM130); MADS boxtranscription enhancer factor 2, polypeptide A (myocyte enhancer factor2A) (MEF2A); MADS box transcription enhancer factor 2, polypeptide C(myocyte enhancer factor 2C) (MEF2C); major histocompatibility complexclass I beta chain (HLA-B); major histocompatibility complex, class I, A(HLA-A); major histocompatibility complex, class I, C (HAL-C); majorhistocompatibility complex, class I, E (HLA-E); major histocompatibilitycomplex, class II, DM BETA (HLA-DMB); major histocompatibility complex,class II, DP beta 1 (HLA-DPB1); major histocompatibility complex, classII, DR beta 1 (HLA-DRB1); Major histocompatibility complex, class II, Ybox-binding protein I; DNA-binding protein B (YB1); malate dehydrogenase1, NAD (soluble) (mdhl); malate dehydrogenase 1, NAD (soluble) (MDH1);malonyl-CoA decarboxylase precursor; maltase-glucoamylase (mg); manicfringe (Drosophila) homolog (MFNG); mannose phosphate isomerase (MPI);mannose phosphate isomerase (mpi); mannose-6-phosphate receptor (cationdependent) (M6PR); mannose-P-dolichol utilitzation defect 1 (MPDU1);mannosidase, alpha B, lysosomal (MANB); mannosyl(alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase(MGAT1); map 4q35 repeat region; MAP kinase-interacting serine/threoninekinase 1 (MKNK1); MAP/ERK kinase kinase 3 (MEKK3); MAP/ERK kinase kinase5 (MEKKS); MAP/microtubule affinity-regulating kinase 3 (MARK3);Marenostrin protein; MASL1; MAX dimerization protein (MAD); MaxiKpotassium channel beta subunit; MBP-2 for MHC binding protein 2; Meis(mouse) homolog 3 (MEIS3); melanoma-associated antigen p97(melanotransferrin); membrane cofactor protein (CD46,trophoblast-lymphocyte cross-reactive antigen) (MCP); membranecomponent, chromosome 17, surface marker 2 (ovarian carcinoma antigenCAl25) (M17S2); membrane metallo-endopeptidase (neutral endopeptidase,enkephalinase, CALLA, CD10) (MME); membrane protein, palmitoylated 1 (55kD) (MPP1); meningioma expressed antigen (MGEA); meningioma-expressedantigen 11 (MEA11); Menkes Disease (ATP7A) putative Cu++-transportingP-type ATPase; metallothionein 2A (MT2A); metaxin 1 (MTX1); methionineadenosyltransferase II, alpha (MAT2A); methylene tetrahydrofolatedehydrogenase (NAD+ dependent), methenyltetrahydrofolate cyclohydrolase(MTHFD2); methylenetetrahydrofolate dehydrogenase (NADP+ dependent),methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolatesynthetase (MTHFD1); methyltransferase, putative; MHC class 1 region;MHC class I antigen (HLA-A2); MHC class I antigen (HLA-A33); MHC class Iantigen (HLA-C); MHC class I antigen B*5801 (HLA-B); MHC class I antigenHLA-A (HLA-A); MHC class I antigen HLA-A (HLA-A-2402 allele); MHC classI antigen HLA-A11K; MHC class I antigen HLA-B (B*48 allele); MHC class Iantigen HLA-B (HLA-B*1502 allele); MHC class I antigen HLA-B(HLA-B*40MD); MHC class I antigen HLA-B (HLA-B*4103 allele); MHC class Iantigen HLA-B gene (HLA-B*4402 variant allele); MHC class I antigenHLA-B GN00110-B*3910; MHC class I antigen HLA-Cw*04011; MHC class Iantigen R69772 HLA-A (A*0302); MHC class I antigen SHCHA (HLA-B*4403variant); MHC class I histocompatibility antigen (HLA-B) (clone C21/14);MHC class I HLA B71; MHC class I HLA-A (Aw33.1); MHC class I HLA-B; MHCclass I HLA-B (HLA-B-08NR allele); MHC class I HLA-B*3512; MHC class IHLA-B44.2 chain; MHC class I HLA-B51-cd3.3; MHC class I HLA-C allele;MHC class I HLA-Cw*0803; MHC class I HLA-Cw6; MHC class I lymphocyteantigen A2 (A2.1) variant DK1; MHC class I mic-B antigen; MHC class Ipolypeptide-related sequence A (MICA); MHC class II DNA Sequence (cloneA37G7-1C11); MHC class II DQ-alpha associated with DRw6, DQw1 protein;MHC class II DQ-beta associated with DR2, DQw1 protein; MHC class IIHAL-DQ-LTR5 (DQ,w8) DNA fragment, long terminal repeat region; MHC classII HLA-DRB1; MHC class II HLA-DRw11-beta-I chain (DRw11.3); MHC class IIlymphocyte antigen (DPw4-beta-1); microsomal stress 70 protein ATPasecore (stch); microtubule-associated protein 4 (MAP4);microtubule-associated protein 7 (MAP7); mineralocorticoid receptor(aldosterone receptor) (MLR); minichromosome maintenance deficient (S.cerevisiae) 3 (MCM31); minichromosome maintenance deficient (S.cerevisiae) 3-associated protein (MCM3AP); minichromosome maintenancedeficient (S. cerevisiae) 5 (cell division cycle 46) (MCM5);mitochondrial 16S rRNA; mitochondrial ATP synthase (F1-ATPase) alphasubunit; mitochondrial ATP synthase c subunit (P1 form); mitochondrialcytochrome b small subunit of complex II; mitochondrial DNA loopattachment sequences (clone LAS34); mitochondrial DNA polymeraseaccessory subunit precursor (MtPolB) nuclear gene encoding mitochondrialprotein; mitochondrial DNA, complete genome; mitochondrial innermembrane preprotein translocase Tim17a; mitochondrial loop attachmentsequence (clone LAS88); mitochondrial NADH dehydrogenase subunit 2(ND2); mitochondrial translational initiation factor 2 (MTIF2);mitochondrion cytochrome b; mitogen inducible gene mig-2;mitogen-activated protein kinase-activated protein kinase 3 (MAPKAPK3);MLN51; moesin (MSN); monocytic leukaemia zinc finger protein (MOZ); MOP1( ); motor protein (Hs.78504); mouse double minute 2, human homolog of;p53-binding protein (MDM2); M-phase phosphoprotein 6 (MPP-6); M-phasephosphoprotein, mpp11; MPS1; Mr 110,000 antigen; mu-adaptin-relatedprotein-2; mu subunit of AP-4 (MU-ARP2); murine leukemia viral (bmi-1)oncogene homolog (BMI1); mutant (Daudi) beta2 -microglobulin; mutated incolorectal cancers (MCC); myeloid cell leukemia sequence 1(BCL2-related) (MCL1); myeloid cell nuclear differentiation antigeN(MNDA); myeloid differentiation primary response gene (88) (MYD88);myeloid leukemia factor 2 (MLF2); myeloid/lymphoid or mixed-lineageleukemia (trithorax (Drosophila) homolog); translocated to, 7 (MLLT7);MYH9 (cellular myosin heavy chain); myomesin (M-protein) 2 (165 kD)(MYOM2); myosin IE (MYO1E); myosin light chain kinase (MLCK); myosinphosphatase, target subunit 1 (MYPT1); myosin, heavy polypeptide 9,non-muscle (MYH9); myosin, light polypeptide, regulatory, non-sarcomeric(20 kD) (MLCB); myosin-I beta; myristoylated alanine-rich protein kinaseC substrate (MARCKS, 80K-L) (MACS); myxovirus (influenza) resistance 1,homolog of murine (interferon-inducible protein p78) (MX1); myxovirus(influenza) resistance 2, homolog of murine (MX2);N-acetylgalactosaminidase, alpha-(NAGA); N-acetylglucosamine receptor 1(thyroid) (NAGR1); NACP/alpha-synuclein; N-acylaminoacyl-peptidehydrolase (APEH); N-acylsphingosine amidohydrolase (acid ceramidase)(ASAH); NAD+-specific isocitrate dehydrogenase beta subunit precursor(encoding mitochondrial protein); NADH dehydrogenase (ubiquinone) 1alpha subcomplex, 5 (13 kD, B13) (NDUFAS); NADH dehydrogenase(ubiquinone) 1 beta subcomplex, 5 (16 kD, SGDH) (NDUFBS); NADHdehydrogenase (ubiquinone) Fe—S protein 2 (49 kD) (NADH-coenzyme Qeductase) (NDUFS2); NADH dehydrogenase (ubiquinone) flavoprotein 2 (24kD) (NDUFV2); NADH:ubiquinone dehydrogenase 51 kDa subunit (NDUFV1);Nardilysin (N-arginine dibasic convertase) (NRD1);nascent-polypeptide-associated complex alpha polypeptide (NACA); naturalkiller cell group 7 sequence (NKG7); natural killer cell transcript 4(NK4); natural killer-associated transcript 3 (NKAT3); naturalkiller-associated transcript 5 (NKATS); natural killer-tumor recognitionsequence (NKTR); N-deacetylase/N-sulfotransferase (heparan glucosaminyl)2 (NDST2); Ndr protein kinase; Nedd-4-like ubiquitin-protein ligaseWWP1; nel (chicken)-like 2 (NELL2); N-ethylmaleimide-sensitive factorattachment protein, alpha (NAPA); N-ethylmaleimide-sensitive factorattachment protein, gamma (NAPG); neural precursor cell expressed,developmentally down-regulated 5 (NEDD5); neural precursor cellexpressed, developmentally down-regulated 8 (NEDD8); neuregulin 1(NRG1); neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS);Neurofibromin 2 (bilateral acoustic neuroma) (NF2); neuronal apoptosisinhibitory protein (NAIP); neuronal cell adhesion molecule (NRCAM);neuropathy target esterase (NTE); neurotrophic tyrosine kinase,receptor, type 1 (NTRK1); neutrophil cytosolic factor 4 (40 kD); NG31;nibrin (NBS); NIK; Ninjurin 1; nerve injury-induced protein-1; Nmi;N-myristoyltransferase 1 (NMT1); No arches-like (zebrafish) zinc fingerprotein (NAR); non-histone chromosome protein 2 (S. cerevisiae)-like 1(NHP2L1); non-muscle alpha-actinin; non-muscle myosin alkali light chain(Hs.77385); non-neuronal enolase (EC 4.2.1.11); non-receptor tyrosinephosphatase 1; normal keratinocyte substraction library mRNA, cloneH22a; notch group protein (N); novel protein; novel T-cell activationprotein; N-sulfoglucosamine sulfohydrolase (sulfamidase) (SGSH); nsulininduced gene 1 (INSIG1); ntegrin, alpha 4 (antigen CD49D, alpha 4subunit of VLA-4 receptor) (ITGA14); nterferon, gamma-inducible protein16 (IFI16); nterleukin 1, beta (IL1RB); nuclear antigen H731-likeprotein; nuclear antigen Sp100 (SP100); nuclear autoantigenic spermprotein (histone-binding) (NASP); Nuclear domain 10 protein (NDP52);Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2); Nuclear factor ofkappa light polypeptide gene enhancer in B-cells 1 (p105) (NFKB1);nuclear factor of kappa light polypeptide gene enhancer in B-cellsinhibitor, alpha (NFKBIA); nuclear factor related to kappa B bindingprotein (NFRKB); nuclear mitotic apparatus protein 1 (NUMA1); nuclearreceptor coactivator 2 (GRIP1); nuclear receptor coactivator 3 (AIB3);nuclear receptor coactivator 4 (ELE1); nuclear receptor interactingprotein 1 (NRIP1); nuclear respiratory factor 1 (NRF1); nuclear RNAhelicase, DECD variant of DEAD box family (DDXL); nuclear transcriptionfactor Y, alpha (NFYA); nuclear transcription factor, X-box binding 1(NFX1); nuclear transport factor 2 (placental protein 15) (PP15);nucleobindin 1 (NUCB1); nucleolar phosphoprotein p130 (P130); nucleolarprotein (KKE/D repeat) (NOP56); nucleolar protein (MSP58); nucleolarprotein 1 (120 kD) (NOL1); nucleolar protein p40; nucleolin (NCL);nucleophosmin (nucleolar phosphoprotein B23, numatrin) (NPM1);nucleophosmin-retinoic acid receptor alpha fusion protein NPM-RAR longform; nucleoporin 153 kD (NUP153); nucleoporin 98 kD (NUP98); nucleosomeassembly protein; nucleosome assembly protein 1-like 1 (NAP1L1);nucleosome assembly protein 1-like 4 (NAP1L4); nucleosome assemblyprotein, 5′UTR; olfactory receptor (OR7-141); oligodendrocyte myelinglycoprotein (OMG); 0-linked N-acetylglucosamine (G1cNAc) transferase(UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase)(OGT); ORF (Hs.77868); ORF1; MER37; origin recognition complex, subunit2 (yeast homolog)-like (ORC2L); ornithine aminotransferase (gyrateatrophy) (OAT); ornithine decarboxylase (ODC); ornithine decarboxylaseantizyme, ORF 1 and ORF 2; orphan receptor (Hs.100221); OS-9 precurosor;ovel centrosomal protein RanBPM (RANBPM); over-expressed breast tumorprotein; oviductal glycoprotein 1, 120 kD (OVGP1); oxidase (cytochromec) assembly 1-like (OXA1L); oxoglutarate dehydrogenase (lipoamide)(OGDH); oxysterol binding protein (OSBP); OZF; p21/Cdc42/Rac1-activatedkinase 1 (yeast Ste20-related) (PAK1); p40; P47 LBC oncogene;p53-induced protein (PIG11); p62 nucleoporin; p63 mRNA for transmembraneprotein; palmitoyl-protein thioesterase (ceroid-lipofuscinosis, neuronal1, infantile; Haltia-Santavuori disease) (PPT); papillary renal cellcarcinoma (translocation-associated) (PRCC); PAR protein; PAX3/forkheadtranscription factor gene fusion; paxillin (PXN); PBK1 protein; PDZdomain protein (Drosophila inaD-like) (INALD); peptidase D (PEPD);peptidylprolyl isomerase A (cyclophilin A) (PPIA); peptidylprolylisomerase D (cyclophilin D) (PPID); peptidylprolyl isomerase E(cyclophilin E) (PPIE); perforin 1 (preforming protein) (PRF1);peroxisomal acyl-CoA thioesterase (PTE1); Peroxisomal acyl-coenzyme Aoxidase; peroxisomal farnesylated protein (PXF);phorbol-12-myristate-13-acetate-induced protein (PMAIP1); Phosphatecarrier, mitochondrial (PHC); phosphate cytidylyltransferase 1, choline,alpha isoform (PCYT1A); phosphatidylinositol 3-kinase delta catalyticsubunit; phosphatidylinositol 4-kinase, catalytic, beta polypeptide(PIK4CB); phosphatidylinositol glycan, class H (PIGH);phosphatidylinositol transfer protein (PI-TPbeta); phosphatidylinositoltransfer protein, membrane-associated (PITPNM);phosphatidylinositol-4-phosphate 5-kinase, type II, alpha (PIP5K2A);phosphatidylinositol-4-phosphate 5-kinase, type II, beta (PIP5K2B);phosphodiesterase 7A (PDE7A); phosphodiesterase IB (PDES1B);phosphoglucomutase 1 (PGM1); phosphogluconate dehydrogenase (PGD);phosphoglycerate kinase 1 (PGK1); phosphoglycerate mutase 1 (brain)(PGAM1); phosphoglycerate mutase 2 (muscle) (PGAM2);phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA);phosphoinositide-3-kinase, catalytic, delta polypeptide (PIK3CD);phosphoinositide-3-kinase, catalytic, gamma polypeptide (PIK3CG);phospholipase C; phospholipase C, delta 1 (PLCD1); phospholipase C,gamma 1 (formerly subtype 148) (PLCG1); phospholipid scramblase;phosphoribosyl pyrophosphate synthetase-associated protein 1 (PRPSAP1);phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamidesynthetase, phosphoribosylaminoimidazole synthetase (GART);phosphorylase kinase, alpha 2 (liver), glycogen storage disease IX(PHKA2); phosphorylase, glycogen; brain (PYGB); phosphorylase, glycogen;liver (Hers disease, lycogen storage disease type VI) (PYGL);phosphorylation regulatory protein HP-10; phosphotidylinositol transferprotein (PITPN); pigment epithelium-derived factor (PEDF); pim-1oncogene (PIM1); pinin, desmosome associated protein (PNN); placenta(Diff33); placenta (Diff48); plasminogen activator, urokinase receptor(PLAUR); platelet factor 4 (PF4); platelet/endothelial cell adhesionmolecule (CD31 ntigen) (PECAM1); platelet-activating factoracetylhydrolase 2 (40 kD) (PAFAH2); platelet-activating factoracetylhydrolase, isoform 1b, alpha subunit (45 kD) (PAFAH1B1);platelet-activating factor receptor (PTAFR); pleckstrin (PLEK);pleckstrin homology, Sec7 and coiled/coil domains 1 (cytohesin 1)(PSCD1); pleckstrin homology, Sec7 and coiled/coil domains, bindingprotein (PSCDBP); pM5 protein; PMP69; poly(A) polymerase (PAP);poly(A)-binding protein-like 1 (PABPL1); poly(rC)-binding protein 1(PCBP1); polyadenylate binding protein; polycystic kidney disease 1(autosomal dominant) (PKD1); polymerase (DNA directed), beta (POLB);polymerase (DNA directed), gamma (POLG); polymerase (RNA) II (DNAdirected) polypeptide A (220 kD) (POLR2A); polymyositis/sclerodermaautoantigen 2 (100 kD) (PMSCL2); polypyrimidine tract binding protein(heterogeneous nuclear ribonucleoprotein I) (PTB); positive regulator ofprogrammed cell death ICH-1L (Ich-1); postmeiotic segregation increased2-like 12 (PMS2L12); postmeiotic segregation increased 2-like 8(PMS2L8); potassium inwardly-rectifying channel, subfamily J, member 15(KCNJ15); potassium voltage-gated channel, KQT-like subfamily, member 1(KCNQ1); POU domain, class 2, associating factor 1 (POU2AF1); POUdomain, class 2, transcription factor 1 (POU2F1); PPAR binding protein(PPARBP); PPAR gamma2; pre-B-cell colony-enhancing factor (PBEF);prefoldin 1 (PFDN1); prefoldin 5 (PRFLD5); pregnancy-associated plasmaprotein A (PAPPA); pre-mRNA splicing factor SRp20, 5′UTR; preproteintranslocase (TIM17); prion protein; prion protein (p27-30)(Creutzfeld-Jakob disease, Gerstmann-Strausler-Scheinker syndrome, fatalfamilial insomnia) (PRNP); procollagen-lysine, 2-oxoglutarate5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome type VI)(PLOD); procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline4-hydroxylase), alpha polypeptide 1 (P4HA1); procollagen-proline,2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta polypeptide(protein disulfide isomerase; thyroid hormone binding protein p55)(P4HB); profilin 1 (PFN1); progesterone receptor-associated p48 protein(P48); prohibitin (PHB); proliferating cell nuclear antigen (PCNA);proliferation-associated gene A (natural iller-enhancing factor A)(PAGA); proline-serine-threonine phosphatase interacting protein 1(PSTPIP1); prolyl endopeptidase (PREP); prolylcarboxypeptidase(angiotensinase C) (PRCP); promyelocytic leukemia (PML); properdin Pfactor, complement (PFC); pro-platelet basic protein (includes plateletbasic protein, beta-thromboglobulin, connective tissue-activatingpeptide III, neutrophil-activating peptide-2) (PPBP); proproteinconvertase subtilisin/kexin type 7 (PCSK7); prosaposin (variant Gaucherdisease and variant metachromatic leukodystrophy) (PSAP);prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase andcyclooxygenase) (PTGS1); prostaglandin-endoperoxide synthase 2(prostaglandin G/H synthase and cyclooxygenase) (PTGS2); prostatecarcinoma tumor antigen (pcta-1); protease inhibitor 1 (anti-elastase),alpha-1-antitrypsin (PI); protease inhibitor 2 (anti-elastase),proteasome (prosome, macropain) 26S subunit, ATPase, 1 (PSMC1);proteasome (prosome, macropain) 26S subunit, ATPase, 3 (PSMC3);proteasome (prosome, macropain) 26S subunit, ATPase, 4 (PSMC4);proteasome (prosome, macropain) 26S subunit, ATPase, 5 (PSMC5);proteasome (prosome, macropain) 26S subunit, ATPase, 6 (PMSC6);proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 (PSMD11);proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 (PSMD2);proteasome (prosome, macropain) 26S subunit, non-ATPase, 5 (PSMD5);proteasome (prosome, macropain) 26S subunit, non-ATPase, 7 (Mov34homolog) (PMSD7); proteasome (prosome, macropain) 26S subunit,on-ATPase, 12 (PMSD12); proteasome (prosome, macropain) activatorsubunit 1 (PA28 alpha) (PSME1); proteasome (prosome, macropain) subunit,alpha type, 3 (PSMA3); proteasome (prosome, macropain) subunit, alphatype, 5 (PSMA5); proteasome (prosome, macropain) subunit, alpha type, 7(PSMA7); proteasome (prosome, macropain) subunit, beta type, 1 (PSMB1);proteasome (prosome, macropain) subunit, beta type, 10 (PSMB10);proteasome (prosome, macropain) subunit, beta type, 6 (PMSB6);proteasome (prosome, macropain) subunit, beta type, 8 (largemultifunctional protease 7) (PSMB8); proteasome (prosome, macropain)subunit, beta type, 9 (large multifunctional protease 2) (PSMB9);proteasome (prosome, macropain) subunit, beta ype, 7 (PSMB7); protectiveprotein for beta-galactosidase (galactosialidosis) (PPGB); protein Aalternatively spliced form 2 (A-2); protein activator of theinterferon-induced protein kinase (PACT); protein disulfideisomerase-related protein (P5); protein geranylgeranyltransferase typeI, beta subunit (PGGT1B); protein homologous to chicken B complexprotein, guanine nucleotide binding (H12.3); protein kinase A anchoringprotein; protein kinase C substrate 80K-H (PRKCSH); protein kinase C,beta 1 (PRKCB1); protein kinase C, delta (PRKCD); protein kinase C, eta(PRKCH); Protein kinase C-like 1 (PRKCL1); protein kinase,AMP-activated, gamma 1 non-catalytic subunit (PRKAG1); protein kinase,cAMP-dependent, regulatory, type I, alpha (tissue specificextinguisher 1) (PRKAR1A); protein kinase, DNA-activated, catalyticpolypeptide (PRKDC); protein kinase, mitogen-activated 1 (MAP kinase 1;p40, p41) (PRKM1); protein kinase, mitogen-activated 6 (extracellularsignal-regulated kinase, p97) (PRKM6); protein kinase,mitogen-activated, kinase 3 (MAP kinase kinase 3) (PRKMK3); proteinphosphatase 1, catalytic subunit, alpha isoform (PPP1CA); proteinphosphatase 1, regulatory subunit 10 (PPPR10); protein phosphatase 1,regulatory subunit 7 (PPP1R7); protein phosphatase 2 (formerly 2A),catalytic subunit, beta isoform (PPP2CB); protein phosphatase 2(formerly 2A), regulatory subunit B″ (PR 72), alpha isoform and (PR130), beta isoform (PPP2R3); protein phosphatase 2, regulatory subunit B(B56), alpha isoform (PPP2R5A); protein phosphatase 2, regulatorysubunit B (B56), delta isoform (PPP2R5D); protein phosphatase 2,regulatory subunit B (B56), gamma isoform (PPP2R5C); protein phosphatase2A regulatory subunit alpha-isotype (alpha-PR65); protein phosphatase 4(formerly X), catalytic subunit (PPP4C); protein tyrosine kinase 2 beta(PTK2B); protein tyrosine phosphatase epsilon; protein tyrosinephosphatase type IVA, member 2 (PTP4A2); protein tyrosine phosphatase,non-receptor type 1 (PTPN1); protein tyrosine phosphatase, non-receptortype 12 (PTPN12); protein tyrosine phosphatase, non-receptor type 2(PTPN2); protein tyrosine phosphatase, non-receptor type 4(megakaryocyte) (PTPN4); protein tyrosine phosphatase, non-receptor type6 (PTPN6); protein tyrosine phosphatase, non-receptor type 7 (PTPN7);protein tyrosine phosphatase, receptor type, alpha polypeptide (PTPRA);protein tyrosine phosphatase, receptor type, c polypeptide (PTPRC);protein tyrosine phosphatase, receptor type, M (PTPRM); protein tyrosinephosphatase, receptor type, N polypeptide 2 (PTPRN2); protein withpolyglutamine repeat (ERPROT213-21); protein-kinase,interferon-inducible double stranded RNA dependent inhibitor (PRKRI);protein-L-isoaspartate (D-aspartate) O-methyltransferase (PCMT1);proteoglycan 1, secretory granule (PRG1); prothymosin, alpha (genesequence 28) (PTMA); prp28, U5 snRNP 100 kd protein (U5-100K);PRP4/STK/WD splicing factor (HPRP4P); PTK7 protein tyrosine kinase 7(PTK7); purinergic receptor P2X, ligand-gated ion channel, 4 (P2RX4);purinergic receptor P2X, ligand-gated ion channel, 7 (P2RX7);puromycin-sensitive aminopeptidase (PSA); putative ATP(GTP)-bindingprotein; putative brain nuclearly-targeted protein (KIAA0765); putativechemokine receptor; GTP-binding protein (HM74); putative dienoyl-CoAisomerase (ECH1); putative G-binding protein; Putative human HLA classII associated protein I (PHAP1); Putative L-type neutral amino acidtransporter (KIAA0436); putative mitochondrial space protein 32.1;putative nucleic acid binding protein; putative outer mitochondrialmembrane 34 kDa translocase Htom34; putative translation initiationfactor (SUI1); putative tumor suppressor protein (123F2); pyrroline5-carboxylate reductase; pyruvate dehydrogenase (lipoamide) alpha 1(PDHA1); pyruvate dehydrogenase (lipoamide) beta (PDHB); Pyruvatedehydrogenase complex, lipoyl-containing component X; E3-binding protein(PDX1); pyruvate kinase, muscle (PKM2); RAB, member of RAS oncogenefamily-like (RABL); RAB1, member RAS oncogene family (RAB1); RAB11A,member RAS oncogene family (RAB11A); RAB11B, member RAS oncogene family(Rab11B); RAB27A, member RAS oncogene family (RAB27A); RAB5B, member RASoncogene family (RAB5B); RAB6, member RAS oncogene family (RAB6); RAB7,member RAS oncogene family (RAB7); RAB7, member RAS oncogene family-like1 (RAB7L1); RAB9, member RAS oncogene family (RAB9); RAD50 (S.cerevisiae) homolog (RAD50); RAD51 (S. cerevisiae) homolog C (RAD51C);Radin blood group (RD); RAE1 (RNA export 1, S. pombe) homolog (RAE1);ra1A-binding protein (RLIP76); RAN binding protein 2-like 1 (RANBP2L1);Ran GTPase activating protein 1 (RANGAP1); transforming growth factor,beta receptor II (70-80 kD) (TGFBR2); RAP1A, member of RAS oncogenefamily (RAP1A); RAR-related orphan receptor C (RORC); RAS guanylreleasing protein 2 (calcium and DAG-regulated); ras homolog genefamily, member A (ARHA); ras homolog gene family, member G (rho G)(ARHG); ras homolog gene family, member H (ARHH); ras inhibitor (RIN1);Ras-GTPase activating protein SH3 domain-binding protein 2 (KIAA0660);Ras-GTPase-activating protein SH3-domain-binding protein (G3BP);ras-related C3 botulinum toxin substrate 2 (rho family, small GTPbinding protein Rac2) (RAC2); RBQ-1; regulator of Fas-induced apoptosis(TOSO); regulator of G protein signalling 6 (RGS6); regulator ofG-protein signalling 14 (RGS14); regulator of G-protein signalling 2, 24kD (RGS2); regulatory factor X, 4 (influences HLA class II expression)(RFX4); regulatory factor X, 5 (influences HLA class II expression(RFX5); replication protein A1 (RPA1); reproduction 8 (D8S2298E);requiem, apoptosis response zinc finger gene (REQ); restin(Reed-Steinberg cell-expressed intermediate filament-associated protein)(RSN); retinoblastoma 1 (including osteosarcoma) (RB1); retinoblastomabinding protein 2 homolog 1 (RBBP2H1); retinoblastoma-binding protein 1(RBBP1); retinoblastoma-binding protein 2 (RBBP2);retinoblastoma-binding protein 4 (RBBP4); retinoblastoma-binding protein7 (RBBP7); retinoblastoma-like 2 (p130) (RBL2); retinoic acid receptorresponder (tazarotene nduced) 3 (RARRES3); retinoic acid receptor, alpha(RARA); retinoic acid responsive (NN8-4AG); retinoid X receptor beta(RXR-beta); REV3 (yeast homolog)-like, catalytic subunit of DNApolymerase zeta (REV3L); Rho GDP dissociation inhibitor (GDI) beta(ARHGDIB); Rho GTPase activating protein 4 (ARHGAP4); Rho-associated,coiled-coil containing protein kinase 2 (ROCK2); ribonuclease 6precursor (RNASE6PL); ribonuclease, RNase A family, 2 (liver,eosinophil-derived neurotoxin) (RNASE2); ribonuclease/angiogenininhibitor (RNH); ribonucleoside diphosphate reductase M1 subunit;ribophorin I (RPN1); ribophorin II (RPN2); ribosomal 18S rRNA; ribosomal28S RNA; ribosomal protein L10 (RPL10); ribosomal protein L11 (RPL11);ribosomal protein L12 (RPL19); ribosomal protein L14 (RPL14); ribosomalprotein L17 (RPL17); ribosomal protein L18 (RPL18); ribosomal proteinL18a (RPL18A); ribosomal protein L18a homologue; ribosomal protein L19(RPL19); ribosomal protein L21 (RPL21); ribosomal protein L22 (RPL22);ribosomal protein L23 (RPL23); ribosomal protein L23a (RPL23A);ribosomal protein L26 (RPL26); ribosomal protein L27 (RPL27); ribosomalprotein L27a (RPL27A); ribosomal protein L28 (RPL28); ribosomal proteinL29 (RPL29); ribosomal protein L3 (RPL3); ribosomal protein L3homologue; ribosomal protein L30 (RPL30); ribosomal protein L31 (RPL31);ribosomal protein L32 (RPL32); ribosomal protein L33-like (RPL33L);ribosomal protein L34 (RPL34); ribosomal protein L37 (RPL37); ribosomalprotein L37a; ribosomal protein L38 (PRL38); ribosomal protein L4(RPL4); ribosomal protein L41 (RPL41); ribosomal protein L5 (RPL5);ribosomal protein L6 (RPL6); ribosomal protein L7 (RPL7); ribosomalprotein L7a (RPL7A); ribosomal protein L8 (RPL8); ribosomal protein L9(RPL9); ribosomal protein S10 (RPS 10); ribosomal protein Sll (RPS 11);ribosomal protein S12 (RPS12); ribosomal protein S13 (RPS13); ribosomalprotein S14 (RPS14); ribosomal protein S15 (RPS15); ribosomal proteinS16 (RPS16); ribosomal protein S17 (RPS17); ribosomal protein S18;ribosomal protein S19 (RPS19); ribosomal protein S2 (RPS2); ribosomalprotein S20 (RPS20); ribosomal protein S21 (RPS21); ribosomal proteinS23 (RPS23); ribosomal protein S24 (RPS24); ribosomal protein S25(RPS25); ribosomal protein S26 (RPS26); ribosomal protein S27((metallopanstimulin 1) (RPS27); ribosomal protein S28 (RPS28);ribosomal protein S29 (RPS29); ribosomal protein S3 (RPS3); ribosomalprotein S3A (RPS3A); ribosomal protein S4, X-linked (RPS4X); ribosomalprotein S4, Y-linked (RPS4Y); ribosomal protein S5 (RPS5); ribosomalprotein S6 (RPS6); ribosomal protein S6 kinase, 90 kD, polypeptide 1(RPS6KA1); ribosomal protein S6 kinase, 90 kD, polypeptide 2 (RPS6KA2);ribosomal protein S7 (RPS7); ribosomal protein S8 (RPS8); ribosomalprotein S9 (RPS9); ribosomal protein, large, PO (RPLP0); ribosomalprotein, large, P1 (RPLP1); ribosomal RNA 28S; ribosomal RNA, 16S; ringfinger protein 3 (RNF3); ring finger protein 4 (RNF4); ring zinc-fingerprotein (ZNF127-Xp); RNA (guanine-7-) methyltransferase (RNMT); RNAbinding motif protein 5 (RBM5); RNA binding motif, single strandedinteracting protein 2 (RBMS2); RNA helicase (putative), (Myc-regulatedDEAD box protein) (MRD8); RNA helicase-related protein; RNA pol IIlargest subunit; RNA polymerase I subunit (RPA40); RTVP-1 protein; S100calcium-binding protein A10 (annexin II ligand, calpactin I, lightpolypeptide (p11)) (S100A10); S100 calcium-binding protein A11(calgizzarin) (S100A11); S100 calcium-binding protein A4 (calciumprotein, calvasculin, metastasin, murine placental homolog) (S100A4);S100 calcium-binding protein A8 (calgranulin A) (S100A8); S100calcium-binding protein A9 (calgranulin B) (S100A9); S164 gene;S-adenosylmethionine decarboxylase 1 (AMD1); SB classIIhistocompatibility antigen alpha-chain; SC35-interacting protein 1(SRRP129); scaffold attachment factor B (SAFB); scRNA molecule,transcribed from Alu repeat; SEC14 (S. cerevisiae)-like (SEC14L);SEC23-like protein B (SEC23B); SEC63 (SEC63); secreted protein, acidic,cysteine-rich (osteonectin) (SPARC); secretory carrier membrane protein1 (SCAMP1); secretory carrier membrane protein 2 (SCAMP2); secretorycarrier membrane protein 3 (SCAMP3); secretory granule proteoglycan core(clones lambda-PG[6,7,8]); selectin L (lymphocyte adhesion molecule 1)(SELL); selectin P ligand (SELPLG); sema domain, immunoglobulin domain(Ig), transmembrane domain (TM) and short cytoplasmic domain,(semaphorin) 4D (SEMA4D); Ser/Arg-related nuclear matrix protein (plentyof prolines 101-like) (SRM160); serine palmitoyltransferase subunit I(SPTI); serine palmitoyltransferase, subunit II (LCB2); serine protease;serine protease inhibitor, Kunitz type, 2 (SPINT2); serine/threoninekinase 10 (STK10); serine/threonine kinase 19 (STK19); serine/threoninekinase 4 (STK4); serine/threonine protein kinase KKIALRE (KKIALRE);serine/threonine protein-kinase (NIK); serologically defined coloncancer antigen 16 (NY-CO-16); serologically defined colon cancer antigen33 (SDCCAG33); serum/glucocorticoid regulated kinase (SGK); SET domain,bifurcated 1 (SETDB1); SH2 domain protein 1A, Duncan's diseaselymphoproliferative syndrome) (SH2D1A); SH3 binding protein (SAB); SH3domain protein 1B (SH3D1B); SH3-binding domain glutamic acid-richprotein like (SH3BGRL); SH3-domain GRB2-like 1 (SH3GL1); SHC (Srchomology 2 domain-containing) transforming protein 1 (SHC1); siahbinding protein 1 (SiahBP1); Sialomucin CD164 (CD164); sialophorin(gpL115, leukosialin, CD43) (SNP); sialyltransferase (STHM);sialyltransferase 1 (beta-galactoside alpha-2,6-sialytransferase)(SIAT1); sialyltransferase 4A (beta-galactosidasealpha-2,3-sialytransferase) (SIAT4A); sialyltransferase 8 (alpha-2,8-polysialytransferase) D (SIAT8D); signal peptidase 25 kDa subunit;signal recognition particle 14 kD (homologous Alu RNA-binding protein)(SRP14); signal recognition particle 54 kD (SRP54); signal recognitionparticle 9 kD (SRP9); signal recognition particle receptor ('dockingprotein') SRPR; signal regulatory protein, beta, 1 (SIRP-BETA-1); signalsequence receptor, alpha (translocon-associated protein alpha) (SSR1);signal sequence receptor, beta (translocon-associated protein beta)(SSR2); signal transducer and activator of transcription (STAT5A);signal transducer and activator of transcription 2, 113 KD (STAT2);signal transducer and activator of transcription 3 (acute-phase responsefactor) (STAT3); signal transducer and activator of transcription 5A(STAT5A); signal transducing adaptor molecule (SH3 domain and ITAMmotif) 1 (STAM); silencing mediator of retinoid and thyroid hormoneaction (SMRT); SIT protein; Sjogren syndrome antigen Al (52 kD,ribonucleoprotein autoantigen SS-A/Ro) (SSA1); SKAP55 homologue(SKAP-HOM); skb1 (S. pombe) homolog (SKB1); skeletal muscle abundantprotein; SMA3 (SMA3); small acidic protein; small EDRK-rich factor 2(SERF2); small inducible cytokine AS (RANTES) (SCYA5); small induciblecytokine subfamily C, member 2 (SCYC2); small nuclear ribonucleoproteinpolypeptide B″ (SNRPB2); small nuclear ribonucleoprotein polypeptide N(SNRPN); small nuclear ribonucleoprotein polypeptides B and B1 (SNRPB);small nuclear RNA activating complex, polypeptide 5, 19 kD (SNAPC5);smallest subunit of ubiquinol-cytochrome c reductase; SMC (mouse)homolog, X chromosome (SMCX); SMT3B protein (2); SNC19; SNC73 protein(SNC73); solute carrier family 1 (neutral amino acid transporter),member 5 (SLC1A5); Solute carrier family 11 (proton-coupled divalentmetal ion transporters), member 1 (SLC11A1); solute carrier family 17(sodium phosphate), member 3 (SLC17A3); solute carrier family 19 (folatetransporter), member 1 (SLC19A1); solute carrier family 2 (facilitatedglucose transporter), member 1 (SLC2A1); solute carrier family 23(nucleobase transporters), member 2 (SLC23A2); solute carrier family 25(mitochondrial carrier; oxoglutarate carrier), member 11 (SLC25A11);solute carrier family 31 (copper transporters), member 2 (SLC31A2);solute carrier family 4, anion exchanger, member 2 (erythrocyte membraneprotein band 3-like 1) (SLC4A2); solute carrier family 4, sodiumbicarbonate cotransporter, member 8 (SLC4A8); solute carrier family 7(cationic amino acid transporter, y+ system), member 5 (SLC7A5); solutecarrier family 7 (cationic amino acid transporter, y+ system), member 6(SLC7A6); solute carrier family 9 (sodium/hydrogen exchanger), isoform 6(SLC9A6); somatic cytochrome c (HCS); SON DNA binding protein (SON); sonof sevenless (Drosophila) homolog 1 (SOS1); sorcin (SRI); sortilin 1(SORT1); sortilin-related receptor, L(DLR class) A repeats-containing(SORL1); sorting nexin 1 (SNX1); sorting nexin 2 (SNX2); Sp3transcription factor (SP3); special AT-rich sequence binding protein 1(binds to nuclear matrix/scaffold-associating DNA's) (SATB1);speckle-type POZ protein (SPOP); spectrin SH3 domain binding protein 1(SSH3BP1); Spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) (SPTAN1);spermidine/spermine N1-acetyltransferase (SAT); spermine synthase (SMS);SPF31 (SPF31); sphingomyelin phosphodiesterase 1, acid lysosomal (acidsphingomyelinase) (SMPD1); spinocerebellar ataxia 1(olivopontocerebellar ataxia 1, autosomal dominant, ataxin 1) (SCA1);spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2, autosomaldominant, ataxin 2) (SCA2); spinocerebellar ataxia 7(olivopontocerebellar atrophy with retinal degeneration) (SCAT);spliceosome associated protein (SAP 145); splicing factor (CC1.3)(CC1.3); splicing factor SRp40-1 (SRp40); splicing factor,arginine/serine-rich 11 (SFRS11); splicing factor, arginine/serine-rich7 (35 kD) (SFRS7); Src-like-adapter (SLA); stannin (SNN); STAT inducedSTAT inhibitor 3 (SSI-3); STE20-like kinase 3 (MST-3); step II splicingfactor SLU7 (SLU7); steroid sulfatase; steroid sulfatase (microsomal),arylsulfatase C, isozyme S (STS); sterol carrier protein 2 (SCP2);sterol 0-acyltransferase (acyl-Coenzyme A: cholesterol acyltransferase)1 (SOAT1); stimulated trans-acting factor (50 kDa) (STAF50); Stromalantigen 2 (STAG2); stromal interaction molecule 1 (STIM1); structurespecific recognition protein 1 (SSRP1); succinate dehydrogenase complex,subunit A, flavoprotein (Fp) (SDHA); succinate dehydrogenase complex,subunit B, iron sulfur (Ip) (SDHB); succinate dehydrogenase complex,subunit C, integral membrane protein, 15 kD (SDHC); succinatedehydrogenase complex, subunit D, Integral membrane protein (SDHD);succinate-CoA ligase, GDP-forming, beta subunit (SUCLG2); succinyl CoAsynthetase; sudD (suppressor of bimD6, Aspergillus nidulans) homolog(SUDD); sulfotransferase family 1A, phenol-preferring, member 1(SULT1A1); superoxide dismutase 1, soluble (amyotrophic lateralsclerosis 1 (adult)) (SOD1); superoxide dismutase 2, mitochondrial(SOD2); supervillin (SVIL); suppression of tumorigenicity 5 (ST5);suppressor of K+ transport defect 1 (SKD1); suppressor of Ty (S.cerevisiae) 3 homolog (SUPT3H); suppressor of Ty (S. cerevisiae) 4homolog 1 (SUPT4H1); suppressor of Ty (S. cerevisiae) 5 homolog(SUPT5H); suppressor of Ty (S. cerevisiae) 6 homolog (SUPT6H);suppressor of variegation 3-9 (Drosophila) homolog 1 (SUV39H1); survivalof motor neuron 1, telomeric (SMN1); SWI/SNF related, matrix associated,actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2);SWI/SNF related, matrix associated, actin dependent regulator ofchromatin, subfamily a, member 4 (SMARCA4); SWI/SNF related, matrixassociated, actin dependent regulator of chromatin, subfamily c, member2 (SMARCC2); SWI/SNF related, matrix associated, actin dependentregulator of chromatin, subfamily e, member 1 (SMARCE1);synaptobrevin-like 1 (SYBL1); synaptosomal-associated protein, 23 kD(SNAP23); syndecan binding protein (syntenin) (SDCBP); synovial sarcoma,translocated to X chromosome (SSXT); syntaxin 16; syntaxin 3A (STX3A);syntaxin 6 (STX6); SYNTAXIN BINDING PROTEIN 3 (UNC-18 HOMOLOG 3)(UNC-18C); syntaxin-16C; SYT interacting protein (SIP); T cellactivation, increased late expression (TACTILE); T cell receptor V alphagene segment V-alpha-7 (clone IGRa11); T cell receptor V alpha genesegment V-alpha-w27; T3 receptor-associating cofactor-1; tafazzin(cardiomyopathy, dilated 3A (X-linked); endocardial fibroelastosis 2;Barth syndrome) (TAZ); tankyrase, TRF1-interacting ankyrin-relatedADP-ribose polymerase (TNKS); TAR DNA-binding protein-43; Tatinteractive protein (60 kD) (TIP60); TATA box binding protein(TBP)-associated factor, RNA polymerase II, F, 55 kD (TAF2F); TATA boxbinding protein (TBP)-associated factor, RNA polymerase II, G, 32 kD(TAF2G); TATA box binding protein (TBP)-associated factor, RNApolymerase II, I, 28 kD (TAF2I); Tax1 (human T-cell leukemia virus typeI) binding protein 1 (TAX1BP1); TBP-associated factor 172 (TAF-172);T-cell death-associated gene 8 (TDAG8); T-cell leukemia/lymphoma 1A(TCL1A); T-cell receptor (delta D2-J1-region) (clone K3B); T-cellreceptor delta gene D2-J1-region, clone K3B; T-cell receptor germlinebeta chain gene V-region (V) V-beta-MT1-1; T-cell receptor germlinebeta-chain gene J2.1 exon; T-cell receptor germline delta-chain D-Jregion; T-cell receptor interacting molecule (TRIM) protein; T-cellreceptor rearranged delta-chain, V-region (V-delta 3-J); T-cellreceptor, alpha (V,D,J,C) (TCRA); T-cell receptor, beta cluster (TCRB);T-cell receptor, delta (V,D,J,C) (TCRD); T-cell, immune regulator 1(TCIRG1); TCF-1 mRNA for T cell factor 1; TCR eta =T cellreceptor(eta-exon); TCR V Beta 13.2; TERA; testis enhanced genetranscript (TEGT); tetracycline transporter-like protein (TETRAN);tetratricopeptide repeat domain 1 (TTC1); tetratricopeptide repeatdomain 2 (TTC2); tetratricopeptide repeat domain 3 (TTC3); TGFB1-inducedanti-apoptotic factor 1 (TIAF1); thioredoxin reductase 1 (TXNRD1);threonyl-tRNA synthetase (TARS); thrombin inhibitor; thrombospondin 1(THBS1); thromboxane A synthase 1 (platelet, cytochrome P450, subfamilyV) (TBXAZ1); thymidine kinase 2, mitochondrial (TK2); thymidylate kinase(CDC8); thymine-DNA glycosylase (TDG); Thymosin, beta 10 (TMSB10);thymosin, beta 4, X chromosome (TMSB4X); thyroid autoantigen 70 kD (Kuantigen) (G22P1); thyroid hormone receptor coactivating protein (SMAP);thyroid hormone receptor interactor 7 (TRIP7); thyroid hormone receptorinteractor 8r (TRIP8); thyroid hormone receptor-associated protein, 230kDa subunit (TRAP230); thyroid receptor interacting protein 15 (TRIP15);TI-227H; TIA1 cytotoxic granule-associated RNA-binding protein (TIA1);tissue inhibitor of metalloproteinase 1 (erythroid potentiatingactivity, collagenase inhibitor) (TIMP1); tissue inhibitor ofmetalloproteinase 2 (TIMP2); tissue specific transplantation antigenP35B (TSTA3); titin (TTN); TNF receptor-associated factor 2 (TRAF2); TNFreceptor-associated factor 3 (TRAF3); toll-like receptor 1 (TLR1);toll-like receptor 2 (TLR2); toll-like receptor 4 (TLR4); toll-likereceptor 5 (TILR5); topoisomerase (DNA) I (TOP1); topoisomerase (DNA) IIbeta (180 kD) (TOP2B); topoisomerase (DNA) III beta (TOP3B); TR3beta;TRAF family member-associated NF-kB activator (TANK); transaldolase 1(TALDO1); transaldolase-related protein; transcobalamin II (TCII);transcription elongation factor B (SIII), polypeptide 1-like (TCEB1L);transcription elongation factor B (SIII), polypeptide 3 (110 kD, elonginA) (TCEB3); transcription factor 12 (HTF4, helix-loop-helixtranscription factors 4) (TCF12); transcription factor 17 (TCF17);transcription factor 4 (TCR4); transcription factor 6-like 1(mitochondrial transcription factor 1-like) (TCF6L1); transcriptionfactor 7-like 2 (T-cell specific, HMG-box) (TCF7L2); transcriptionfactor binding to IGHM enhancer 3 (TFE3; transcription factor IL-4 Stat;transcription factor TFIID; transcriptional adaptor 2 (ADA2, yeast,homolog)-like (TADA2L); transducin (beta)-like 1 (TBL1); transducin-likeenhancer of split 3, homolog of Drosophila E(sp1) (TLE3);Transformation/transcription domain-associated protein (TRRAP);transformation-sensitive, transforming growth factor beta-stimulatedprotein TSC-22 (TSC22); transforming growth factor, beta receptor III(betaglycan, 300 kD) (TGFBR3); transforming growth factor, beta-induced,68 kD (TGFBI); transgelin 2 (TAGLN2); trans-Golgi network protein (46,48, 51 kD isoforms) (TGN51); transient receptor potential channel 1(TRPC1); transketolase (Wernicke-Korsakoff syndrome) (TKT); translationfactor suil homolog (GC20); translin (TSN); translin-associated factor X(TSNAX); transmembrane glycoprotein (A33); transmembrane protein (63kD), endoplasmic reticulum/Golgi intermediate compartment (P63);transmembrane protein 1 (TMEM2); transmembrane trafficking protein(TMP21); transporter 1, ABC (ATP binding cassette) (TAP1); TreacherCollins-Franceschetti syndrome 1 (TCOF1); triosephosphate isomerase 1(TPI1); tropomyosin; tropomyosin 4 (TPM4); TRPM-2 protein; tryptophanrich basic protein (WRB); tryptophanyl-tRNA synthetase (WARS); Tstranslation elongation factor, mitochondrial (TSFM); ttopoisomerase(DNA) II beta (180 kD); Tu translation elongation factor, mitochondrial(TUFM); tuberous sclerosis 1 (TSC1); tuberous sclerosis 2 (TSC2);tubulin, alpha 1 (testis specific) (TUBA1); tubulin, alpha, ubiquitous(K-ALPHA-1); tubulin-specific chaperone c (TBCC); tumor necrosis factor(ligand) superfamily, member 10 (TNFSF10); tumor necrosis factor(ligand) superfamily, member 13 (TNFSF13); tumor necrosis factor(ligand) superfamily, member 14 (TNFSF14); tumor necrosis factor(ligand) superfamily, member 6 (TNFSF6); tumor necrosis factor (ligand)superfamily, member 8 (TNFSF8); tumor necrosis factor alpha-induciblecellular protein containing leucine zipper domains (FIP2); Tumornecrosis factor receptor superfamily member 7 (TNFRSF7); tumor necrosisfactor receptor superfamily, member 10b (TNFRSF10B); tumor necrosisfactor receptor superfamily, member 10c, decoy without an intracellulardomain (TNFRSF10C); tumor necrosis factor receptor superfamily, member12 (translocating chain-association membrane protein) (TNFRSF12); tumornecrosis factor receptor superfamily, member 14 (herpesvirus entrymediator) (TNFRSF14); tumor necrosis factor receptor superfamily, member1B (TNFRSF1B); tumor necrosis factor receptor superfamily, member 6(TNFRSF6); tumor necrosis factor receptor superfamily, member 7(TNFRSF7); tumor necrosis factor, alpha-induced protein 2 (TNFAIP2);tumor necrosis factor, alpha-induced protein 3 (TNFAIP3); tumor protein53-binding protein, 1 (TP53BP1); tumor protein p53 (Li-Fraumenisyndrome) (TP53); Tumor protein p53-binding protein (TP53BPL); tumorprotein, translationally-controlled 1 (TPT1); tumor rejection antigen(gp96) 1 (TRA1); tumorous imaginal discs (Drosophila) homolog (TID1);TXK tyrosine kinase (TXK); type II integral membrane protein (NKG2-E);TYRO protein tyrosine kinase binding protein (TYROBP); tyrosine3-monooxygenase/tryptophan 5-monooxygenase activation protein, betapolypeptide (YWHAB); tyrosine 3-monooxygenase/tryptophan 5-monooxygenaseactivation protein, zeta polypeptide (YWHAZ); Tyrosine kinase 2 (TYK2);tyrosyl-tRNA synthetase (YARS); U1 small nuclear RNA; U2(RNU2) smallnuclear RNA auxillary factor 1 (non-standard symbol) (U2AF1); U22 snoRNAhost gene (UHG); U4/U6-associated RNA splicing factor (HPRP3P); U49small nuclear RNA; U5 snRNP-specific protein (220 kD), ortholog of S.cerevisiae Prp8p (PRP8); U5 snRNP-specific protein, 116 kD (U5-116 KD);U5 snRNP-specific protein, 200 kDa (DEXH RNA helicase family)(U5-200-KD); Uba80 mRNA for ubiquitin; ubiquinol-cytochrome c reductase(6.4 kD) subunit (UQCR); ubiquitin A-52 residue ribosomal protein fusionproduct 1 (UBA52); ubiquitin activating enzyme El-like protein (GSA7);ubiquitin C (UBC); ubiquitin carboxyl-terminal esterase L3 (ubiquitinthiolesterase) (UCHL3); ubiquitin fusion degradation 1-like (UFD1L);ubiquitin protein ligase E3A (human papilloma virus E6-associatedprotein, Angelman syndrome) (UBE3A); ubiquitin specific protease 10(USP10); ubiquitin specific protease 11 (USP11); ubiquitin specificprotease 15 (USP15); ubiquitin specific protease 19 (USP19); ubiquitinspecific protease 4 (proto-oncogene) (USP4); ubiquitin specific protease7 (herpes virus-associated) (USP7); ubiquitin specific protease 8(USPS); ubiquitin-activating enzyme E1 (A1S9T and BN75 temperaturesensitivity complementing) (UBE1); ubiquitin-activating enzyme E1, like(UBE1L); UBIQUITIN-BINDING PROTEIN P62; phosphotyrosine independentligand for the Lck SH2 domain p62 (P62); ubiquitin-conjugating enzyme E2variant 1 (UBE2V1); ubiquitin-conjugating enzyme E2 variant 2 (UBE2V2);ubiquitin-conjugating enzyme E2B (RAD6 homolog) (UBE2B);ubiquitin-conjugating enzyme E2G 2 (homologous to yeast UBC7) (UBE2G2);ubiquitin-conjugating enzyme E2H (homologous to yeast UBC8) (UBE2H);ubiquitin-conjugating enzyme E2L1 (UBE2L1); ubiquitin-conjugating enzymeE2L 3 (UBE2L3); ubiquitin-conjugating enzyme E2L (UBE2L6);ubiquitin-like 1 (sentrin) (UBL1);UDP-N-acetyl-alpha-D-galactosamine:polypeptideN-acetylgalactosaminyltransferase 2 (Ga1NAc-T2) (GALNT2); unactiveprogesterone receptor, 23 Kd (P23); unconventional myosin-ID (MYO1F);uncoupling protein homolog (UCPH); uppressor of Ty (S. cerevisiae) 6homolog; upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1); upstreambinding factor (hUBF); UV radiation resistance associated gene (UVRAG);vacuolar proton-ATPase, subunit D; V-ATPase, subunit D (ATP6DV); v-aktmurine thymoma viral oncogene homolog 1 (AKT1); Vanin 2 (VNN2);vasodilator-stimulated phosphoprotein (VASP); vav 1 oncogene (VAV1); vav2 oncogene (VAV2); v-crk avian sarcoma virus CT10 oncogene homolog(CRK); v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3(ERBB3); Vesicle-associated membrane protein 1 (synaptobrevin 1)(VAMP1); vesicle-associated membrane protein 3 (cellubrevin) (VAMP3);v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS); villin 2(ezrin) (VIL2); villin-like protein; vimentin (VIM); vinculin (VCL);vitamin A responsive; cytoskeleton related (JWA); v-jun avian sarcomavirus 17 oncogene homolog (JUN); v-myb avian myeloblastosis viraloncogene homolog (MYB); voltage-dependent anion channel 1 (VDAC1);voltage-dependent anion channel 3 (VDAC3); von Hippel-Lindau syndrome(VHL); v-raf murine sarcoma 3611 viral oncogene homolog 1 (ARAF1);v-raf-1 murine leukemia viral oncogene homolog 1 (RAF1); v-ral simianleukemia viral oncogene homolog B (ras related; GTP binding protein)(RALB); V-rel avian reticuloendotheliosis viral oncogene homolog A(nuclear factor of kappa light polypeptide gene enhancer in B-cells 3(p65)) (RELA); v-yes-1 Yamaguchi sarcoma viral related oncogene homolog(LYN); WD repeat domain 1 (WDR1); WD-repeat protein (HAN11);Williams-Beuren syndrome chromosome region 1 (WBSCR1); Wiskott-Aldrichsyndrome protein interacting protein (WASPIP); X (inactive)-specifictranscript (XIST); xeroderma pigmentosum, complementation group C (XPC);XIAP associated factor-1; XIB; X-linked anhidroitic ectodermaldysplasia; X-ray repair complementing defective repair in Chinesehamster cells 5 (double-strand-break rejoining; Ku autoantigen, 80 kD)(XRCC5); XRP2 protein; yeloid differentiation primary response gene (88)(MYD88); zeta-chain (TCR) associated protein kinase (70 kD) (ZAP70);zinc finger protein (Hs.47371); zinc finger protein (Hs.78765); zincfinger protein 10 (KOX 1) (ZNF10); zinc finger protein 136 (clonepHZ-20) (ZNF136); zinc finger protein 140 (clone pHZ-39) (ZNF140); zincfinger protein 143 (clone pHZ-1) (ZNF143); zinc finger protein 148(pHZ-52) (ZNF148); zinc finger protein 173 (ZNF173); zinc finger protein198 (ZNF198); zinc finger protein 200 (ZNF200); zinc finger protein 207(ZNF207); zinc finger protein 216 (ZNF216); zinc finger protein 217(ZNF217); zinc finger protein 230 (ZNF230); Zinc finger protein 239(ANF239); zinc finger protein 261 (ZNF261); zinc finger protein 262(ANF262); zinc finger protein 263 (ZNF263); zinc finger protein 264(ZNF264); zinc finger protein 42 (myeloid-specific retinoiccid-responsive) (ZNF42); zinc finger protein 45 (a Kruppel-associatedbox (KRAB) domain polypeptide) (ZNF45); zinc finger protein 76(expressed in testis) (ZNF76); zinc finger protein 84 (HPF2) (ZNF84);zinc finger protein 85 (ZNF85)); zinc finger protein 9 (ZNF9); zincfinger protein C2H2-25 (ZNF25); zinc finger protein clone L3-4; zincfinger protein homologous to Zfp-36 in mouse (ZFP36); zinc fingerprotein HZF4; zinc finger protein RIZ; zinc finger protein, subfamily1A, 1 (Ikaros) (LYF1); zinc finger transcriptional regulator (GOS24);zinc-finger helicase (hZFH); Zn-15 related zinc finger protein WO;ZNF80-linked ERV9 long terminal repeat; ZW10 (Drosophila) homolog,centromere/kinetochore protein (ZW10); and zyxin (ZYX); therebyidentifying at least one potential marker of prostate cancer.
 2. Themethod of claim 1, wherein determining the level in blood samples ofhuman subjects having prostate cancer, and/or wherein determining thelevel in blood samples of human subjects not having prostate cancer iseffected using at least one oligonucleotide of predetermined sequence.3. The method of claim 2, wherein the at least one oligonucleotide isspecific for RNA encoded only by the gene in blood of human subjects,and/or is specific for cDNA complementary to RNA encoded only by thegene in blood of human subjects.
 4. The method of claim 2, whereindetermining the level in blood samples of human subjects having prostatecancer, and/or wherein determining the level in blood samples of humansubjects not having prostate cancer is effected by amplifying RNAencoded by the gene to form amplified product, using at least oneprimer, and quantifying the amplified product, wherein the at least oneoligonucleotide comprises the at least one primer.
 5. The method ofclaim 2, wherein determining the level in blood samples of humansubjects having the disease, and/or wherein determining the level inblood samples of human subjects not having the disease is effected byhybridizing cDNA complementary to RNA encoded by the gene with at leastone immobilized probe to form hybridization product, and quantifying thehybridization product, wherein the at least one oligonucleotidecomprises the at least one probe.
 6. The method of claim 1, whereindetermining the level in blood samples of human subjects having prostatecancer is effected by quantifying cDNA generated from RNA encoded by thegene and/or by quantifying EST generated from RNA encoded by the gene;and/or wherein determining the level in blood samples of human subjectsnot having prostate cancer is effected by quantifying cDNA generatedfrom RNA encoded by the gene and/or by quantifying EST generated fromRNA encoded by the gene.
 7. The method of claim 1, wherein the level inthe blood samples of subjects having prostate cancer is relative to alevel of RNA encoded by a housekeeping gene in the blood samples ofsubjects having prostate cancer; and/or wherein the level in the bloodsamples of subjects not having prostate cancer is relative to a level ofRNA encoded by a housekeeping gene in the blood samples of subjects nothaving prostate cancer.
 8. The method of claim 1, wherein the subjectsnot having prostate cancer are healthy subjects.
 9. The method of claim1, wherein the blood samples of human subjects having prostate cancercomprise one or more cell types selected from the group consisting of:granulocytes, monocytes, CD19+ cells and CD3+ cells; and/or wherein theblood samples of human subjects not having prostate cancer comprise oneor more cell types selected from the group consisting of: granulocytes,monocytes, CD19+ cells and CD3+ cells.
 10. The method of claim 1,wherein the difference is a decrease in the level in the blood samplesof subjects having prostate cancer relative to the level in the bloodsamples of subjects not having prostate cancer.